Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 001	07/03/2019	Neurology	Traumatic brain injury	Phase 1	Lost	18146A	NCT04149860	Not Applicable	TrialTroveID-359827	Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Progressive Supranuclear Palsy (All) Cohort 2: Neurodegenerative Disorders, unrelated to Parkinson/stroke/Alhzeimer/MND Cohort 3: Corticobasal generation or Frontotemporal dementia with Parkinsonism (CBD or FTDP) Cohort 4: Behavorial variant frontotemporal degeneration (bvFTD) Cohort 5: Nonfluent variant primary progressive aphasia (nfvPPA) Cohort 6: Tauopathy-like neurodegenerative disorders (PSP,CBD/FTDP,bvFTD,nvPPA) - SSI Cohort 7: Traumatic Brain Injury (All)	Cohort 1 : 1258 Cohort 2 : 5652 Cohort 3 : 70 Cohort 4 : 569 Cohort 5 : 645 Cohort 6 : 2542 Cohort 7 : 87164
ICSPECIC 002	07/03/2019	Gastrointestina	Crohn's disease	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Crohn's diseases (All) Cohort 2: Crohn's diseases (All) with remicade, remsima,inflectra Cohort 3: Crohn's diseases (All) with remicade	Cohort 1 : 34394 Cohort 2 : 7632 Cohort 3 : 5743
ICSPECIC 003	07/03/2019	Oncology	Bladder cancer	Phase 2	Award	INCB 54828-20	NCT04003610	EudraCT Numbe	TrialTroveID-352482	A Phase II, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	cohort 1 : Bladder Cancer (Adults) cohort 2 : Bladder Cancer with Chemotherapy (Adults) cohort 3 : Bile duct malignant neoplasms (Adults) cohort 4 : Intrahepatic bile duct carcinoma (Adults)	cohort 1 : 52809 cohort 2 : 6028 cohort 3 : 8914 cohort 4 : 5179
ICSPECIC 004	08/03/2019	Oncology	Non-small cell lung cancer	Phase 2	Award	MS200095_003	NCT03940703	EudraCT Numbe	TrialTroveID-348972	A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Lung cancer Cohort 2: Metastatic lung cancer Cohort 3: Packs of Osimertinib prescribed	Cohort 1 : 133328 Cohort 2 : 73509 Cohort 3 : 3720

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 005	08/03/2019	Hematology	Multiple myeloma	Phase 2	Award	INCB 01158-20	NCT03837509	EudraCT Numbe	TrialTroveID-343424	A Randomized Open-label Phase I/II Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Multiple Myeloma (All) Cohort 2: Chemotherapy treated Multiple Myeloma (All) Cohort 3: RR patients	Cohort 1 : 5959 Cohort 2 : 4919 Cohort 3 : 1405
ICSPECIC 006	11/03/2019	Cardiovascular	Cardiovascular Disease	Phase 2	Award	APD791-202	NCT04848220	EudraCT Numbe	TrialTroveID-394461	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutaneous Coronary Intervention	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1 : Myocardial infraction; Angina Pectoris; Acute Ischemic Cardiopathy (All) Cohort 2 : Myocardial infraction; Angina Pectoris; Acute Ischemic Cardiopathy (non fatal) Cohort 3 : Myocardial infraction; Angina Pectoris; Acute Ischemic Cardiopathy with PCI	Cohort 1 : 576550 Cohort 2 : 552787 Cohort 3 : 144785
ICSPECIC 007	12/03/2019	Endocrinology	Diabetes mellitus type 2	Phase 4	Award	LPS14947	NCT04075513	EudraCT Numbe	TrialTroveID-356327	A 12-week Randomized, Controlled Trial to Compare TOUJEO® and TRESIBA® in Terms of Glucose Values in Target Range and Variability During Continuous Glucose Monitoring in Patients With Type 1 Diabetes Mellitus	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Type I diabetes (All) Cohort 2: Type I diabetes (Adults) Cohort 3: Type I diabetes without renal complications /end stage renal disease (Adults) Cohort 4: Type I diabetes without renal complications/end stage renal disease/eye diseases (Adults)	Cohort 1 : 115521 Cohort 2 : 111812 Cohort 3 : 92252 Cohort 4 : 81818
ICSPECIC 008	14/03/2019	Dermatology	Psoriasis	Phase 3b	Award	TILD-19-12	NCT03997786	EudraCT Numbe	TrialTroveID-336519	A Multicenter, Randomized, Placebo and Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque Psoriasis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Psoriasis Cohort 2: Psoriasis 6-18 yrs	Cohort 1 : 21872 Cohort 2 : 229

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 009	14/03/2019	Oncology	Non-small cell lung cancer	Phase 3a	Award	INCMGA0012-3	NCT04203511	Not Applicable	TrialTroveID-363741	A Randomized, Double-Blind, Placebo-Controlled Phase III Study of INCMGA00012, an Anti-PD-1 Antibody, in Combination With Chemoradiation in Participants With Unresectable, Stage III Non-Small Cell Lung Cancer (POD1UM-301)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016-2018	France	Cohort 1: Lung Cancer (All) Cohort 2: Lung Cancer with chemotherapy or radiotherapy (All) Cohort 3: Lung Cancer with chemotherapy (All) Cohort 4: Lung Cancer treated with Cetuximab (All) Cohort 5: NSCLC EGFR kinsase inhibitors Consumption (Afatinib, erlotinib, gefitinib - 2016-2018)	Cohort 1 : 96968 Cohort 2 : 36744 Cohort 3 : 29561 Cohort 4 : 96 Cohort 5 : 58714.3638
ICSPECIC 010	15/03/2019	Hematology	Acute myeloid leukemia	Phase 3a	Award	AML003	NCT03504410	EudraCT Numbe	TrialTroveID-298198	Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613® (Devimistat) in Combination With High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) Therapy and Control Sub-groups: Combination of Mitoxantrone, Etoposide and Cytarabine (MEC) and Combination of Fludarabine, Cytarabine, and Filgrastim (FLAG) in Older Patients (> or = 50 Years) With Relapsed/Refractory Acute Myeloid Leukemia (AML)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Myeloid Leukemia (All) Cohort 2: Acute Myeloid Leukemia (All) Cohort 3: Acute Myeloblastic Leukemia (All) Cohort 4: Acute Myeloblastic Leukemia (60+ years old) Cohort 5: Acute Myeloblastic Leukemia with chemotherapy treatment (60+ years old) Cohort 6: RR Patient (60+ years old) Cohort 7: RR Patient with treatment (60+ years old)	Cohort 1 : 14331 Cohort 2 : 9856 Cohort 3 : 9400 Cohort 4 : 6670 Cohort 5 : 4000 Cohort 6 : 2778 Cohort 7 : 1797
ICSPECIC 011	18/03/2019	Oncology	Malignant tumor of breast	Phase 3a	Award	DESTINY-B03	NCT03529110	EudraCT Numbe	TrialTroveID-315079	A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	cohort 1 : Breast Cancer (Adults) cohort 2 : Breast Cancer with Trastuzumab Emtansine (Adults) cohort 3 : Metastatic Breast Cancer (Adults) cohort 4 : Metastatic Breast Cancer with Trastuzumab Emtansine (All)	cohort 1 : 95111 cohort 2 : 577 cohort 3 : 46731 cohort 4 : 561
ICSPECIC 012	20/03/2019	Cardiovascular	Lipid metabolism disorders	Phase 1	Award	mRNA-3927-P1	NCT04159103	Not Applicable	Not Applicable	A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants With Propionic Acidemia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Propionic Acidemia (All) Cohort 2: Propionic Acidemia (< 2 Years old) Cohort 3: Propionic Acidemia (2-11 Years old) Cohort 4: Propionic Acidemia (12-18 Years old) Cohort 5: Propionic Acidemia (Adults) Cohort 6: Number of Propionic Acidemia associated medical procedures	Cohort 1 : 234 Cohort 2 : 37 Cohort 3 : 107 Cohort 4 : 36 Cohort 5 : 59 Cohort 6 : 6646

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 013	20/03/2019	Psychiatry	Schizophrenia	Phase 3a	Award	ACP-103-039	Not Applicable	EudraCT Numbe	TrialTroveID-312298	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (Enhance-2)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2016	France	Cohort 1: Symptomatic Diagnosis associated to Schizophrenia (All) Cohort 2: Diagnosis of Schizophrenia (18-55) Cohort 3: Diagnosis of Schizophrenia (18-55) without commorbid psychatric disorders Cohort 4: Diagnosis of Schizophrenia (18-55) without commorbid psychatric disorders not taking Clozapine Cohort 5: Diagnosis of treatment resistant Schizophrenia (18-55) Cohort 6: Diagnosis of treatment resistant Schizophrenia (18-55) without commorbid psychatric disorders	Cohort 1 : 496595 Cohort 2 : 161228 Cohort 3 : 146952 Cohort 4 : 111243 Cohort 5 : 40642 Cohort 6 : 37413
ICSPECIC 014	21/03/2019	Women's Healt	Female barrier contraception	Phase 3a	Lost	MIT-Es001-C30	NCT04792385	EudraCT Numbe	TrialTroveID-377682	A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics associated with the use of a Combined Oral Contraceptive Containing 15 mg Estetrol monohydrate and 3 mg Drospirenone in Post-menarchal Female Adolescents for 6 cycles	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016-2018	France	Cohort 1: Menstrual cycle related conditions (All) Cohort 2: Menstrual cycle related conditions (12-17 years old) Cohort 3: Menorrhagia // irregular menstrual cycle // Anovulation (12-17 years old) Cohort 4: Hospital prescribed, retail delivered G03A ATC class drugs (2016) Cohort 5: Hospital prescribed, retail delivered G03A ATC class drugs (2017) Cohort 6: Hospital prescribed, retail delivered G03A ATC class drugs (2018) Cohort 7: Hospital prescribed, retail delivered G03A ATC class drugs (2016-2018)	Cohort 1 : 26996 Cohort 2 : 792 Cohort 3 : 187 Cohort 4 : 848817 Cohort 5 : 918410 Cohort 6 : 877358 Cohort 7 : 2643790
ICSPECIC 015	21/03/2019	Oncology	Non-small cell lung cancer	Phase 4	Lost	AFAMOSI	NCT04413201	EudraCT Numbe	TrialTroveID-375900	AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line Setting	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016-2018	France	Cohort 1: Lung Cancer (All) Cohort 2: Lung Cancer with chemotherapy (All) Cohort 3: Lung Cancer treated with Cetuximab (All) Cohort 4: EGFR kinsase inhibitors Consumption (2016-2018)	Cohort 1 : 96968 Cohort 2 : 29561 Cohort 3 : 96 Cohort 4 : 57230
ICSPECIC 016	21/03/2019	Oncology	Non-small cell lung cancer	Phase 4	Award	1200-0316	NCT04179890	Not Applicable	Not Applicable	UpSwinG: Real World Study on TKI Activity in Uncommon Mutations and Sequencing Giotrif®	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1 : Lung Cancer (All) Cohort 2 : Lung Cancer with chemotherapy (All) Cohort 3 : Lung Cancer treated with Cetuximab (All)	Cohort 1 : 96968 Cohort 2 : 29561 Cohort 3 : 96

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 017	22/03/2019	Oncology	Solid tumor configuration	Phase 2	Award	INCB 86550-20	NCT04629339	EudraCT Numbe	TrialTroveID-383002	A Phase II Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve with Selected Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Bladder Cancer (Adults) Cohort 2: Bladder Cancer with Chemotherapy (Adults) Cohort 3: Bile duct malignant neoplasms (Adults) Cohort 4: Intrahepatic bile duct carcinoma (Adults)	Cohort 1 : 52809 Cohort 2 : 6028 Cohort 3 : 8914 Cohort 4 : 5179
ICSPECIC 018	25/03/2019	Hematology	Malignant lymphoma (clinical)	Phase 2	Award	DTRM-555_001	NCT04305444	Not Applicable	TrialTroveID-369651	Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: DLBCL (All) Cohort 2: DLBCL with Chemotherapy (All) Cohort 3: DLBCL (FL transformation) Cohort 4: DLBCL (CLL transformation) Cohort 5: Transformed DLBCL (FL or CLL)	Cohort 1 : 9756 Cohort 2 : 6058 Cohort 3 : 416 Cohort 4 : 200 Cohort 5 : 616
ICSPECIC 019	26/03/2019	Gastrointestina	Ulcerative colitis	Phase 2	Award	ABX464-103	NCT03760003	EudraCT Numbe	TrialTroveID-306036	A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose, Induction Study to Evaluate the Safety, Tolerability and Optimal Dose of ABX464 Compared With Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Have Inadequate Response, Loss of Response, or Intolerance With at Least One of the Following Agents: Immunosuppressant Treatment (i.e. Azathioprine, 6-mercaptopurine, Methotrexate), Tumor Necrosis Factor Alpha [TNF-a] Inhibitors, Vedolizumab, JAK Inhibitors and/or Corticosteroid Treatment	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: UC Patients Cohort 2: UC Patients - exclusions	Cohort 1 : 20870 Cohort 2 : 19424
ICSPECIC 020	27/03/2019	Oncology	Malignant tumor of breast	Phase 3a	Award	DS8201-A-U30	NCT03734029	EudraCT Numbe	TrialTroveID-336411	A Phase III, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Breast cancer patients (All) Cohort 2: Breast cancer patients (18+) Cohort 3: Breast cancer patients metastatic (adults) Cohort 4: Breast cancer patients metastatic tested (adults) Cohort 5: Breast cancer patients metastatic and treated with chemo (adults) Cohort 6: Breast cancer patients metastatic tested and treated with chemo (adults) Cohort 7: Breast cancer patients metastatic tested and treated with Eribulin (adults)	Cohort 1 : 96755 Cohort 2 : 96763 Cohort 3 : 47294 Cohort 4 : 21898 Cohort 5 : 12744 Cohort 6 : 5293 Cohort 7 : 450

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 021	27/03/2019	Oncology	Metastatic cancer	Phase 2	Award	ANCHOR-CRC	NCT03693170	EudraCT Numbe	TrialTroveID-333859	Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2016	France	Cohort 1: Total Adult Population (>17) Cohort 2: Colorectal Cancers Cohort 3: Metastatic Colorectal Cancers (Inclusion only) Cohort 4: Stroke+Diabetes+infectious+lung diseases mCrC Cohort 5: Diabetes+infectious+lung diseases mCrC Cohort 6: infectious+lung diseases mCrC Cohort 7: lung diseases mCrC Cohort 8: Metastatic Colorectal Cancers (inclusion & exclusion) Cohort 9: Metastatic Colorectal Cancers under Chemiotherapy Cohort 10: Metastatic Colorectal Cancers under Chemiotherapy (Bevacizumab) Cohort 11: Metastatic Colorectal Cancers under Chemiotherapy (Cetuximab)	Cohort 1 : NA Cohort 2 : 122405 Cohort 3 : 47334.0000000001 Cohort 4 : 41160 Cohort 5 : 39168 Cohort 6 : 34148 Cohort 7 : 34039 Cohort 8 : 33991 Cohort 9 : 18654 Cohort 10 : 7331 Cohort 11 : 2004
ICSPECIC 022	28/03/2019	Respiratory	Asthma	Phase 3	Lost	214263	NCT04937387	Not Applicable	TrialTroveID-407291	GSK IL33r mAb Phase IIb/ III Program Asthma - 209636 2b (Safety Extension 12 Month)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Asthma (all) Cohort 2: Asthma (18+) Cohort 3: Asthma (12-17 years old)	Cohort 1 : 145962 Cohort 2 : 110530 Cohort 3 : 5048
ICSPECIC 023	29/03/2019	Oncology	Solid tumor configuration	Phase 1	Award	AN0025S0103	NCT04432857	EudraCT Numbe	TrialTroveID-340110	An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Urothelial Cancer (All) Cohort 2: Urothelial Cancer (Adults) Cohort 3: Urothelial Cancer with chemotherapy (Adults)	Cohort 1 : 72919 Cohort 2 : 72598 Cohort 3 : 7896
ICSPECIC 024	01/04/2019	Cardiovascular	Cardiovascular Disease	Phase 3b	Pendin	CTQJ230A1230	NCT04023552	EudraCT Numbe	TrialTroveID-268186	A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease (Lp(a)HORIZON)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Myocardial infraction with Peripheral Vascular Disease Cohort 2: Coronary Artery Disease with peripheral vascular disease Cohort 3: CVD/Myocardial infraction Patient counts (normalized index) Cohort 4: Hypercholesterolemia or family history of metabolic disorders Cohort 5: LDL Apheresis Cohort 6: High LpA Patients (Q2) Cohort 7: LpA proxy (normalized index) Cohort 8: Lpa + CVD (50/50)	Cohort 1 : 264 Cohort 2 : 204 Cohort 3 : 15090 Cohort 4 : 338952 Cohort 5 : 80 Cohort 6 : 289 Cohort 7 : 113950 Cohort 8 : 65021

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 025	03/04/2019	Gastrointestina	Drug-induced constipation	Phase 1	Lost	1907V921F	Not Applicable	EudraCT Numbe	TrialTroveID-350225	A Phase 1/2, Multicentre, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Naldemedine in Paediatric Patients Who Are Receiving or Who Are About to Receive Treatment with Opioids	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Patients with Opioid treatment related complications (All) Cohort 2: Patients with Opioid treatment related complications (Pediatric) Cohort 3: Patients with Opioid treatment related complications and Pain (All) Cohort 4: Patients with Opioid treatment related complications and Pain (Pediatric) Cohort 5: Patients with Opioid treatment related complications and Pain and constipation (All) Cohort 6: Patients with Opioid treatment related complications and Pain and constipation (Pediatric) Cohort 7: Criteria Details Cohort 8: Patients with Opioid treatment related complications Cohort 9: Patients with Opioid treatment related complications and Pain Cohort 10: Patients with Opioid treatment related complications and Pain and constipation	Cohort 1 : 14950 Cohort 2 : 504 Cohort 3 : 3428 Cohort 4 : 61 Cohort 5 : 1113 Cohort 6 : 29 Cohort 7 : All Cohort 8 : 14950 Cohort 9 : 3428 Cohort 10 : 1113
ICSPECIC 026	03/04/2019	Neurology	Neuropathic pain	Phase 3a	Awarde	802NP301	NCT03070132	EudraCT Numbe	TrialTroveID-211016	A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2016	France	Cohort 1: Trigeminal Neuralgia Cohort 2: Trigeminal Neuralgia adults Cohort 3: Trigeminal Neuralgia adults without HIV Cohort 4: Trigeminal Neuralgia adults without HIV nor HepC	Cohort 1 : 3362 Cohort 2 : 3337 Cohort 3 : 3332 Cohort 4 : 3323
ICSPECIC 027	03/04/2019	Neurology	Neuropathic pain	Phase 3a	Awarde	802NP302	NCT03637387	EudraCT Numbe	TrialTroveID-297527	A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Disorders of trigeminal nerve Cohort 2: Trigeminal neuralgia adults Cohort 3: Trigeminal neuralgia as main reason for hospitalisation, adults excluding clinically evident neurological deficit Cohort 4: Trigeminal neuralgia as main reason for hospitalisation, adults excluding clinically evident neurological deficit and also excluding tumours, AI and MS	Cohort 1 : 4143 Cohort 2 : 3249 Cohort 3 : 1830 Cohort 4 : 1574
ICSPECIC 028	04/04/2019	Cardiovascular	Myocardial infarction	Phase 3a	Lost	ID-076A301	NCT04957719	EudraCT Numbe	TrialTroveID-356554	An International, Multi-center, Phase III Study to Evaluate Efficacy and Safety of Subcutaneous Self-administration of Selatogrel in Patients with AMI	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Acute myocardial infaction (all) Cohort 2: Acute myocardial infaction (adults)	Cohort 1 : 104805 Cohort 2 : 104756

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 029	04/04/2019	Gastrointestina	Crohn's disease	Phase 2	Award	GS-US-419-401	NCT03046056	EudraCT Numbe	TrialTroveID-295666	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Crohn's (adults) Cohort 2: Crohn's (adults) excluding ischemic colitis, toxic mega-colon,ulcerative colitis Cohort 3: Crohn's (adults) excluding ischemic colitis, toxic mega-colon,ulcerative colitis, without malignant neoplasms Cohort 4: Crohn's (adults) excluding ischemic colitis, toxic mega-colon,ulcerative colitis, without malignant neoplasms nor infectious diseases Cohort 5: Crohn's (adults) excluding ischemic colitis, toxic mega-colon,ulcerative colitis, without malignant neoplasms nor infectious diseases, nor lymphocyte depleting therapies Cohort 6: Crohn's (adults) excluding ischemic colitis, toxic mega-colon,ulcerative colitis, without malignant neoplasms nor infectious diseases, nor lymphocyte depleting therapies including drugs (infliximab,adalimumab,certolizumab) Cohort 7: Crohn's (adults) with drugs	Cohort 1 : 29884 Cohort 2 : 28451 Cohort 3 : 28366 Cohort 4 : 28160 Cohort 5 : 28113 Cohort 6 : 6934 Cohort 7 : 7437
ICSPECIC 030	04/04/2019	Gastrointestina	Crohn's disease	Phase 2	Award	GS-US-419-401	NCT03077412	EudraCT Numbe	TrialTroveID-297479	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	cohort 1 : Crohn's (adults) cohort 2 : Crohn's (adults) with anal fistula cohort 3 : Crohn's (adults) with anal fistula without toxic mega-colon, ulcerative colitis, ischemic colitis nor HIV,HBV,HCV nor maliignant neoplasms cohort 4 : Endocarditis (Adults) with staph aureus	cohort 1 : 29884 cohort 2 : 1202 cohort 3 : 932 cohort 4 : 2074
ICSPECIC 031	05/04/2019	Infectious Disea	Influenza A (H1N1)	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Influenza patients (all) Cohort 2: Influenza patients (adults) Cohort 3: Influenza patients under respiratory (adults) Cohort 4: Influenza patients under respiratory without surinfection (adults)	Cohort 1 : 18567 Cohort 2 : 13876 Cohort 3 : 569 Cohort 4 : 399
ICSPECIC 032	05/04/2019	Psychiatry	Major depressive disorder	Phase 4	Lost	18314A	NCT04220996	EudraCT Numbe	TrialTroveID-364954	Interventional, Open-label Effectiveness Study of Flexible Doses of Vortioxetine on Depressive Symptoms in Patients With Major Depressive Disorder Comorbid With Generalized Anxiety Disorder.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Depression (All) Cohort 2: Major Depression (All) Cohort 3: Major Depression (Adults) Cohort 4: Major Depression with anxiety (Adults) Cohort 5: Major Depression with generalized anxiety disorder (Adults) Cohort 6: Major Depression with generalized anxiety disorder and dementia (Adults)	Cohort 1 : 191224 Cohort 2 : 27134 Cohort 3 : 26966 Cohort 4 : 3559 Cohort 5 : 1062 Cohort 6 : 56

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 033	05/04/2019	Oncology	Metastatic cancer	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Pancreatic Cancer (all) Cohort 2: Pancreatic Cancer (adults) Cohort 3: Metastatic Pancreatic Cancer (stage IV) Cohort 4: Metastatic Pancreatic Cancer (stage IV) without chemo	Cohort 1 : 33081 Cohort 2 : 33044 Cohort 3 : 10337 Cohort 4 : 3969
ICSPECIC 034	05/04/2019	Other	PIK3CA-related overgrowth spectrum (PROS)	Phase 4	Lost	CBYL719F1200	NCT04285723	Not Applicable	Not Applicable	Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Have Received Alpelisib as Part of a Compassionate Use Program (EPIK-P1)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Congenital Malformation Syndromes (> 2 years old) Cohort 2: Congenital Malformation Syndromes associated with Gigantism or limb malformation Cohort 3: Congenital Malformation Syndromes associated with Gigantism or limb malformation with CLOVES syndrom	Cohort 1 : 3850 Cohort 2 : 1407 Cohort 3 : 156
ICSPECIC 035	05/04/2019	Infectious Disea	Staphylococcal infection	Phase 3a	Lost	CF-301-105	NCT04160468	Not Applicable	TrialTroveID-354144	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	cohort 1 : Endocarditis (All) cohort 2 : Endocarditis (Adults) cohort 3 : Endocarditis (Adults) with staph aureus or sepsis due to staph aureus cohort 4 : Endocarditis (Adults) with staph aureus	cohort 1 : 10637 cohort 2 : 10526 cohort 3 : 2770 cohort 4 : 2074
ICSPECIC 036	08/04/2019	Neurology	Migraine	Phase 4	Award	18256	NCT05127486	Not Applicable	TrialTroveID-406570	A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Migraine (All) Cohort 2: Migraine (Adults)	Cohort 1 : 92337 Cohort 2 : 85006

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 037	10/04/2019	Gastrointestina	Gastroenteritis	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Congenital Malformation Syndromes (> 2 years old) Cohort 2: Congenital malformation syndromes predominantly associated with short stature Cohort 3: Congenital malformation syndromes predominantly associated with short stature (18-40) Cohort 4: Congenital malformation syndromes predominantly associated with short stature and Willi Prader Symptoms Cohort 5: Congenital malformation syndromes predominantly associated with short stature and Willi Prader Symptoms (18-40) Cohort 6: Congenital malformation syndromes predominantly associated with short stature Cohort 7: Congenital malformation syndromes predominantly associated with short stature and Willi Prader Symptoms	Cohort 1 : 3850 Cohort 2 : 1010 Cohort 3 : 256 Cohort 4 : 97 Cohort 5 : 35 Cohort 6 : 1010 Cohort 7 : 97
ICSPECIC 038	10/04/2019	Neurology	Neuropathy	Phase 4	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: PKAN Patients (All) Cohort 2: PKAN Patients (6-65 years old) Cohort 3: PKAN Patients with prothesis (6-65 years old)	Cohort 1 : 42 Cohort 2 : 34 Cohort 3 : 16
ICSPECIC 039	11/04/2019	Gastrointestina	Short bowel syndrome	Phase 3	Lost	TA799-007	NCT04627025	EudraCT Numbe	TrialTroveID-387138	A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: SBS (All) Cohort 2: SBS with parenteral nutrition (All) Cohort 3: SBS with parenteral nutrition without irradiation colitis (All) Cohort 4: SBS with parenteral nutrition without irradiation colitis/sclerodermia (All) Cohort 5: SBS with parenteral nutrition without irradiation colitis/sclerodermia/coeliac disease/tropical sprue (All) Cohort 6: SBS with parenteral nutrition without irradiation colitis/sclerodermia/coeliac disease/tropical sprue/HBV/HIV (All) Cohort 7: SBS with parenteral nutrition without irradiation colitis/sclerodermia/coeliac disease/tropical sprue/HBV/HIV (adults)	Cohort 1 : 2867 Cohort 2 : 885 Cohort 3 : 787 Cohort 4 : 786 Cohort 5 : 786 Cohort 6 : 773 Cohort 7 : 383
ICSPECIC 040	11/04/2019	Dermatology	Venous ulcer of leg	Not Applic	Lost	PD-568268	NCT04181320	Not Applicable	Not Applicable	Multicentre, Prospective, Randomized, Open-label, Assessor Blinded Study to Evaluate Granulox® Used as Adjunct Therapy to Defined Standard of Care vs. Defined Standard of Care for the Treatment of Predominantly Chronic Venous Leg Ulcers (VLUs)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Chronic Venous Insufficiency (All) Cohort 2: Chronic Venous Insufficiency with Venous Leg Ulcer (All) Cohort 3: Chronic Venous Insufficiency with Venous Leg Ulcer with debridment(All)	Cohort 1 : 44419 Cohort 2 : 2774 Cohort 3 : 123

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 041	16/04/2019	Oncology	Head and neck cancer	Phase 3	Lost	NANORAY-312	NCT04892173	Not Applicable	TrialTroveID-346499	A Phase III Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Cancer of the oral cavity, oropharynx, hypopharynx (All) Cohort 2: Cancer of the oral cavity, oropharynx, hypopharynx (between 18-85 years old) Cohort 3: Cancer of the oral cavity, oropharynx, hypopharynx treated with Cetuximab (between 18-85 years old)	Cohort 1 : 9136 Cohort 2 : 8914 Cohort 3 : 852
ICSPECIC 042	17/04/2019	Oncology	Neurofibromatosis syndrome	Phase 2	Lost	D1346C00004	Not Applicable	EudraCT Numbe	Not Applicable	A Phase I/II, Single-Arm, Open label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥ 1 to < 7 Years with Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Neurofibromatosis (all) Cohort 2: Neurofibromatosis (children) Cohort 3: Neurofibromatosis (young adults)	Cohort 1 : 2390 Cohort 2 : 805 Cohort 3 : 322
ICSPECIC 043	18/04/2019	Neurology	Multiple sclerosis	Phase 2	Award	231MS201	NCT04079088	EudraCT Numbe	TrialTroveID-273308	A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 or Glatiramer Acetate Therapies in Relapsing Multiple Sclerosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: MS (all) Cohort 2: MS (18-55yrs) Cohort 3: MS treated with other forms of chemo (18-55yrs)	Cohort 1 : 26699 Cohort 2 : 15314 Cohort 3 : 5861
ICSPECIC 044	18/04/2019	Cardiovascular	Cardiomyopathy	Phase 1	Award	CT-G20 1.2	NCT04418297	Not Applicable	TrialTroveID-346208	A Randomized, Double-Blind, Placebo-Controlled, Sequential, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Hypertrophic cardiomyopathy (all) Cohort 2: Hypertrophic cardiomyopathy (adults) Cohort 3: Obstructive hypertrophic cardiomyopathy (adults)	Cohort 1 : 29745 Cohort 2 : 29406 Cohort 3 : 4527

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 045	23/04/2019	Hematology	Multiple myeloma	Phase 1	Lost	EDO-S101-100	NCT03687125	EudraCT Numbe	TrialTroveID-333696	Phase I/II Open-label Trial of Tinostamustine Conditioning and Autologous Stem Cell Transplantation for Salvage Treatment in Relapsed / Refractory Multiple Myeloma (TITANIUM 1)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Multiple Myeloma (All) Cohort 2: Chemotherapy treated Multiple Myeloma (All) Cohort 3: RR patients	Cohort 1 : 5709 Cohort 2 : 4717 Cohort 3 : 1332
ICSPECIC 046	24/04/2019	Oncology	Non-small cell lung cancer	Phase 4	Lost	D5161R00017	NCT05103605	Not Applicable	TrialTroveID-417404	Positioning, Utilization and Effectiveness of Osimertinib in First Line in Real-life Therapeutic Strategy in France Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Brest Cancer (All) Cohort 2: Metastatic Brest Cancer (All) Cohort 3: Metastatic Brest Cancer (adults) Cohort 4: Metastatic Brest Cancer with histological test (adults) Cohort 5: Metastatic Brest Cancer with histological test not treated with HER2+ specific treatment (adults) Cohort 6: Chemotherapy treated; Metastatic Brest Cancer with histological test and chemotherapy not treated with HER2+ specific treatment (adults) Cohort 7: Chemotherapy naïve; Metastatic Brest Cancer with histological test (adults)	Cohort 1 : 95091 Cohort 2 : 46732 Cohort 3 : 46731 Cohort 4 : 20200 Cohort 5 : 19270 Cohort 6 : 3924 Cohort 7 : 13743
ICSPECIC 047	24/04/2019	Neurology	Alzheimer's disease	Phase 3a	Award	GV971-004	NCT04520412	EudraCT Numbe	TrialTroveID-373189	A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Alzheimers (all) Cohort 2: Mild to medium Alzheimers (all) Cohort 3: Mild to medium Alzheimers (50-85) Cohort 4: Mild to medium Alzheimers (50-85) excluding different other causes of dementia	Cohort 1 : 106112 Cohort 2 : 15697 Cohort 3 : 8545 Cohort 4 : 7563
ICSPECIC 048	25/04/2019	Oncology	Malignant tumor of breast	Phase 3a	Lost	HLX10-013-TNE	NCT04301739	Not Applicable	TrialTroveID-369475	A Randomized, Double-Blind, International Multi-Centre, Phase III Clinical Study to Evaluate Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Breast Cancer Cohort 2: Breast Cancer (Between 18-55 years old)	Cohort 1 : 95091 Cohort 2 : 28297

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 049	30/04/2019	Oncology	Malignant tumor of pancreas	Phase 2	Lost	2020-012-GLOI	NCT04579757	EudraCT Numbe	TrialTroveID-386496	An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Pancreatic cancer (All) Cohort 2: Endocrine Pancreatic cancer (All) Cohort 3: Endocrine Pancreatic cancer with metastasis (All)	Cohort 1 : 28237 Cohort 2 : 1333 Cohort 3 : 828
ICSPECIC 050	30/04/2019	Gastrointestina	Moderately to Severely Active Ulcerative Colitis	Phase 2	Lost	APD334-210	NCT04607837	EudraCT Numbe	TrialTroveID-388171	A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: UC or Crohns Cohort 2: Crohn's disease Cohort 3: UC Cohort 4: Both UC and Crohn's Cohort 5: UC or Crohns on infliximab,adalimumab,golimumab Cohort 6: Crohns on infliximab,adalimumab,golimumab	Cohort 1 : 56571 Cohort 2 : 33700 Cohort 3 : 24047 Cohort 4 : 1570 Cohort 5 : 8413 Cohort 6 : 6604
ICSPECIC 051	30/04/2019	Dermatology	Pityriasis	Phase 2	Lost	00019343	NCT01483599	EudraCT Numbe	TrialTroveID-157805	A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X-PLORE)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	cohort 1 : PRP Patients (All)	cohort 1 : 56
ICSPECIC 052	01/05/2019	Respiratory	COPD	Phase 3a	Award	SHP670-301	NCT02722304	Not Applicable	TrialTroveID-275793	A Stage 1, Prospective, Randomized, Placebo-Controlled, Double- Blind Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Subjects with A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Chronic Obstructive Pulmonary Disease Cohort 2: COPD with plasmatic protein anomaly (including alpha 1 antitrypsin) Cohort 3: COPD with plasmatic protein anomaly w/o cor pulmonare Cohort 4: COPD with plasmatic protein anomaly w/o cor pulmonare/cpap Cohort 5: COPD with plasmatic protein anomaly w/o cor pulmonare / cpap / IgA deficiency Cohort 6: COPD with plasmatic protein anomaly w/o cor pulmonare / cpap / IgA deficiency (adults)	Cohort 1 : 260942 Cohort 2 : 2454 Cohort 3 : 2431 Cohort 4 : 2100 Cohort 5 : 2100 Cohort 6 : 2100

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 053	02/05/2019	Hematology	Hemophilia	Phase 4	Lost	SHP-660-403	NCT04158934	Not Applicable	TrialTroveID-361079	Evaluation of Long-term Safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, Rurioctocog Alfa Pegol) in Patients With Haemophilia A - An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Haemophilia A (all) Cohort 2: Haemophilia A (>11 years old)	Cohort 1 : 2168 Cohort 2 : 1771
ICSPECIC 054	02/05/2019	Neurology	Parkinson's disease	Phase 2	Award	PD-1105	NCT03562494	Not Applicable	TrialTroveID-285325	A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2015-2016	France	Cohort 1: Parkinson (2016) Cohort 2: Parkinson (2015) Cohort 3: Parkinson (seen in 2015 and 2016) Cohort 4: Parkinson (new patients in 2016) Cohort 5: Parkinson (new patients in 2016, between 40-75 years old)	Cohort 1 : 69770 Cohort 2 : 59005 Cohort 3 : 18903 Cohort 4 : 50883 Cohort 5 : 14023
ICSPECIC 055	03/05/2019	Nephrology	Polycystic kidney disease	Phase 3a	Lost	PA-ADPKD-303	NCT04152837	Not Applicable	TrialTroveID-360566	An Open-Label Study of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Previously Experienced Abnormal Liver Chemistry Test Results While Receiving Tolvaptan: The ALERT Study	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Cystic Kidney Disease (All) Cohort 2: Polycystic Kidney Disease (All) Cohort 3: Autosomal Dominant Polycystic Kidney Disease (All) Cohort 4: Autosomal Dominant Polycystic Kidney Disease Between 18-60 years old) Cohort 5: Autosomal Dominant Polycystic Kidney Disease Between 18-60 years old) without HIV/HBV	Cohort 1 : 6778 Cohort 2 : 5243 Cohort 3 : 2022 Cohort 4 : 881 Cohort 5 : 866
ICSPECIC 056	06/05/2019	Cardiovascular	Cardiovascular Disease	Phase 4	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Coronary Artery Bypass Graft or Heart valve Replacement or dissection of aorta (All) Cohort 2: Aortocoronary bypass graft with revasculation Cohort 3: Prosthetic heart valve with replacement Cohort 4: Dissection of aorta with aorta replacement	Cohort 1 : 31872 Cohort 2 : 18705 Cohort 3 : 11956 Cohort 4 : 4761

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 057	07/05/2019	Neurology	Multiple sclerosis	Phase 3a	Award	800MS301	NCT03870763	EudraCT Numbe	TrialTroveID-341352	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Multiple Sclerosis (All) Cohort 2: Multiple Sclerosis (pediatric 10-17yrs old) Cohort 3: Multiple Sclerosis (pediatric) patients on the drug Natalizumab	Cohort 1 : 26699 Cohort 2 : 135 Cohort 3 : 31
ICSPECIC 058	07/05/2019	Other	Pulmonary Arterial Hypertension	Phase 2	Lost	GB002-2101	NCT04456998	EudraCT Numbe	TrialTroveID-326815	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Pulmonary Eosinophilia Cohort 2: Pulmonary Eosinophilia and asthma Cohort 3: Pulmonary Eosinophilia and asthma (adults)	Cohort 1 : 462 Cohort 2 : 173 Cohort 3 : 164
ICSPECIC 059	07/05/2019	Oncology	Neuroendocrine tumors	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: GI Cancer (All) Cohort 2: GI Cancer and carcinoid syndrome (All) Cohort 3: GI Cancer and carcinoid syndrome (between 18 and 70 years old) Cohort 4: GI Cancer and somatostatine analog topography (All) Cohort 5: Endocrine Pancreas Tumor Cohort 6: Endocrine Pancreas Tumor (between 18 and 70 years old) Cohort 7: Endocrine Pancreas Tumor or GI tract cancer with carcinoid syndrome	Cohort 1 : 99015 Cohort 2 : 183 Cohort 3 : 167 Cohort 4 : 117 Cohort 5 : 1331 Cohort 6 : 1209 Cohort 7 : 1376
ICSPECIC 060	09/05/2019	Dermatology	Congenital Ichthyosis	Phase 2	Award	235-9051-202	NCT04154293	Not Applicable	Not Applicable	A Randomized, Parallel, Double-Blind, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Two Concentrations of Topical TMB-001 for the Treatment of Congenital Ichthyosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Congenital Ichthyosis (all) Cohort 2: Congenital Ichthyosis (6 and above) Cohort 3: Congenital Ichthyosis (18 and above) Cohort 4: Congenital Ichthyosis (Pediatric 6-17)	Cohort 1 : 231 Cohort 2 : 145 Cohort 3 : 113 Cohort 4 : 32

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 061	09/05/2019	Neurology	Neuropathic pain	Phase 2	Lost	THN101-201	Not Applicable	Not Applicable	TrialTroveID-337806	A Phase II Safety,Tolerability and Pharmacokinetics Study of THN101-201 in Patients Suffering from Neuropathic Pain	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Neuropathic Pain (All) Cohort 2: Diabete related Neuropathic Pain (All) Cohort 3: Post-zona nevralgia Cohort 4: Diabetes or Herpes related nevralgia	Cohort 1 : 56997 Cohort 2 : 1651 Cohort 3 : 1159 Cohort 4 : 2754
ICSPECIC 062	14/05/2019	Cardiovascular	Cardiovascular Disease	Phase 3a	Lost	APH-19	NCT04681170	EudraCT Numbe	TrialTroveID-354180	Phase III, Single Arm, Open Label, International, Multi Centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid Lowering Therapy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Hypercholesterolemia Cohort 2: Hypercholesterolemia with Family history Cohort 3: Hypercholesterolemia (between 5-18 years old)	Cohort 1 : 340687 Cohort 2 : 6475 Cohort 3 : 186
ICSPECIC 063	15/05/2019	Gastrointestina	Ulcerative colitis	Phase 3a	Award	APD334-301	NCT03945188	EudraCT Numbe	TrialTroveID-320661	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1 : Ulcerative colitis Cohort 2 : Ulcerative colitis (adult) Cohort 3 : Ulcerative colitis (adult) without tuberculosis/HCV/HBV/Cirrhosis/Renal Disease/malignancy	Cohort 1 : 42445 Cohort 2 : 40896 Cohort 3 : 9840
ICSPECIC 064	17/05/2019	Dermatology	Atopic dermatitis	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Atopic dermatitis (All) Cohort 2: Atopic dermatitis (ref) Cohort 3: Mild - Moderate Atopic dermatitis Cohort 4: Mild - Moderate Atopic dermatitis (Pediatric) Cohort 5: Mild - Moderate Atopic dermatitis (Adults)	Cohort 1 : 4580 Cohort 2 : 4517 Cohort 3 : 4011 Cohort 4 : 1260 Cohort 5 : 2027

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 065	21/05/2019	Rheumatology	Rheumatoid arthritis	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: rheumatoid arthritis patients (All) Cohort 2: rheumatoid arthritis patients (18+)	Cohort 1 : 46514 Cohort 2 : 46456
ICSPECIC 066	23/05/2019	Oncology	Glioblastoma	Phase 3a	Lost	CAN008-G-202	Not Applicable	Not Applicable	TrialTroveID-411472	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Study To Evaluate The Effectiveness And Safety Of CAN008 And Temozolomide In The Treatment Of Newly Diagnosed Patients with Glioblastoma During And After Radiotherapy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Brain Tumor Cohort 2: Brain Tumor treated with avastin Cohort 3: Brain Tumor with radiotherapy Cohort 4: Pubmed Cohort 5: Clinical Trial Research Articles (Glioblastoma) Cohort 6: Physicians Cohort 7: Physicians Count	Cohort 1 : 14386 Cohort 2 : 1007 Cohort 3 : 1776 Cohort 4 : Article Count Cohort 5 : 201 Cohort 6 : Neurology and/or Oncology Cohort 7 : 3458
ICSPECIC 067	23/05/2019	Ophthalmology	Atopic conjunctivitis	Phase 3a	Lost	KB046	NCT01554956	Not Applicable	Not Applicable	A Historically Controlled Phase II/III Study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed With Ligneous Conjunctivitis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Chronic conjunctivitis Cohort 2: Disorders of plasma-protein metabolism,not elsewhere classified Cohort 3: Chronic conjunctivitis and disorders of plasma-protein metabolism,not elsewhere classified Cohort 4: Chronic conjunctivitis and (Disorders of plasma-protein metabolism,not elsewhere classified or other specified coagulation defects or scar conditions and fibrosis of skin) Cohort 5: Conjunctivitis and disorders of plasma-protein metabolism,not elsewhere classified	Cohort 1 : 159 Cohort 2 : 7266 Cohort 3 : 2 Cohort 4 : 2 Cohort 5 : 53
ICSPECIC 068	29/05/2019	Oncology	Endometrial carcinoma	Phase 3a	Lost	DUO-E	NCT04269200	EudraCT Numbe	TrialTroveID-367594	A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Endometrial Cancer (Adults)	Cohort 1 : 128

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 069	03/06/2019	Gastrointestina	Ulcerative colitis	Phase 3a	Award	I6T-MC-AMBI	NCT04469062	EudraCT Numbe	TrialTroveID-379245	A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in Participants With Moderately to Severely Active Ulcerative Colitis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Ulcerative colitis Cohort 2: Ulcerative colitis (18-80 yr olds) Cohort 3: Ulcerative colitis (18-80 yr olds) without TB nor hepatitis Cohort 4: Ulcerative colitis (18-80 yr olds) without TB nor hepatitis nor colonic surgery Cohort 5: Ulcerative colitis (18-80 yr olds) without TB nor hepatitis nor colonic surgery on drugs Cohort 6: Ulcerative colitis (18-80 yr olds) without TB nor hepatitis nor colonic surgery on drugs	Cohort 1 : 21475 Cohort 2 : 18892 Cohort 3 : 18851 Cohort 4 : 18764 Cohort 5 : 18250 Cohort 6 : 324
ICSPECIC 070	04/06/2019	Oncology	Solid tumor configuration	Phase 1	Lost	TPX-0046-01	NCT04161391	Not Applicable	TrialTroveID-355871	A Phase I/II Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Thyroid / Lung Cancer (All) Cohort 2: Thyroid / Lung Cancer (Adults) Cohort 3: Thyroid / Lung Cancer with Chemotherapy (Adults)	Cohort 1 : 108345 Cohort 2 : 108216 Cohort 3 : 29939
ICSPECIC 071	04/06/2019	Dermatology	Psoriasis	Phase 2	Pendin	SCD-044-19-14	NCT04566666	Not Applicable	TrialTroveID-385598	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Psoriasis (All) Cohort 2: Psoriasis (18+) Cohort 3: Psoriasis without psoriarsis (18+) Cohort 4: Psoriasis without psoriarsis or heart conditions (18+) Cohort 5: Psoriasis without psoriarsis or heart conditions with biologic treatment (18+)	Cohort 1 : 19906 Cohort 2 : 19684 Cohort 3 : 14693 Cohort 4 : 8901 Cohort 5 : 833
ICSPECIC 072	04/06/2019	Ophthalmology	Diabetic retinopathy	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Diabetes type I or II (all) Cohort 2: Diabetes type I or II (18 and above) Cohort 3: Diabetes type I or II with ocular complications (18 and above) Cohort 4: Diabetic Retinopathy Cohort 5: Diabetic Retinopathy with Pan Retinal Photocoagulation (PRP)	Cohort 1 : 942985 Cohort 2 : 932307 Cohort 3 : 59072 Cohort 4 : 44821 Cohort 5 : 305

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 073	05/06/2019	Other	Blocked central line	Phase 3a	Award	CUSA-081-HEM	NCT03594175	EudraCT Numbe	Not Applicable	A Phase 3, Randomized, Double-Blind, Active and Placebo-Controlled Study on the Use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Had placement of catheter into central venous line Cohort 2: Had placement of catheter into central venous line (adults) Cohort 3: Had placement of catheter into central venous line with complications Cohort 4: Had placement of catheter into central venous line with complications without dialysis Cohort 5: Had placement of catheter into central venous line with complications without dialysis nor hypertension Cohort 6: Had placement of catheter into central venous line with complications without dialysis nor hypertension nor infections Cohort 7: On thrombolytic catheter unblocking agent Cohort 8: Had placement of catheter into central venous line and on thrombolytic catheter unblocking agent Cohort 9: Had placement of catheter into central	Cohort 1 : 155045 Cohort 2 : 146914 Cohort 3 : 7429 Cohort 4 : 6882 Cohort 5 : 3631 Cohort 6 : 3003 Cohort 7 : 760 Cohort 8 : 316 Cohort 9 : 161
ICSPECIC 074	05/06/2019	Other	Toxic effect of chemical	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Head and Neck / Ovarian / Testicle Cancer Cohort 2: Head and Neck / Ovarian / Testicle Cancer with hearing loss Cohort 3: Head and Neck / Ovarian / Testicle Cancer with Ototoxicity Cohort 4: Head and Neck / Ovarian / Testicle Cancer with tonal audiometry Cohort 5: Head and Neck Cancer patient with Ototoxicity (Redistributed) Cohort 6: tonal audiometry (All)	Cohort 1 : 68880 Cohort 2 : 415 Cohort 3 : 34 Cohort 4 : 156 Cohort 5 : 151 Cohort 6 : 5194
ICSPECIC 075	05/06/2019	Rheumatology	Osteoarthritis	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Arthritis of the hip (ALL) Cohort 2: Arthritis of the hip (65+) Cohort 3: Arthroplasty Cohort 4: Arthritis of the hip (65+) with arthroplasty Cohort 5: Patients with hip arthritis and arthroplasty (65+) excluding seizures/parkinsons/Depression,bipolar,schizophrenia, Heart failure/Myocardial infaction Cohort 6: Sarcopenic patients with hip arthritis and arthroplasty (65+) Cohort 7: Sarcopenic patients with hip arthritis and arthroplasty (65+) excluding seizures Cohort 8: Sarcopenic patients with hip arthritis and arthroplasty (65+) excluding seizures/parkinsons Cohort 9: Sarcopenic patients with hip arthritis and arthroplasty (65+) excluding seizures/parkinsons/Depression,bipolar,schizophrenia Cohort 10: Sarcopenic patients with hip arthritis and arthroplasty (65+) excluding	Cohort 1 : 94100 Cohort 2 : 72491 Cohort 3 : 49167 Cohort 4 : 23863 Cohort 5 : 18067 Cohort 6 : 403 Cohort 7 : 387 Cohort 8 : 372 Cohort 9 : 302 Cohort 10 : 232
ICSPECIC 076	05/06/2019	Oncology	Genitourinary cancers	Phase 1	Lost	CRSP-ONC-001	NCT04035434	EudraCT Numbe	TrialTroveID-324194	A Phase I Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1 : Late stage renal disease (all) Cohort 2 : Late stage renal disease (18+) Cohort 3 : Late stage renal disease (18+) on dialysis Cohort 4 : Late stage renal disease (18+) on dialysis with renal cell carcinoma	Cohort 1 : 80038 Cohort 2 : 79574 Cohort 3 : 54260 Cohort 4 : 794

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 077	11/06/2019	Other	Acute Hepatic Porphyrias	Phase 3	Lost	ALN-AS1-003	NCT03338816	Not Applicable	Not Applicable	ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Patients with Cerebral Amyloid Angiotrophy	Cohort 1: 3152
ICSPECIC 078	11/06/2019	Allergy	Angioedema	Phase 3	Awarde	SHP643-303	NCT04206605	EudraCT Numbe	TrialTroveID-363965	A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema with Normal C1-Inhibitor (C1-INH) and Acquired Angioedema (AAE) Due to C1-INH Deficiency	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Angioneurotic edema and or defects in the complement system (all ages)~angiodema patients Cohort 2: Angioneurotic edema and or defects in the complement system (12 years and above) Cohort 3: Angioneurotic edema (12 years and above) Cohort 4: Defects in the complement system (12 and above) Cohort 5: Non histaminergic angioedema Cohort 6: Non histaminergic angioedema patients on drugs Cohort 7: Non histaminergic angioedema patients with B cell lymphoproliferative diseases~AEE type1 Cohort 8: Non histaminergic angioedema patients 12-34yrs~HAE Cohort 9: Non histaminergic 12-34yrs old angioedema patients on drugs~HAE on drugs Cohort 10: Sum of non histaminergic angioedema patients on drugs and angioedema patients with B cell lymphoproliferative diseases	Cohort 1 : 2603 Cohort 2 : 2490 Cohort 3 : 2281 Cohort 4 : 241 Cohort 5 : 1751 Cohort 6 : 223 Cohort 7 : 15 Cohort 8 : 318 Cohort 9 : 56 Cohort 10 : 71
ICSPECIC 079	17/06/2019	Transplantation	Graft versus host disease	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Stem cell transplant Cohort 2: Stem cell transplant (adults) Cohort 3: Stem cell transplant (adults) with Graft vs Host Disease Cohort 4: Stem cell transplant (adults) with chronic Graft vs Host Disease	Cohort 1 : 5221 Cohort 2 : 4269 Cohort 3 : 1874 Cohort 4 : 1030
ICSPECIC 080	17/06/2019	Cardiovascular	Cholesterol level	Phase 4	Lost	DSE-HCL-01-19	NCT04271280	Not Applicable	Not Applicable	Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe - a MultInatioNal ObservatIonal Study (SANTORINI)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Hypercholesterolemia (all) Cohort 2: Hypercholesterolemia (adult) Cohort 3: Hypercholesterolemia (adult) with Coronary atherosclerosis Cohort 4: Primary Hypercholesterolemia (adult) Cohort 5: Primary Hypercholesterolemia (adult) with Coronary atherosclerosis	Cohort 1 : 549354 Cohort 2 : 549191 Cohort 3 : 134023 Cohort 4 : 104171 Cohort 5 : 44715

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 081	18/06/2019	Oncology	Bladder cancer	Phase 3a	Lost	SGN22E-003/E	NCT04223856	EudraCT Numbe	TrialTroveID-362538	An Open-label, Randomized, Controlled Phase III Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Urothelial cancer (all) Cohort 2: Urothelial cancer (adults) Cohort 3: Urothelial cancer (adults) with cystectomy	Cohort 1 : 52349 Cohort 2 : 52300 Cohort 3 : 5721
ICSPECIC 082	25/06/2019	Nephrology	Kidney disease	Phase 3	Award	021FSGS16010	NCT03493685	EudraCT Numbe	TrialTroveID-297891	A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Hypercholesterolemia (all) Cohort 2: Hypercholesterolemia (adult) Cohort 3: Hypercholesterolemia (adult) with Coronary atherosclerosis Cohort 4: Primary Hypercholesterolemia (adult) Cohort 5: Primary Hypercholesterolemia (adult) with Coronary atherosclerosis	Cohort 1 : 984 Cohort 2 : 819 Cohort 3 : 477 Cohort 4 : 469 Cohort 5 : 453
ICSPECIC 083	26/06/2019	Cardiovascular	Heart failure	Phase 3a	Lost	PB2452-PT-CL-	NCT04286438	EudraCT Numbe	TrialTroveID-355496	A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Hemorrhagic disorder due to circulating anticoagulants (All) Cohort 2: Hemorrhagic disorder due to circulating anticoagulants (Emergency Admission Only) Cohort 3: Hemorrhagic disorder due to circulating anticoagulants with blood transfusion (Emergency Admission Only) Cohort 4: Ticagrelor (retail delivered) in PTD Cohort 5: Ticagrelor (Hospital Pescribed, retail delivered) in PTD	Cohort 1 : 29690 Cohort 2 : 27031 Cohort 3 : 3194 Cohort 4 : 31653903 Cohort 5 : 1963412
ICSPECIC 084	26/06/2019	Neurology	Narcolepsy	Phase 1	Lost	TAK-988-1502	NCT04082481	Not Applicable	TrialTroveID-356789	A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-988 in Healthy Subjects	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Narcolepsy and Cataplexy (all ages) Cohort 2: Narcolepsy and Cataplexy (18+)	Cohort 1 : 740 Cohort 2 : 662

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 085	26/06/2019	Respiratory	COPD	Phase 3a	Award	RPL554-CO-302	NCT04542057	EudraCT Numbe	TrialTroveID-374651	A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1 : COPD (40+)	Cohort 1 : 166465
ICSPECIC 086	01/07/2019	Psychiatry	Impaired cognition	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: All Diabetes with neurologic complications, polyneuritis Cohort 2: Adult patients : Diabetes with neurologic complications, polyneuritis Cohort 3: Adult patients : Diabetes with neurologic complications Cohort 4: Adult patients : Diabetes with neurologic complications, polyneuritis and insulin treated Cohort 5: Adult patients : Diabetes with neurologic complications, polyneuritis, with pain	Cohort 1 : 59920 Cohort 2 : 59889 Cohort 3 : 44057 Cohort 4 : 22459 Cohort 5 : 4945
ICSPECIC 087	02/07/2019	Oncology	Solid tumor configuration	Phase 1	Lost	RTX-240-01	NCT04372706	Not Applicable	TrialTroveID-341736	Phase I/II Study of RTX-240 Monotherapy and in Combination With Pembrolizumab	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Colorectal (All) Cohort 2: Colorectal (Chemo)	Cohort 1 : 87713 Cohort 2 : 11765
ICSPECIC 088	03/07/2019	Transplantation	Chemo-induced nausea	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Chemotherapy Cohort 2: Neuropathies or adverse effects of other antitumour drugs during their therapeutic use with chemotherapy Cohort 3: Neuropathies with chemotherapy	Cohort 1 : 167898 Cohort 2 : 15976 Cohort 3 : 2509

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 089	03/07/2019	Oncology	Solid tumor configuration	Phase 3a	Award	IMGN853-0416	NCT04209855	EudraCT Numbe	TrialTroveID-349800	MIRASOL: A Randomized, Open-label, Phase III Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: ovarian cancer Cohort 2: ovarian cancer females Cohort 3: ovarian cancer females on chemo	Cohort 1 : 26139 Cohort 2 : 25306 Cohort 3 : 19624
ICSPECIC 090	08/07/2019	Hematology	Diffuse large B-cell lymphoma	Phase 2	Lost	H-46862 BESTA	NCT04288726	Not Applicable	TrialTroveID-368841	A Phase 1 Study Evaluating the Safety and Activity of Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1 : DLBCL patients	Cohort 1 : 15826
ICSPECIC 091	08/07/2019	Oncology	Solid tumor configuration	Phase 1	Award	AK104-101	NCT03261011	Not Applicable	TrialTroveID-307717	A Phase IA/IB Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1 : Patients with Anti-PD1 treatment (Pembrolizumab / Nivolumab) Cohort 2 : Patients with Anti-PD1 treatment (Pembrolizumab / Nivolumab) and anti CTLA4 treatment (Ipilimumab)	Cohort 1 : 14764 Cohort 2 : 140
ICSPECIC 092	10/07/2019	Oncology	Sarcoma of soft tissue	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Malignant neoplasm of connective and soft tissue Cohort 2: Malignant neoplasm of connective and soft tissue (10 years and above)	Cohort 1 : 5295 Cohort 2 : 5109

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 093	11/07/2019	Immunology	Autoimmune vasculitis	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Behcet's disease Cohort 2: Behcet's disease (18 to 60 years old) Cohort 3: Behcet's disease (18 to 60 years old) with chemotherapy	Cohort 1 : 1479 Cohort 2 : 1171 Cohort 3 : 180
ICSPECIC 094	15/07/2019	Oncology	Head and neck cancer	Phase 3	Lost	D7310C00001	NCT04590963	EudraCT Numbe	TrialTroveID-358311	A Phase III Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with an Immune Checkpoint Inhibitor.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: H&N Cancer 12 months Cohort 2: Newly diagnosed H&N Cancer 12 months Cohort 3: Newly diagnosed H&N Cancer 12 months within Pembro/Nivo within 2 months Cohort 4: Newly diagnosed H&N Cancer 12 months within Pembro/Nivo within 2 months & Cetux Cohort 5: H&N Cancer most recent 3 months Cohort 6: Newly diagnosed H&N Cancer most recent 3 months Cohort 7: Newly diagnosed H&N Cancer most recent 3 months within Pembro/Nivo within 2 months Cohort 8: Newly diagnosed H&N Cancer most recent 3 months within Pembro/Nivo within 2 months & Cetux	Cohort 1 : 30383 Cohort 2 : 12186 Cohort 3 : 181 Cohort 4 : 20 Cohort 5 : 10659 Cohort 6 : 3390 Cohort 7 : 56 Cohort 8 : 6
ICSPECIC 095	15/07/2019	Neurology	Neuropathy	Phase 4	Award	DGD-44-065	NCT04373564	Not Applicable	Not Applicable	Prospective Evaluation of Potential Effects of Repeated Gadolinium-based Contrast Agent (GBCA) Administrations of the Same GBCA on Motor and Cognitive Functions in Neurologically Normal Adults in Comparison to a Non-GBCA Exposed Control Group	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Patients with MRI (All) Cohort 2: Patients with MRI (adults) Cohort 3: Patients with MRI without neurodegenerative disorders (adults) Cohort 4: Patients with MRI without neurodegenerative disorders or multiple sclerosis (adults) Cohort 5: Patients with MRI without neurodegenerative disorders or multiple sclerosis (Candidate;adults) Cohort 6: Breast Cancer Patients with MRI without neurodegenerative disorders or multiple sclerosis (adults) Cohort 7: Colorectal Cancer Patients with MRI without neurodegenerative disorders or multiple sclerosis (adults) Cohort 8: Pancreatic Cancer Patients with MRI without neurodegenerative disorders or multiple sclerosis (adults) Cohort 9: Chronic hepatic disease Patients with MRI without neurodegenerative disorders or multiple	Cohort 1 : 355280 Cohort 2 : 163023 Cohort 3 : 159638 Cohort 4 : 156306 Cohort 5 : 9215 Cohort 6 : 3073 Cohort 7 : 2099 Cohort 8 : 1110 Cohort 9 : 2933 Cohort 10 : 151 Cohort 11 : 350 Cohort 12 : NA Cohort 13 : 3073 Cohort 14 : 2099 Cohort 15 : 1110 Cohort 16 : 2933 Cohort 17 : 147091
ICSPECIC 096	17/07/2019	Oncology	Cervical cancer	Phase 2	Award	MS200647_00	NCT04246489	EudraCT Numbe	TrialTroveID-366464	A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Cervix Cancer (all) Cohort 2: Cervix Cancer (all) actively treated Cohort 3: Cervix Cancer (all) actively treated with Chemotherapy Cohort 4: Cervix Cancer (all) Newly diagnosed	Cohort 1 : 11184 Cohort 2 : 8727 Cohort 3 : 5587 Cohort 4 : 4071

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 097	17/07/2019	Neurology	Duchenne muscular dystrophy	Phase 1	Award	SRP-9001-103	NCT04626674	Not Applicable	TrialTroveID-384173	An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Charcot Marie Tooth Disease Cohort 2: Charcot Marie Tooth Disease patients aged between 15 and 35	Cohort 1 : 1937 Cohort 2 : 233
ICSPECIC 098	17/07/2019	Ophthalmology	Retinopathy	Phase 3	Lost	VGFTe-ROP-19	NCT04101721	EudraCT Numbe	Not Applicable	Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Extreme and unspecified Preterm births (All) Cohort 2: Preterm births with Retinopathy of prematurity (All) Cohort 3: Preterm births, unspecified (All) Cohort 4: Retinopathy of prematurity (All)	Cohort 1 : 53268 Cohort 2 : 787 Cohort 3 : 50202 Cohort 4 : 660
ICSPECIC 099	19/07/2019	Hepatology	Cirrhosis of liver	Phase 3a	Lost	GFT505B-319-1	NCT04526665	EudraCT Numbe	Not Applicable	A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Cholangitis Cohort 2: Cholangitis (adults) Cohort 3: Primary biliary cirrhosis	Cohort 1 : 13437 Cohort 2 : 13180 Cohort 3 : 1863
ICSPECIC 100	23/07/2019	Oncology	Non-small cell lung cancer	Phase 1	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: AML Cohort 2: AML with chemotherapy Cohort 3: Myelodyplastic syndromes (MDS)	Cohort 1 : 8741 Cohort 2 : 5287 Cohort 3 : 16434

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 101	25/07/2019	Dermatology	Actinic keratosis	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1: Efudix treated Patients	Cohort 1 : 3232
ICSPECIC 102	26/07/2019	Hematology	Acute myeloid leukemia	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2017-2018	France	Cohort 1: AML (All) Cohort 2: AML without Acute promyeloctic Leukemia (All) Cohort 3: AML without Acute promyeloctic Leukemia (New patients in 2018) Cohort 4: AML without Acute promyeloctic Leukemia (New patients in 2018, 75 years old and older) Cohort 5: AML without Acute promyeloctic Leukemia undergoing chemotherapy (New patients in 2018) Cohort 6: Chemotherapy naive AML without Acute promyeloctic Leukemia patients Cohort 7: AML without Acute promyeloctic Leukemia (New patients in 2018) Cohort 8: AML without Acute promyeloctic Leukemia undergoing chemotherapy (New patients in 2018) Cohort 9: AML without Acute promyeloctic Leukemia (New patients in 2018) Cohort 10: Chemotherapy naive AML without Acute promyeloctic Leukemia patients	Cohort 1 : 11011 Cohort 2 : 10905 Cohort 3 : 6748 Cohort 4 : 2793 Cohort 5 : 4695 Cohort 6 : 2053 Cohort 7 : 6748 Cohort 8 : 4695 Cohort 9 : 6748 Cohort 10 : 2053
ICSPECIC 103	30/07/2019	Women's Healt	Overactive bladder	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Urinary Incontinence (All) Cohort 2: Urinary Incontinence (18-90 years old)	Cohort 1 : 61192 Cohort 2 : 55174
ICSPECIC 104	30/07/2019	Women's Healt	Overactive bladder	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Urinary Incontinence (All) Cohort 2: Urinary Incontinence (18-90 years old)	Cohort 1 : 61192 Cohort 2 : 55174

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 105	30/07/2019	Women's Healt	Overactive bladder	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Urinary Incontinence (All) Cohort 2: Urinary Incontinence (18-90 years old)	Cohort 1 : 61192 Cohort 2 : 55174
ICSPECIC 106	30/07/2019	Dermatology	Itching	Phase 2	Award	KPL-716-C201	NCT03816891	Not Applicable	Not Applicable	A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : Prurigo Nodularis patients (All) Cohort 2 : Prurigo Nodularis patients (18-75)	Cohort 1 : 2005 Cohort 2 : 1303
ICSPECIC 107	30/07/2019	Neurology	Parkinson's disease	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2017-2018	France	cohort 1 : Parkinson Disease (2017) cohort 2 : Parkinson Disease (new 2018) cohort 3 : Parkinson Disease (new 2017)	cohort 1 : 79733 cohort 2 : 51913 cohort 3 : 52746
ICSPECIC 108	31/07/2019	Rheumatology	Osteoarthritis	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: Patients with Autologous Chondrocyte Implantation procedures Cohort 2: Patient with Knee Replacement procedures (total or partial) (Cohort 3: Patient with Meniscus surgeries (Minor or Manjor)	Cohort 1 : 204 Cohort 2 : 87348 Cohort 3 : 14319

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 109	31/07/2019	Hematology	Chronic myeloid leukemia	Phase 2	Award	CLR_15_03	NCT02629692	EudraCT Numbe	TrialTroveID-260619	A Two-Part Phase I/II Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL).	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: CML Cohort 2: CML adults Cohort 3: Iclusig (Ponatinib) dispensation (units) from Jan 2018 till Feb2019 Cohort 4: Iclusig prescribed according to Xponent panel data with CML adult patients Cohort 5: Iclusig prescribed(units from Jan 2018 till Feb2019) according to Xponent panel data proportionate to CML adult patients	Cohort 1 : 3016 Cohort 2 : 2989 Cohort 3 : 1536,86 units Cohort 4 : 1073 Cohort 5 : 211,54 units/person
ICSPECIC 110	01/08/2019	Oncology	Chemotherapy-induced Peripheral Neuropathy	Phase 2	Award	3-2001B	NCT04492436	Not Applicable	TrialTroveID-380766	A Randomized, Double-blind, Placebo-controlled, Multi-national, Multi-center, Parallel-group, Phase 2b Assessing ART-123's Effect on Preventing Sensory Symptoms of OIPN in Unresectable mCRC Subjects Receiving Oxaliplatin-containing Chemo	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: Colon Cancer patients (All) Cohort 2: Colon Cancer patients (18+) Cohort 3: Colon Cancer patients (18+) with drug induced Polyneuropathies	Cohort 1 : 136104 Cohort 2 : 136059 Cohort 3 : 2548
ICSPECIC 111	01/08/2019	Oncology	Solid tumor configuration	Phase 1	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Epithelial cancers Cohort 2: Epithelial cancers (adults) Cohort 3: Epithelial cancers without chemotherapy (adults)	Cohort 1 : 702774 Cohort 2 : 701843 Cohort 3 : 442471
ICSPECIC 112	01/08/2019	Nephrology	End stage renal disease	Phase 3a	Award	SNFCT2017-06	NCT04195906	EudraCT Numbe	TrialTroveID-363330	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: ESRD Cohort 2: ESRD 18+ Cohort 3: ESRD 18+ with Dyalisis Cohort 4: ESRD 18+ with Dyalisis and calcium disorder Cohort 5: ESRD 18+ with Dyalisis and Calciphilaxis Cohort 6: ESRD 18+ with Sodium Thiosulfate	Cohort 1 : 96704 Cohort 2 : 96553 Cohort 3 : 78775 Cohort 4 : 3470 Cohort 5 : 479 Cohort 6 : 231

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 113	08/08/2019	Hematology	Hemolytic Anemia	Phase 3a	Award	ALXN1830-WA	NCT04256148	EudraCT Numbe	TrialTroveID-354327	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: AutoImmune Hemolytic Anemia (Adults)	Cohort 1 : 2804
ICSPECIC 114	13/08/2019	Neurology	Epilepsy	Phase 2	Award	N01269	NCT04666610	EudraCT Numbe	TrialTroveID-391740	A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: epilepsy (All) Cohort 2: Abscense epilepsy - Petit Mal (All) Cohort 3: Abscense epilepsy - Petit Mal (Pediatric) Cohort 4: Abscense epilepsy - Petit Mal without Generalized epilepsy (Pediatric) Cohort 5: Abscense epilepsy - Petit Mal without Generalized epilepsy (0-3) Cohort 6: Abscense epilepsy - Petit Mal without Generalized epilepsy (4-7) Cohort 7: Abscense epilepsy - Petit Mal without Generalized epilepsy (8-12) Cohort 8: Abscense epilepsy - Petit Mal without Generalized epilepsy (13-18)	Cohort 1 : 148862 Cohort 2 : 22290 Cohort 3 : 4447 Cohort 4 : 3864 Cohort 5 : 537 Cohort 6 : 588 Cohort 7 : 769 Cohort 8 : 1970
ICSPECIC 115	15/08/2019	Oncology	Metastatic cancer	Phase 3a	Award	NuTide121	NCT04163900	EudraCT Numbe	TrialTroveID-211124	A Phase III, Open-label, Randomized Head-to-head Study of NUC-1031 + Cisplatin Versus CisGem in Patients With Advanced or Metastatic BTC (Biliary Tract Cancer)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Biliary Tract Cancer (All) Cohort 2: Biliary Tract Cancer (Adults) Cohort 3: Biliary Tract Cancer treated with chemotherapy (Adults) Cohort 4: Biliary Tract Cancer treated with Biliary Drainage (Adults)	Cohort 1 : 9983 Cohort 2 : 9978 Cohort 3 : 1906 Cohort 4 : 940
ICSPECIC 116	22/08/2019	Respiratory	Fibrosis of lung	Phase 3a	Lost	WA42293	NCT04552899	EudraCT Numbe	TrialTroveID-340637	A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Other interstitial pulmonary diseases with fibrosis Cohort 2: Other interstitial pulmonary diseases with fibrosis (40-80yrs) Cohort 3: Other interstitial pulmonary diseases with fibrosis (40-80yrs) without Alzheimers, acute respiratory failure,Polymyositis,Sicca syndrome [Sjögren],Bird fancier's lung, Sarcoidosis of lung and Progressive systemic sclerosis Cohort 4: Other interstitial pulmonary diseases with fibrosis (40-80yrs) with chronic respiratory failure Cohort 5: Other interstitial pulmonary diseases with fibrosis (40-80yrs) with chronic respiratory failure without Alzheimers, acute respiratory failure,Polymyositis,Sicca syndrome [Sjögren],Bird fancier's lung, Sarcoidosis of lung and Progressive systemic sclerosis	Cohort 1 : 20151 Cohort 2 : 18120 Cohort 3 : 11219 Cohort 4 : 5884 Cohort 5 : 2568

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 117	27/08/2019	Oncology	Malignant Melanoma	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Melanomas Cohort 2: Metastatic Melanomas Cohort 3: Brain Metastatic Melanomas Cohort 4: Brain Metastatic Melanomas without other brain disorders,headaches Cohort 5: Brain Metastatic Melanomas without other brain disorders,headaches without chemotherapy Cohort 6: Brain Metastatic Melanomas without other brain disorders,headaches treated with ipilimumab Cohort 7: Brain Metastatic Melanomas treated with ipilimumab Cohort 8: Brain Metastatic Melanomas Cohort 9: Brain Metastatic Melanomas without other brain disorders,headaches	Cohort 1 : 13479 Cohort 2 : 8363 Cohort 3 : 2476 Cohort 4 : 864 Cohort 5 : 293 Cohort 6 : 64 Cohort 7 : 194 Cohort 8 : 2476 Cohort 9 : 864
ICSPECIC 118	28/08/2019	Oncology	Neoplasm of biliary tract	Phase 2	Awarde	MS200647_005	NCT04066491	EudraCT Numbe	TrialTroveID-355937	A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: BTC (all) Cohort 2: BTC (adults) Cohort 3: Cohort 2-BTC (adults) without PDL Cohort 4: Cohort 1-BTC (adults) without PD1 nor chemo nor immunotherapy Cohort 5: BTC (adults) without chemo nor immunotherapy Cohort 6: Cohort 3-BTC (adults) with checkpoint inhibitors Cohort 7: Cohort 4-BTC (adults) with pembrolizumab	Cohort 1 : 13063 Cohort 2 : 13051 Cohort 3 : 13016 Cohort 4 : 6947 Cohort 5 : 6947 Cohort 6 : 35 Cohort 7 : 7779
ICSPECIC 119	28/08/2019	Hematology	Acute myeloid leukemia	Phase 2	Awarde	SY-1425-201	NCT02807558	EudraCT Numbe	TrialTroveID-265173	A Biomarker-Directed Phase II Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: AML&CML (all) Cohort 2: AML&CML (adults) Cohort 3: AML&CML (adults) with chemo Cohort 4: AML&CML (adults) with chemo and on azacitadine	Cohort 1 : 16884 Cohort 2 : 16440 Cohort 3 : 9749 Cohort 4 : 4401
ICSPECIC 120	30/08/2019	Oncology	Malignant tumor of prostate	Phase 3a	Lost	2020-PSMA	NCT04734184	EudraCT Numbe	Not Applicable	A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Prostate Cancer patients (All) Cohort 2: Prostate Cancer patients with Radiotherapy (All) Cohort 3: Prostate Cancer patients (Diagnosed in 2018) Cohort 4: Prostate Cancer patients without chemotherapy (Diagnosed in 2018) Cohort 5: Prostate Cancer patients without chemotherapy with radiation therapy or prostatectomy (Diagnosed in 2018) Cohort 6: Prostate Cancer patients without chemotherapy with radiation therapy (Diagnosed in 2018)	Cohort 1 : 110479 Cohort 2 : 20786 Cohort 3 : 48234 Cohort 4 : 46133 Cohort 5 : 9521 Cohort 6 : 2531

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 121	30/08/2019	Neurology	Amyotrophic lateral sclerosis	Phase 3	Award	233AS102	NCT03070119	EudraCT Numbe	TrialTroveID-296928	An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: ALS Cohort 2: ALS (adults) Cohort 3: ALS (adults) without Alzheimers, Parkinsons,Myalgia	Cohort 1 : 8543 Cohort 2 : 8495 Cohort 3 : 8231
ICSPECIC 122	05/09/2019	Oncology	Solid tumor configuration	Phase 2	Award	D419EC00001	NCT03837899	EudraCT Numbe	TrialTroveID-343419	Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination With Tremelimumab in Pediatric Patients With Advanced Solid Tumors and Hematological Malignancies	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Non-Hodgkin's Lymphoma Cohort 2 : Other Solid Tumors Cohort 3 : Sarcoma	Cohort 1 : 595 Cohort 2 : 2424 Cohort 3 : 1423
ICSPECIC 123	06/09/2019	Acute Care	Contusion of brain	Not Applic	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: patients with Leukoencephalopathy with vanishing white matter (G37.9/E75.29/G93.49) Cohort 2: patients with Ataxia/spasticity (R27.0/R25)	Cohort 1: 2600 Cohort 2: 214
ICSPECIC 124	10/09/2019	Oncology	Glioblastoma multiforme	Phase 3	Award	EF-32	NCT04471844	Not Applicable	TrialTroveID-377045	EF-32: Pivotal, Randomized, Open-Label Study of Optune (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Malignant neoplasm of the brain Cohort 2: Malignant neoplasm of the brain without Malignant neoplasm of the brainstem Cohort 3: Malignant neoplasm of the brain without Malignant neoplasm of the brainstem with radiotherapy	Cohort 1 : 21455 Cohort 2 : 20394 Cohort 3 : 6724

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 125	10/09/2019	Nephrology	Nephritis	Phase 2	Award	K020-218	NCT03933410	Not Applicable	Not Applicable	A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects With A Urea Cycle Disorder With Inadequate Control on Standard of Care	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	cohort 1 : Urea Cycle Disorder Patients (All) cohort 2 : Urea Cycle Disorder Patients (> 16 years old) cohort 3 : Urea Cycle Disorder Patients without Liver Transplant (> 16 years old)	cohort 1 : 968 cohort 2 : 719 cohort 3 : 708
ICSPECIC 126	11/09/2019	Nephrology	IgA nephropathy	Phase 3	Award	021FSGS16010	NCT03493685	EudraCT Numbe	TrialTroveID-297891	A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: Adult Recurrent and persistent hematuria with other morphologic changes patients	Cohort 1 : 1277
ICSPECIC 127	12/09/2019	Oncology	Non-small cell lung cancer	Phase 2	Lost	SPI-POZ-203	NCT04172597	Not Applicable	TrialTroveID-361808	A Phase II Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Glioma Cohort 2: Glioma (adults) Cohort 3: Glioma (adults) metastatic	Cohort 1 : 21455 Cohort 2 : 18054 Cohort 3 : 2429
ICSPECIC 128	12/09/2019	Infectious Disea	Influenza	Phase 3	Lost	V118-24	NCT02583256	EudraCT Numbe	TrialTroveID-266628	A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to Either the Same or Alternate Type of Vaccine, Adjuvanted or Non-adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV or QIV), Administered to Subjects Previously Vaccinated in Trial V118_05 (NCT01964989) Roll over study of V118_05	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Seniors admitted in the hospital (65+) Cohort 2: Seniors with Influenza infection (65+) Cohort 3: Influvac Tetra Unit (Hospital Prescribed, retail delivered)	Cohort 1 : 4182584 Cohort 2 : 24333 Cohort 3 : 18297.048

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 129	12/09/2019	Dermatology	Hidradenitis Suppurativa	Phase 3a	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Hidradenitis_Suppurativa Cohort 2: Hidradenitis_Suppurativa (adults) Cohort 3: Hidradenitis_Suppurativa (adults) without IBD, HIV,HBV, HCV Cohort 4: Hidradenitis_Suppurativa (adults) without IBD, HIV,HBV, HCV without biologics Cohort 5: Hidradenitis_Suppurativa (adults) without IBD, HIV,HBV, HCV with biologics	Cohort 1 : 5974 Cohort 2 : 5804 Cohort 3 : 5645 Cohort 4 : 5357 Cohort 5 : 288
ICSPECIC 130	12/09/2019	Dermatology	Hidradenitis Suppurativa	Phase 3a	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Hidradenitis_Suppurativa Cohort 2 : Hidradenitis_Suppurativa (adults) Cohort 3 : Hidradenitis_Suppurativa (adults) without IBD, HIV,HBV, HCV Cohort 4 : Hidradenitis_Suppurativa (adults) without IBD, HIV,HBV, HCV without biologics Cohort 5 : Hidradenitis_Suppurativa (adults) without IBD, HIV,HBV, HCV with biologics	Cohort 1 : 5974 Cohort 2 : 5804 Cohort 3 : 5645 Cohort 4 : 5357 Cohort 5 : 288
ICSPECIC 131	12/09/2019	Hepatology	Wilson Disease	Phase 2	Lost	ALXN1840-WD	NCT04422431	EudraCT Numbe	TrialTroveID-376557	A Phase 2, Single-arm, Pathologist-blinded Study Using Liver Biopsy Specimens to Assess Copper Concentration and Histopathologic Changes in Patients With Wilson Disease Who Are Treated With ALXN1840 for 48 Weeks Followed by an Extension Treatment Period With ALXN1840 for up to an Additional 48 Weeks.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: Wilson's disease patients Cohort 2: Wilson's disease patients 3-18y Cohort 3: Wilson's disease patients 3-10y Cohort 4: Wilson's disease patients 11-18y	Cohort 1: 287 Cohort 2: 50 Cohort 3: 21 Cohort 4: 31
ICSPECIC 132	16/09/2019	Dermatology	Alopecia	Phase 2	Lost	APD334-205	NCT04556734	Not Applicable	Not Applicable	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study, With a 28-Week Open-Label Extension, to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Alopecia Areata	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Alopecia patients (All) Cohort 2: Non-cicatricial Alopecia Patients (All) Cohort 3: Alopecia Aerata	Cohort 1 : 1489 Cohort 2 : 1083 Cohort 3 : 305

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 133	16/09/2019	Gastrointestina	Ulcerative colitis	Phase 3a	Award	I6T-MC-AMAN	NCT03518086	EudraCT Numbe	TrialTroveID-323902	A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: UC Patients (All) Cohort 2: UC Patients (18-80) Cohort 3: UC Patients without Tuberculosis (18-80) Cohort 4: UC Patients without Tuberculosis/Hepatitis (18-80) Cohort 5: UC Patients without Tuberculosis/Hepatitis treated with biologics (18-80) Cohort 6: UC Patients without Tuberculosis/Hepatitis treated with Adalimumab (18-80) Cohort 7: UC Patients without Tuberculosis/Hepatitis treated with Golimumab (18-80) Cohort 8: UC Patients without Tuberculosis/Hepatitis treated with infliximab (18-80) Cohort 9: UC Patients without Tuberculosis/Hepatitis treated with Vedolizumab (18-80)	Cohort 1 : 21111 Cohort 2 : 19200 Cohort 3 : 19161 Cohort 4 : 19074 Cohort 5 : 7184 Cohort 6 : 359 Cohort 7 : 58 Cohort 8 : 5037 Cohort 9 : 2302
ICSPECIC 134	16/09/2019	Neurology	Spinal cord disease	Phase 2	Award	232SM203	NCT04089566	EudraCT Numbe	TrialTroveID-357159	Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: SMA and MND (All) Cohort 2: SMA (All) Cohort 3: SMA with intrathecal procedures (All) Cohort 4: SMA (adults) Cohort 5: SMA (Pediatric) Cohort 6: Intrathecal procedures (All)	Cohort 1 : 9828 Cohort 2 : 914 Cohort 3 : 142 Cohort 4 : 392 Cohort 5 : 528 Cohort 6 : 409629
ICSPECIC 135	16/09/2019	Oncology	Gastrointestinal stromal tumor	Phase 2	Award	DZB-CS-202	NCT04604132	EudraCT Numbe	TrialTroveID-365799	A Phase Ib/II Study of Derazantinib as Monotherapy and Combination Therapy With Paclitaxel, Ramucirumab or Atezolizumab in Patients With HER2-Negative Gastric Adenocarcinoma Harboring FGFR Genetic Aberrations (FIDES-03)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Total Gastric Cancer Patients Cohort 2 : Age 18 to 75 Cohort 3 : HER2 Positive Patients Cohort 4 : HER2 Negative Patients Cohort 5 : FGFR Mutated Patients Cohort 6 : FGFR Negative (Wild) Patients Cohort 7 : Patients treated with paclitaxel as single agent	Cohort 1 : 5708 Cohort 2 : 5239 Cohort 3 : 1105 Cohort 4 : 2932 Cohort 5 : 159 Cohort 6 : 265 Cohort 7 : 169
ICSPECIC 136	18/09/2019	Rheumatology	Rheumatoid arthritis	Phase 4	Award	A3921332	nct04517669	Not Applicable	TrialTroveID-382256	A Non-Interventional Multinational Study of Tofacitinib in Patients Treated for Psoriatic Arthritis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Psoriatic Arthritis Patients (all) Cohort 2: Number of Tofacitinib unit (Hospital Prescribed, Retail Delivered)	Cohort 1 : 5289 Cohort 2 : 4320.8

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 137	19/09/2019	Neurology	Ischemic stroke	Phase 2	Award	BT200-02	NCT04103034	Not Applicable	TrialTroveID-357939	A Single/Multiple Ascending Dose Phase 1 Study of the Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Human Volunteers	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Transient ischemic attack Cohort 2 : Transient ischemic attack (over 40) Cohort 3 : Transient ischemic attack (over 40) with cerebral atherosclerosis Cohort 4 : Transient ischemic attack (over 40) with cerebral atherosclerosis without carotid endarteroctomy	Cohort 1 : 36131 Cohort 2 : 34546 Cohort 3 : 1587 Cohort 4 : 1523
ICSPECIC 138	23/09/2019	Hematology	Hemophilia	Phase 3a	Lost	MAA-304	NCT04489537	EudraCT Numbe	TrialTroveID-341842	Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptacog Alfa (Activated) For On Demand Treatment and Control of Bleeding Episodes in Subjects With Hemophilia A or Hemophilia B, With Inhibitors: The Crimson 1 Study	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Transient ischemic attack Cohort 2: Transient ischemic attack (over 40) Cohort 3: Transient ischemic attack (over 40) with cerebral atherosclerosis Cohort 4: Transient ischemic attack (over 40) with cerebral atherosclerosis without carotid endarteroctomy	Cohort 1 : 36131 Cohort 2 : 34546 Cohort 3 : 1587 Cohort 4 : 1523
ICSPECIC 139	24/09/2019	Acute Care	Shock	Phase 4	Lost	HC-G-H-1209	NCT02715466	EudraCT Numbe	TrialTroveID-275298	Prospective, Controlled, Double-Blind, Randomized Multicentric Study On The Efficacy And Safety Of An Early Target Controlled Plasma Volume Replacement Therapy With A Balanced Gelatine Solution vs A Balanced Electrolyte Solution In Patients With Severe Sepsis Gelatin in ICU and Sepsis (GENIUS)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Severe Sepsis / Septic Shock (All) Cohort 2: Severe Sepsis / Septic Shock with use of resuscitation fluid (All)	Cohort 1 : 243291 Cohort 2 : 27299
ICSPECIC 140	24/09/2019	Hematology	Hemophilia	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Factor VII deficiency Cohort 2: Factor VII deficiency (adults) Cohort 3: Factor VII deficiency (adults) given drug Novoseven	Cohort 1 : 3203 Cohort 2 : 3058 Cohort 3 : 62

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 141	24/09/2019	Dermatology	Atopic dermatitis	Not Applic	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Netherton patients	Cohort 1 : 3645
ICSPECIC 142	24/09/2019	Cardiovascular	Pulmonary arterial hypertension	Phase 3a	Award	ROR-PH-301	NCT03626688	EudraCT Numbe	TrialTroveID-305440	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: PAH Cohort 2: PAH (> 17) Cohort 3: PAH (> 17) with cardiac event Cohort 4: PAH (> 17) with cardiac event with stay > 2 with associated GHM	Cohort 1 : 43329 Cohort 2 : 42477 Cohort 3 : 27035 Cohort 4 : 25600
ICSPECIC 143	24/09/2019	Dermatology	Epidermolysis bullosa	Phase 3a	Award	D325AC00002	NCT04612790	Not Applicable	Not Applicable	A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Bullous pemphigoid Cohort 2 : Bullous pemphigoid (adults)	Cohort 1 : 3448 Cohort 2 : 3442
ICSPECIC 144	25/09/2019	Cardiovascular	Acute congestive heart failure	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Paroxysmal Tachycardia (All) Cohort 2: Supraventricular Tachycardia (All) Cohort 3: Supraventricular Tachycardia (Pediatrics) Cohort 4: Supraventricular Tachycardia (5-11) Cohort 5: Supraventricular Tachycardia (12-17)	Cohort 1 : 26942 Cohort 2 : 17600 Cohort 3 : 1448 Cohort 4 : 240 Cohort 5 : 543

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 145	25/09/2019	Dermatology	Atopic dermatitis	Phase 2	Award	D3256C00001	NCT04605094	EudraCT Numbe	TrialTroveID-387954	A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study With a 36-Week Extension to Investigate the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Despite Treatment With Topical Medications (The HILLIER Study)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Dermatitis (All) Cohort 2 : Dermatitis (Exclusion) Cohort 3 : Dermatitis (Exclusion,12-18) Cohort 4 : Dermatitis (Exclusion,18+) Cohort 5 : Dermatitis (Dupilumab) Cohort 6 : Dermatitis (Dupilumab, 12-18) Cohort 7 : Dermatitis (Dupilumab, 18+)	Cohort 1 : 6225 Cohort 2 : 5981 Cohort 3 : 381 Cohort 4 : 3825 Cohort 5 : 122 Cohort 6 : 13 Cohort 7 : 112
ICSPECIC 146	02/10/2019	Endocrinology	Diabetes mellitus	Phase 2	Lost	IMCY-T1D-003	NCT04524949	EudraCT Numbe	TrialTroveID-370661	A Phase IIa, Randomized, Double-blind Placebo-controlled, Dose Comparison, Multi-centre Adaptive Design Clinical Trial to Evaluate the Immune Signature of the Treatment With the Imotope IMCY-0098 and Its Effect on the Preservation of Beta-cell Function in Adult Patients With a Recent Onset Type 1 Diabetes	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Type 1 diabetes Cohort 2: Type 1 diabetes as principal diagnosis at admission Cohort 3: Type 1 diabetes as principal diagnosis at admission between july and decembe Cohort 4: Type 1 diabetes as principal diagnosisat admission between july and december (adults) Cohort 5: Type 1 diabetes as principal diagnosis at admission between july and december (adults) admitted via ER	Cohort 1 : 118214 Cohort 2 : 26546 Cohort 3 : 13391 Cohort 4 : 9878 Cohort 5 : 9259
ICSPECIC 147	02/10/2019	Rheumatology	Psoriatic arthritis	Phase 4	Lost	CR109043	NCT04929210	EudraCT Numbe	TrialTroveID-406822	A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naïve Participants With Active Psoriatic Arthritis Axial Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Psoriatic arthritis Cohort 2: Psoriatic arthritis (adults) Cohort 3: Psoriatic arthritis (adults) on secukinumab Cohort 4: Psoriatic arthritis (adults)on Ustelinumab Cohort 5: Psoriatic arthritis (adults)on both Ustelinumab and secukinumab	Cohort 1 : 5839 Cohort 2 : 5804 Cohort 3 : 89 Cohort 4 : 68 Cohort 5 : 11
ICSPECIC 148	03/10/2019	Other	Amyloidosis	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Neuropathic heredofamilial amyloidosis Cohort 2: Polyneuropathy in other endocrine and metabolic diseases Cohort 3: Polyneuropathy in other endocrine and metabolic diseases with Neuropathic heredofamilial amyloidosis Cohort 4: Polyneuropathy in other endocrine and metabolic diseases with Neuropathic heredofamilial amyloidosis aged between 18-75	Cohort 1 : 454 Cohort 2 : 141 Cohort 3 : 81 Cohort 4 : 69

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 149	03/10/2019	Infectious Disea	RSV	Phase 3a	Award	VAC18193RSV3	NCT04908683	EudraCT Numbe	TrialTroveID-405453	A Randomized, Double-blind, Placebo-controlled Phase III Efficacy study of an Ad26.RSV.preF-based vaccine in the prevention of Lower Respiratory Tract disease caused by RSV in adults aged 60 years and older	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Hospitalized Patients (65+) Cohort 2: Hospitalized Patients without major chronic affection (65+) Cohort 3: Potentially Healthy Hospitalized Patients without major chronic affection nor cancer nor COPD (65+) Cohort 4: Hospitalized Patients with RSV (65+)	Cohort 1 : 5170833 Cohort 2 : 4609288 Cohort 3 : 3236053 Cohort 4 : 3676
ICSPECIC 150	07/10/2019	Cardiovascular	Deep venous thrombosis	Phase 3	Award	DU176b-D-U31	NCT02798471	EudraCT Numbe	TrialTroveID-280481	A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: Pediatric Venous Thromboembolism	Cohort 1: 21586
ICSPECIC 151	07/10/2019	Gastrointestina	Ulcerative colitis	Phase 3a	Award	APD334-302	NCT03996369	EudraCT Numbe	TrialTroveID-335403	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Ulcerative colitis (All) Cohort 2: Ulcerative colitis without TB (all) Cohort 3: UC without tuberculosis/HCV (All) Cohort 4: UC without tuberculosis/HCV/HBV (All) Cohort 5: UC without tuberculosis/HCV/HBV/Cirrhosis (All) Cohort 6: UC without tuberculosis/HCV/HBV/Cirrhosis/Renal Disease/ (All) Cohort 7: UC without tuberculosis/HCV/HBV/Cirrhosis/Renal Disease/malignancy (All) Cohort 7: UC without tuberculosis/HCV/HBV/Cirrhosis/Renal Disease/malignancy (40 years old+)	Cohort 1 : 21475 Cohort 2 : 21437 Cohort 3 : 21382 Cohort 4 : 21355 Cohort 5 : 21151 Cohort 6 : 20032 Cohort 7 : 13828 Cohort 8 : 9592
ICSPECIC 152	07/10/2019	Oncology	Solid tumor configuration	Phase 1	Lost	MS201964_00	NCT03724890	Not Applicable	TrialTroveID-335803	A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: HNSC patients Cohort 2: HNSC adults patients Cohort 3: HNSC adults patients patients who have had surgery Cohort 4: HNSC adults patients who have had surgery, and radiotherapy and or chemotherapy Cohort 5: Metastatic HNSC adults patients have had radiotherapy and or chemotherapy	Cohort 1 : 69028 Cohort 2 : 68680 Cohort 3 : 5224 Cohort 4 : 3164 Cohort 5 : 1720

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 153	07/10/2019	Oncology	Malignant tumor of ovary	Phase 3b	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Endo/fallopian/ovarian cancer patients (All) Cohort 2 : Endo/fallopian/ovarian cancer patients in Chemotherapies (All) Cohort 3 : Metastatic Endo/fallopian/ovarian cancer patients in Chemotherapies (All) Cohort 4 : Stage II/IV Endo/fallopian/ovarian cancer patients in Chemotherapies (All) Cohort 5 : Stage II/IV Endo/fallopian/ovarian cancer patients (GHM only)	Cohort 1 : 290945 Cohort 2 : 41316 Cohort 3 : 25727 Cohort 4 : 5242 Cohort 5 : 20628
ICSPECIC 154	07/10/2019	Cardiovascular	Thromboembolism of vein	Phase 3a	Award	DU176b-D-U31	NCT02798471	EudraCT Numbe	TrialTroveID-280481	A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Venous Thromboembolism Cohort 2 : Venous Thromboembolism 2years and under Cohort 3 : Venous Thromboembolism 2years and under with central venous access	Cohort 1 : 30681 Cohort 2 : 344 Cohort 3 : 141
ICSPECIC 155	07/10/2019	Cardiovascular	Cardiovascular Disease	Phase 3a	Award	DU176b-C-U31	NCT03395639	EudraCT Numbe	TrialtroveID-316322	An Open-label, Randomised, Parallel-group, Multicentre, Observational Trial to Evaluate Safety and Efficacy of Edoxaban Tosylate in Children From 38 Weeks Gestational Age to Less Than 18 Years of Age With Cardiac Diseases at Risk of Thromboembolic Events	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : patients with heart failure Cohort 2 : patients with heart failure (adults)	Cohort 1 : 35734 Cohort 2 : 22251
ICSPECIC 156	09/10/2019	Oncology	Solid tumor configuration	Phase 1	Lost	SPK101JG	NCT04511845	Not Applicable	TrialTroveID-381883	A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Patients with Colo-rectal, Lung, Ovarian or Pancreatic Duct Cancer (all) Cohort 2: Patients with Colo-rectal, Lung, Ovarian or Pancreatic Duct Cancer (Treated with Cetuximab and/or Bevacizumab) Cohort 3: Patients with Colo-rectal, Lung, Ovarian or Pancreatic Duct Cancer (Treated with Cetuximab) Cohort 4: Patients with Colo-rectal, Lung, Ovarian or Pancreatic Duct Cancer (Treated with Bevacizumab) Cohort 5: Colo-rectal Cancer Patients (All) Cohort 6: Colo-rectal Cancer Patients (Treated with Cetuximab and/or Bevacizumab) Cohort 7: Colo-rectal Cancer Patients (Treated with Cetuximab) Cohort 8: Colo-rectal Cancer Patients (Treated with Bevacizumab) Cohort 9: Lung Cancer (All) Cohort 10: Lung Cancer (Treated with Cetuximab and/or Bevacizumab)	Cohort 1 : 289823 Cohort 2 : 24088 Cohort 3 : 3901 Cohort 4 : 20941 Cohort 5 : 134081 Cohort 6 : 15409 Cohort 7 : 3540 Cohort 8 : 12597 Cohort 9 : 133542 Cohort 10 : 4762 Cohort 11 : 399 Cohort 12 : 4407 Cohort 13 : 23842 Cohort 14 : 4183 Cohort 15 : 17 Cohort 16 : 4171 Cohort 17 : 543 Cohort 18 : 289823

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 157	09/10/2019	Oncology	Head and neck cancer	Phase 3	Award	19-070	NCT04128696	EudraCT Numbe	TrialTroveID-358224	A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Head and neck cancers Cohort 2 : Head and neck cancers with secondary and unspecified malignant neoplasm of lymph nodes Cohort 3 : Head and neck cancers with secondary and unspecified malignant neoplasm of lymph nodes excluding secondary malignant neoplasm of respiratory, digestive organs, other and unspecified sites Cohort 4 : Head and neck cancers with secondary and unspecified malignant neoplasm of lymph nodes excluding secondary malignant neoplasm of respiratory, digestive organs, other and unspecified sites including chemotherapy and radiotherapy	Cohort 1 : 54022 Cohort 2 : 14473 Cohort 3 : 9788 Cohort 4 : 7745
ICSPECIC 158	10/10/2019	Transplantation	Graft versus host disease	Phase 3a	Lost	BMTCTN1802	NCT04128319	Not Applicable	TrialTroveID-265639	An Open-Label, Single-Arm, Multicenter Study, of Combination Anti-CD3/CD7 Immunotoxin (T-Guard) for Steroid-Refractory Acute Graft-versus-Host Disease)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: BMT (All) Cohort 2: Allogenous HSCT (All) Cohort 3: Allogenous HSCT (Adults) Cohort 4: Allogenous HSCT with GvHD (Adults) Cohort 5: Allogenous HSCT with acute GvHD (Adults)	Cohort 1 : 9402 Cohort 2 : 4349 Cohort 3 : 3471 Cohort 4 : 1488 Cohort 5 : 629
ICSPECIC 159	10/10/2019	Hematology	Anemia	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: FOP patients	Cohort 1: 66
ICSPECIC 160	14/10/2019	Oncology	Malignant tumor of colon	Phase 1	Award	MEN1611-02 N	NCT04495621	EudraCT Numbe	TrialTroveID-374193	Open-label, Multicentre, Phase Ib/II Study of Men1611, A PI3K Inhibitor, and Cetuximab in Patients With PIK3CA Mutated Metastatic Colorectal Cancer Failing Irinotecan, Oxaliplatin, 5-FU and Anti-EGFR Containing Regimens	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Cancers Cohort 2: Colorectal cancer Cohort 3: Colorectal cancer (adults) Cohort 4: Metastatic colorectal cancer (adults) Cohort 5: Colorectal cancer (adults) with chemo	Cohort 1 : 1187725 Cohort 2 : 134081 Cohort 3 : 134034 Cohort 4 : 61106 Cohort 5 : 60737

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 161	14/10/2019	Oncology	Bladder cancer	Phase 2	Award	213152	NCT04349280	EudraCT Numbe	TrialTroveID-372105	A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Bladder cancer Cohort 2: Bladder cancer (adults) Cohort 3: Bladder cancer (adults) with chemotherapy Cohort 4: Metastatic Bladder cancer (adults) Cohort 5: Metastatic Bladder cancer (adults) with chemotherapy	Cohort 1 : 71155 Cohort 2 : 71093 Cohort 3 : 21479 Cohort 4 : 2012 Cohort 5 : 1115
ICSPECIC 162	14/10/2019	Hematology	Sickle cell disease	Phase 1	Lost	BO42452	NCT04912869	EudraCT Numbe	TrialTroveID-405616	A Phase IB Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : PNH (all) Cohort 2 : PNH(>17) Cohort 3 : PNH(>17) with Soliris Cohort 4 : Soliris all patients	Cohort 1 : 533 Cohort 2 : 525 Cohort 3 : 342 Cohort 4 : 744
ICSPECIC 163	16/10/2019	Women's Healt	Polycystic ovarian syndrome	Not Applic	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Polycystic ovarian syndrome Cohort 2: Polycystic ovarian syndrome (adults under 46) Cohort 3: Polycystic ovarian syndrome (adults under 46) without type1 diabetes Cohort 4: Polycystic ovarian syndrome (adults under 46) without type1 nor type2 diabetes	Cohort 1 : 2454 Cohort 2 : 2226 Cohort 3 : 2171 Cohort 4 : 2045
ICSPECIC 164	21/10/2019	Rheumatology	Osteoarthritis Knee Pain	Phase 2	Lost	Protocol CLR_1	NCT04506463	Not Applicable	TrialTroveID-381501	A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Single-administration, Multiple-Dose Study to Demonstrate the Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Osteoarthritis Cohort 2: Osteoarthritis aged 40 and above Cohort 3: Osteoarthritis aged 40 and above with injections in lower extremeties Cohort 4: Osteoarthritis aged 40 and above with the knee replacement	Cohort 1 : 145084 Cohort 2 : 143572 Cohort 3 : 3611 Cohort 4 : 9985

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 165	21/10/2019	Oncology	Solid tumor configuration	Phase 1	Award	Sym021-01	NCT03311412	Not Applicable	TrialTroveID-311031	A Phase I, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy and , in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3), and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Solid tumours Cohort 2 : Lung tumours Cohort 3 : Lung cancer (adults) with chemo Cohort 4 : Lung cancer (adults) with chemo and drugs Cohort 5 : Endometrial cancer adults Cohort 6 : Endometrial cancer adults with chemo Cohort 7 : Endometrial cancer adults with chemo with drugs Cohort 8 : Urothelial cancer adult Cohort 9 : Urothelial cancer adult with chemo Cohort 10 : Urothelial cancer adult with chemo on drugs Cohort 11 : Cholangiocarcinoma adults Cohort 12 : Cholangiocarcinoma adults on chemo Cohort 13 : Cholangiocarcinoma adults on chemo drugs	Cohort 1 : 208098 Cohort 2 : 133508 Cohort 3 : 79814 Cohort 4 : 20784 Cohort 5 : 16672 Cohort 6 : 6081 Cohort 7 : 49 Cohort 8 : 71083 Cohort 9 : 21478 Cohort 10 : 529 Cohort 11 : 11763 Cohort 12 : 5389 Cohort 13 : 31
ICSPECIC 166	24/10/2019	Pneumology	Lung cancer	Late Phase	Award	CA209-7HX	NCT04500535	Not Applicable	TrialTroveID-381159	A Multi-Center, Longitudinal, Prospective, Observational, Multi-Cohort Study of Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment (LIST, Lung Initiative on Sequence Therapy)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Sarah Harmand	MCO	2018	France	Cohort 1: patients treated with nivolumab Cohort 2: patients treated with chemotherapy Cohort 3: patient with Malignant neoplasm of bronchia and lung diagnosis (any treatment)	Cohort 1 : 11469 patient-site with nivolumab Cohort 2 : 63398 patient-site with chemotherapy Cohort 3 : 102828 patient-site with C34 diagnosis (any treatment)
ICSPECIC 167	29/10/2019	Respiratory	Bronchopulm dysplasia newborn	Phase 2	Award	AT-100/001	NCT04662151	Not Applicable	TrialTroveID-365093	A Phase 1b, Randomized, Open-Label, Dose-Determined Study Evaluating the Safety and Tolerability Profile of Intervention With AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: Pre-term Neonates (All) Cohort 2: Neonates with respiratory distress (All) Cohort 3: Pre-term Neonates with respiratory distress Cohort 4: Pre-term Neonates with confirmed Bronchopulmonay Dysplasia	Cohort 1 : 64893 Cohort 2 : 31397 Cohort 3 : 19594 Cohort 4 : 3063
ICSPECIC 168	29/10/2019	Infectious Disea	Acute hepatitis	Phase 3a	Award	EIG-LNF-011	NCT03719313	EudraCT Numbe	TrialTroveID-335560	A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Hepatitis B or D with Delta component Cohort 2: Hepatitis B or D with Delta component adults	Cohort 1 : 9465 Cohort 2 : 9280

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 169	29/10/2019	Neurology	Charcot Marie-Tooth	Phase 2	Lost	TBD	Not Applicable	Not Applicable	TrialTroveID-403590	A Prospective, Controlled Phase IIa Study of IFB-088 in Patients with Amyotrophic Lateral Sclerosis (ALS)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: Charcot Marie Tooth Disease Cohort 2: Charcot Marie Tooth Disease patients aged between 18 and 65 Cohort 3: Charcot Marie Tooth Disease patients aged between 18 and 65 with symptoms	Cohort 1: 2321 Cohort 2: 1136 Cohort 3: 238
ICSPECIC 170	31/10/2019	Oncology	Basal cell carcinoma	Phase 2	Award	INCA 0186-101	NCT04989387	Not Applicable	TrialTroveID-410452	A Phase I, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Non melanoma Skin tumors Cohort 2 : Neoplasm of uncertain behavior of skin (Basocellular Carcinoma)	Cohort 1 : 99299 Cohort 2 : 1618
ICSPECIC 171	07/11/2019	Neurology	Neuropathic pain	Phase 3a	Award	LESVIPREGA/20	Not Applicable	EudraCT Numbe	TrialTroveID-405668	A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Clinical Study to Evaluate Efficacy and Safety of the Once-Daily Extended-Release Pregabalin and the Immediate-Release Pregabalin in Peripheral Neuropathic Pain	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Diabetes with neurological complications Cohort 2 : Diabetes with neurological complications and diabetic polyneuropathy Cohort 3 : Type II Diabetes with neurological complications and diabetic polyneuropathy Cohort 4 : Zoster with other nervous system involvement	Cohort 1 : 44107 Cohort 2 : 26334 Cohort 3 : 23332 Cohort 4 : 1410
ICSPECIC 172	12/11/2019	Cardiovascular	Pulmonary hypertension	Phase 4	Award	mein/19/Zone-	NCT05257148	EudraCT Numbe	TrialTroveID-426072	Open-label, Multicenter, Multinational, Interventional Clinical Trial to Assess Effectiveness and SAfety of the Extemporaneous Combination of Nebivolol and Zofenopril Calcium in Grade 1 to 2 Hypertensive patIents Versus Each monotherapy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Hypertension Patients (All) Cohort 2 : Hypertension Patients (18-65) Cohort 3 : Hypertension Patients (18-65, ambulatory) Cohort 4 : Hypertension Patients (18-65, ambulatory, with exclusions) Cohort 5 : ATENOLOL (Hospital prescribed, retail delivered, PTD) Cohort 6 : ENALAPRIL (Hospital prescribed, retail delivered, PTD) Cohort 7 : Normalized patient count (treated Hypertension patients)	Cohort 1 : 1810474 Cohort 2 : 455116 Cohort 3 : 102002 Cohort 4 : 89322 Cohort 5 : 5075072 Cohort 6 : 4386471 Cohort 7 : 92364

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 173	12/11/2019	Gastrointestina	Esophagitis	Phase 2	Award	APD334-206	NCT04682639	EudraCT Numbe	TrialTroveID-370978	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : EOE Cohort 2 : EOE adults Cohort 3 : EOE and dysphagia adults	Cohort 1 : 82336 Cohort 2 : 73016 Cohort 3 : 126769
ICSPECIC 174	14/11/2019	Oncology	Non-small cell lung cancer	Phase 2	Award	MS200647_00(	NCT03840902	EudraCT Numbe	TrialTroveID-343483	A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Lung cancer Cohort 2: Lung cancer adult	Cohort 1 : 112941 Cohort 2 : 112918
ICSPECIC 175	14/11/2019	Gastrointestina	Crohn's disease	Phase 4	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Anal fistula Cohort 2: Anal abscess Cohort 3: Anal fistula and anal abscess Cohort 4: Anal fistula and anal abscess (adults) Cohort 5: Anal fistula and anal abscess (adults) with surgical procedures	Cohort 1 : 16846 Cohort 2 : 17716 Cohort 3 : 30921 Cohort 4 : 29776 Cohort 5 : 10702
ICSPECIC 176	14/11/2019	Oncology	Prostate Cancer	Phase 2	Award	ARC-6	NCT04381832	Not Applicable	TrialTroveID-368501	A Phase Ib/II, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : prostate cancer Cohort 2 : prostate cancer adults Cohort 3 : prostate cancer adult male Cohort 4 : metastatic prostate cancer adult male Cohort 5 : metastatic prostate cancer adult male on chemo	Cohort 1 : 110479 Cohort 2 : 110456 Cohort 3 : 110432 Cohort 4 : 26845 Cohort 5 : 11460

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 177	21/11/2019	Oncology	Peripheral T-cell lymphoma	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Angioblastic or UndefinedPeripheral T Cell Lymphoma Cohort 2: Angioblastic or UndefinedPeripheral T Cell Lymphoma (Adults) Cohort 3: Angioblastic or UndefinedPeripheral T Cell Lymphoma (Adults, With Chemotherapy)	Cohort 1 : 1767 Cohort 2 : 1754 Cohort 3 : 1315
ICSPECIC 178	21/11/2019	Women's Healt	Endometriosis (clinical)	Phase 2	Award	TUC3PII-01	NCT05138562	EudraCT Numbe	TrialTroveID-419651	A Phase IIa, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of Orally Administered TU2670 in Subjects with Mod to Severe Endometriosis-Associated Pain	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Endometriosis Cohort 2: Endometriosis 18-45 yr olds Cohort 3: Endometriosis 18-45 yr olds without oophorectomy and hysterectomy Cohort 4: Endometriosis 18-45 yr olds without oophorectomy, hysterectomy, pain Cohort 5: Endometriosis 18-45 yr olds without oophorectomy, hysterectomy, pain nor malignancies Cohort 6: Endometriosis 18-45 yr olds without oophorectomy, hysterectomy, pain nor malignancienor late stage kidney disease Cohort 7: Endometriosis 18-45 yr olds without oophorectomy, hysterectomy, pain nor malignancienor late stage kidney disease nor kidney disease Cohort 8: Endometriosis 18-45 yr olds without oophorectomy, hysterectomy, pain nor malignancienor late stage kidney disease nor kidney disease diagnosed with laparotomy and laparoscopy	Cohort 1 : 44861 Cohort 2 : 28206 Cohort 3 : 25223 Cohort 4 : 22055 Cohort 5 : 21875 Cohort 6 : 21869 Cohort 7 : 21804 Cohort 8 : 2548
ICSPECIC 179	22/11/2019	Dermatology	Skin ulcer	Phase 2	Lost	1368-0016	NCT04015518	EudraCT Numbe	TrialTroveID-353170	Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIb Dose-finding Study to Evaluate Safety and Efficacy of Different Subcutaneous Doses of BI 655130 in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: Palmoplantar Pustolosis	Cohort 1: 427
ICSPECIC 180	26/11/2019	Respiratory	Chronic Obstructive Respiratory Disorder	Not Applic	Lost	2020-03	NCT04742270	Not Applicable	Not Applicable	Feasibility of Implementing SIMEOX® Using Tele-physiotherapy and Evaluation of Compliance With SIMEOX® at Home for Bronchial Drainage in Patients With Bronchiectasis Other Than Cystic Fibrosis and Who Have Difficulties in Accessing Regular Respiratory Physiotherapy Sessions	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Bronchiectasis	Cohort 1 : 27077

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 181	26/11/2019	Oncology	Hepatocellular carcinoma	Phase 4	Lost	E7080-M000-5	NCT04763408	Not Applicable	TrialTroveID-397367	A Multicentre, Observational, Phase IV Study to Evaluate the Safety and Tolerability of Lenvatinib in Patients With Advanced or Unresectable Hepatocellular Carcinoma (STELLAR)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	cohort 1 : Hepatocellular carcinoma cohort 2 : Hepatocellular carcinoma (adults) cohort 3 : Hepatocellular carcinoma (adults) without chemo cohort 4 : Metastatic Hepatocellular carcinoma (adults)	cohort 1 : 21470 cohort 2 : 21437 cohort 3 : 18622 cohort 4 : 4879
ICSPECIC 182	27/11/2019	Infectious Disea	E. coli infection	Phase 3a	Lost	VAC52416BAC3	NCT04899336	EudraCT Numbe	TrialTroveID-404846	Randomized, double-blind, placebo-controlled, multicenter phase 3 study to assess the efficacy, safety and immunogenicity of vaccination with ExPEC9V in the prevention of invasive extraintestinal pathogenic Escherichia Coli disease in adults aged 60 years and older with a history of Urinary Tract Infection in the past 2 years	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	cohort 1 : UTI cohort 2 : UTI(60+) cohort 3 : Complicated UTI (60+) cohort 4 : Non-complicated UTI (60+) cohort 5 : E coli cohort 6 : E coli (60 years and above) cohort 7 : E coli (60 years and above) with prostatitis	cohort 1 : 432773 cohort 2 : 315161 cohort 3 : 254355 cohort 4 : 71850 cohort 5 : 327562 cohort 6 : 237994 cohort 7 : 24535
ICSPECIC 183	28/11/2019	Oncology	Bladder cancer	Not Applic	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Sarah Harmand	MCO	2017	France	Cohort 1: Malignant neoplasm of renal pelvis,ureter,bladder and of other and unspecified urinary organs diagnosis	Cohort 1 : 44645
ICSPECIC 184	04/12/2019	Oncology	Malignant tumor of breast	Phase 2	Award	B-PRECISE-01	NCT03767335	Not Applicable	Not Applicable	MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer (B-PRECISE-01)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: Breast cancer Cohort 2: HER2+ breast cancer	Cohort 1 : 134656 Cohort 2 : 31516

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 185	05/12/2019	Medical Genetic	Hyperarginininemia	Phase 3a	Award	CAEB1102-300	NCT03921541	Not Applicable	Not Applicable	PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Urea Cycle Disorder - including arginase deficiency (All) Cohort 2: Urea Cycle Disorder - including arginase deficiency (2 years old and older)	Cohort 1 : 1120 Cohort 2 : 1033
ICSPECIC 186	09/12/2019	Dermatology	Alopecia	Phase 3a	Pendin	CP543.5002	NCT05041803	EudraCT Numbe	Not Applicable	A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Alopecia areata Cohort 2: Alopecia areata (adults)	Cohort 1 : 1081 Cohort 2 : 914
ICSPECIC 187	09/12/2019	Neurology	Rett Syndrome	Phase 3	Lost	GWND18064	NCT03848832	EudraCT Numbe	TrialTroveID-338736	A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Rett's syndrome	Cohort 1 : 414
ICSPECIC 188	10/12/2019	Gastrointestina	Erosive esophagitis	Phase 2	Award	D9612C09998	Not Applicable	EudraCT Numbe	TrialTroveID-412684	A Phase III Study to Assess the Efficacy and Safety of Nexium for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Oesophagitis and/or GERD and/or Ulcerative Oesophagitis Cohort 2: Oesophagitis and/or GERD and/or Ulcerative Oesophagitis w/ endoscopy Cohort 3: Oesophagitis and/or GERD and/or Ulcerative Oesophagitis (<11) Cohort 4: Oesophagitis and/or GERD and/or Ulcerative Oesophagitis (<11) w/ endoscopy Cohort 5: Oesophagitis and/or GERD and/or Ulcerative Oesophagitis Cohort 6: Oesophagitis and/or GERD and/or Ulcerative Oesophagitis (<11)	Cohort 1 : 266832 Cohort 2 : 204491 Cohort 3 : 14458 Cohort 4 : 2123 Cohort 5 : 266832 Cohort 6 : 14458

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 189	13/12/2019	Cardiovascular	Hypercortisolism	Phase 2	Award	CLCI699C2203	NCT03708900	EudraCT Numbe	TrialTroveID-334654	A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : cushing syndrome Cohort 2 : cushing syndrome (6-18)	Cohort 1 : 1392 Cohort 2 : 40
ICSPECIC 190	16/12/2019	Oncology	Solid tumor configuration	Phase 1	Lost	RLY-4008-101	NCT04526106	Not Applicable	TrialTroveID-382784	A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Intrahepatic bile duct carcinoma (All) Cohort 2: Intrahepatic bile duct carcinoma (Chemo) Cohort 3: Malignant neoplasm of other and unspecified parts of biliary tract (All) Cohort 4: Malignant neoplasm of other and unspecified parts of biliary tract (Chemo) Cohort 5: Malignant neoplasm of endometrium (All) Cohort 6: Malignant neoplasm of endometrium (Chemo) Cohort 7: Liver cell carcinoma (All) Cohort 8: Liver cell carcinoma (Chemo) Cohort 9: Normalized_Patients Cohort 10: Bile Duct Cancer (C221) Cohort 11: Biliary Tract Cancer (C24) Cohort 12: Endometrial Cancer (C541) Cohort 13: Liver Cell Carcinoma (C220)	Cohort 1 : 6933 Cohort 2 : 3505 Cohort 3 : 5604 Cohort 4 : 2576 Cohort 5 : 16672 Cohort 6 : 6261 Cohort 7 : 21459 Cohort 8 : 3707 Cohort 9 : 4055 Cohort 10 : 6933 Cohort 11 : 5604 Cohort 12 : 16672 Cohort 13 : 21459
ICSPECIC 191	17/12/2019	Women's Healt	Cervical neoplasia	Phase 3a	Lost	YHGT-CEV-R1	NCT04484415	EudraCT Numbe	TrialTroveID-368013	A Double Blind, Prospective, Randomized, Placebo Controlled, Multi-center Phase 3 Study to Evaluate Efficacy and Safety of Cevira in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Patients undergoing Colposcopy and cervix - related procedures Cohort 2: Patients undergoing Colposcopy and cervix - related procedures without malignant tumors Cohort 3: Patients undergoing Colposcopy and cervix - related procedures without malignant tumors or cervical polyps Cohort 4: HSIL (Candidate) Cohort 5: Patients undergoing Colposcopy and cervix - related procedures without malignant tumors or cervical polyps with in situ cervix carcinomna Cohort 6: Patients undergoing Colposcopy and cervix - related procedures without malignant tumors or cervical polyps with HPV infection	Cohort 1 : 40207 Cohort 2 : 36211 Cohort 3 : 35724 Cohort 4 : 8957 Cohort 5 : 7076 Cohort 6 : 2373
ICSPECIC 192	17/12/2019	Dermatology	Psoriasis	Phase 3a	Award	SB17-3001	NCT04967508	EudraCT Numbe	TrialTroveID-407287	A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SB17 (proposed ustekinumab biosimilar) Compared to Stelara in Subjects with Moderate to Severe Plaque Psoriasis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Psoriasis Cohort 2 : Psoriasis vulgaris Cohort 3 : Psoriasis vulgaris adult Cohort 4 : Psoriasis vulgaris adult excluding overweight Cohort 5 : Severe Psoriasis vulgaris adult Cohort 6 : Severe psoriasis vulgaris adult excluding overweight	Cohort 1 : 21872 Cohort 2 : 4354 Cohort 3 : 4312 Cohort 4 : 3442 Cohort 5 : 1057 Cohort 6 : 853

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 193	27/12/2019	Immunology	Primary immunodeficiency	Phase 3	Lost	KB070	NCT04944979	Not Applicable	Not Applicable	A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Primary Immunodeficiency disease Cohort 2: Primary Immunodeficiency under 18 Cohort 3: Primary Immunodeficiency disease 2-17 yrs	Cohort 1 : 15960 Cohort 2 : 913 Cohort 3 : 777
ICSPECIC 194	02/01/2020	Rheumatology	Systemic sclerosis	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Systemic Sclerosis Cohort 2: Systemic Sclerosis (adults)	Cohort 1 : 6860 Cohort 2 : 5821
ICSPECIC 195	07/01/2020	Oncology	Nasopharingeal carcinoma	Phase 2	Lost	HLX10HLX07-0	NCT04297995	Not Applicable	TrialTroveID-363785	Evaluate the Efficacy and Safety of HLX10, PD-1 mAb, in Combination With HLX07, EGFR mAb, in Patients With Advanced Head And Neck Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Nasopharyngeal Carcinoma Cohort 2: Nasopharyngeal Carcinoma adults	Cohort 1 : 1952 Cohort 2 : 1905
ICSPECIC 196	09/01/2020	Endocrinology	Hypoparathyroidism	Phase 1	Lost	AZP-3601-CLI-0	NCT05239221	Not Applicable	Not Applicable	A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZP-3601, a Synthetic Parathyroid Hormone Analog, in Healthy Subjects and in Subjects With Hypoparathyroidism	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: Hypoparathyroidism Cohort 2: Hypoparathyroidism 18-75 years Cohort 3: Hypoparathyroidism 18-75 years with exclusions	Cohort 1: 1231 Cohort 2: 827 Cohort 3: 234

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 197	10/01/2020	Hematology	Thrombocytopenic disorder	Phase 3a	Award	281102	NCT03393975	Not Applicable	Not Applicable	A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: cTTP (all) Cohort 2: cTTP 0-5yrs old Cohort 3: cTTP 6-11yrs old	Cohort 1 : 1798 Cohort 2 : 17 Cohort 3 : 17
ICSPECIC 198	10/01/2020	Neurology	Alzheimer's disease	Phase 2	Lost	AH0003	NCT04867616	EudraCT Numbe	TrialTroveID-402936	A Patient and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Alzheimers Disease Cohort 2: Alzheimers disease among older persons (60 to 85yrs)	Cohort 1 : 51541 Cohort 2 : 25525
ICSPECIC 199	13/01/2020	Oncology	Malignant tumor of colon	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Colorectal cancer Cohort 2: Metastatic colorectal cancer Cohort 3: Metastatic colorectal cancer with chemotherapy Cohort 4: Metastatic Colorectal cancer with chemo and pembrolizumab and nivolumab	Cohort 1 : 133881 Cohort 2 : 62905 Cohort 3 : 45427 Cohort 4 : 363
ICSPECIC 200	13/01/2020	Hematology	Acute myeloid leukemia	Phase 1	Award	ASTX727-07	NCT04657081	Not Applicable	TrialTroveID-388275	A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination With Venetoclax in Adult Patients With Acute Myeloid Leukemia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Acute Myeloid Leukemia Cohort 2 : Acute Myeloid Leukemia (adults)	Cohort 1 : 11724 Cohort 2 : 11372

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 201	14/01/2020	Psychiatry	Major depressive disorder	Phase 3b	Lost	ACP-103-066	NCT03968159	Not Applicable	TrialTroveID-336284	A Randomized, Double-blind, Placebo-controlled, Phase III Study of Pimavanserin in Patients with Adjunctive Major Depressive Disorder	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Major depressive disorder Cohort 2: Major depressive disorder (18-55 years) Cohort 3: Major depressive disorder (18-55 years) with sexual dysfunction	Cohort 1 : 226715 Cohort 2 : 74137 Cohort 3 : 326
ICSPECIC 202	15/01/2020	Cardiovascular	Heart disease	Phase 1	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: All Autosomal recessive hypophosphatemic rickets Cohort 2: Autosomal recessive hypophosphatemic rickets adults Cohort 3: Autosomal recessive hypophosphatemic rickets children (5-12 years of age)	Cohort 1 : 14966 Cohort 2 : 13121 Cohort 3 : 381
ICSPECIC 203	15/01/2020	Gastrointestina	Postgastric surgery syndrome	Phase 3	Lost	HC-G-H-1504	NCT03278548	Not Applicable	Not Applicable	Prospective, Randomized, Controlled, Double-blind, Multi-centre, Multinational Study on the Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Traumatic shock, injured in morto-vehicle accident accident, hypovolemic shock Cohort 2: Traumatic shock, injured in morto-vehicle accident accident, hypovolemia patients (adults) Cohort 3: Traumatic shock, injured in morto-vehicle accident accident, hypovolemia patients (adults) without intracranial nor cerebral haemorrhage Cohort 4: Abdominal surgery Cohort 5: Traumatic shock, injured in morto-vehicle accident accident, hypovolemia patients (adults) without intracranial nor cerebral haemorrhage with elective surgery	Cohort 1 : 36253 Cohort 2 : 34036 Cohort 3 : 33346 Cohort 4 : 176209 Cohort 5 : 4573
ICSPECIC 204	15/01/2020	Acute Care	Traumatic injury	Phase 3b	Lost	HC-G-H-1505	NCT03338218	Not Applicable	Not Applicable	Pragmatic, Prospective, Randomized, Controlled, Double-blind, Multi-centre, Multinational Study on the Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma Patients	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Traumatic shock, injured in morto-vehicle accident Cohort 2: Traumatic shock, injured in morto-vehicle accident accident, hypovolemic shock Cohort 3: Traumatic shock, injured in morto-vehicle accident accident, hypovolemia patients (adults) Cohort 4: Traumatic shock, injured in morto-vehicle accident accident, hypovolemia patients (adults) without intracranial nor cerebral haemorrhage Cohort 5: Traumatic shock,injured in morto-vehicle accident accident, hypovolemia patients (adults) without intracranial nor cerebral haemorrhage with transfusion Cohort 6: Traumatic shock, injured in morto-vehicle accident accident, hypovolemia patients (adults) without intracranial nor cerebral haemorrhage with surgery	Cohort 1 : 4464 Cohort 2 : 36253 Cohort 3 : 34036 Cohort 4 : 33346 Cohort 5 : 3619 Cohort 6 : 2915

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 205	15/01/2020	Hematology	Blood coagulation disorder	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Births Cohort 2: Confirmed Pregnancies Cohort 3: High risk Pregnancies Cohort 4: Maternal care for positively tested iso-immunisation Rh Cohort 5: High risk pregancy with postively tested iso-immunization RhD	Cohort 1 : 569674 Cohort 2 : 220318 Cohort 3 : 211461 Cohort 4 : 10032 Cohort 5 : 2432
ICSPECIC 206	21/01/2020	Hematology	Chronic lymphocytic leukemia	Phase 2	Award	GCT3013-03	NCT04623541	EudraCT Numbe	TrialTroveID-384358	A Phase Ib/II, Open-label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: CLL (All) Cohort 2: CLL (Chemo) Cohort 3: Follicular Lymphoma (All) Cohort 4: Follicular Lymphoma (Chemo) Cohort 5: DLBCL (All) Cohort 6: DLBCL (Chemo) Cohort 7: CLL Cohort 8: FL Cohort 9: DLBCL	Cohort 1 : 14782 Cohort 2 : 6574 Cohort 3 : 10088 Cohort 4 : 7944 Cohort 5 : 14730 Cohort 6 : 12138 Cohort 7 : 14782 Cohort 8 : 10088 Cohort 9 : 14730
ICSPECIC 207	21/01/2020	Immunology	Autoimmune disease	Phase 1	Lost	AEVI-007-AOSD	NCT04752371	Not Applicable	Not Applicable	A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AEVI-007 in Subjects With Adult Onset Still's Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Still Disease with Adult Onset (18-75) Cohort 2: Still Disease with Adult Onset treated with Infliximab/Golimumab/Abatacept/Tociluzumab / Rituximab (18-75)	Cohort 1 : 725 Cohort 2 : 183
ICSPECIC 208	21/01/2020	Ophthalmology	Retinitis pigmentosa	Phase 3a	Lost	MGT-RPGR-021	NCT04671433	EudraCT Numbe	TrialTroveID-392122	Phase 3 Randomized, Controlled Study of AAV5-RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Hereditary retinal dystrophy (All) Cohort 2: Hereditary retinal dystrophy (5-85 years old) Cohort 3: Male Hereditary retinal dystrophy (5-85 years old)	Cohort 1 : 732 Cohort 2 : 630 Cohort 3 : 316

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 209	21/01/2020	Rheumatology	Lupus erythematosus	Phase 3	Award	230LE301	Not Applicable	EudraCT Numbe	Not Applicable	A Phase 3 Placebo-Controlled Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute and Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Cutaneous Lupus Erythematosus Cohort 2 : Cutaneous Lupus Erythematosus adults	Cohort 1 : 3567 Cohort 2 : 3497
ICSPECIC 210	21/01/2020	Infectious Disea	Diphtheria	Phase 4	Award	212645	NCT04535037	EudraCT Numbe	TrialTroveID-383425	A Phase IV, Single-blind, Randomised, Controlled, Multi-country Study to Evaluate the Immunogenicity and Safety of GSK's Infanrix Hexa (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis (DTaP5-HBV-IPV Hib), When Administered Intramuscularly According to a 2-, 4- and 12-month Schedule in Healthy Infants and Toddlers	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Infanrix Hexa Cohort 2: Vaxelis	Cohort 1: 44168 Cohort 2: 1318
ICSPECIC 211	22/01/2020	Other	Amyloidosis	Phase 2	Award	CAEL101-203	NCT04304144	Not Applicable	TrialTroveID-369567	CAEL101-203: A Phase 2, Open-label, Multicenter Dose Selection Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Other amyloidosis and unspecified amyloidosis Cohort 2: Other amyloidosis Cohort 3: Other amyloidosis with heart involvement	Cohort 1 : 1934 Cohort 2 : 916 Cohort 3 : 99
ICSPECIC 212	22/01/2020	Infectious Disea	RSV	Phase 3a	Award	483-20-CB	NCT03959488	EudraCT Numbe	TrialTroveID-285340	A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY) A study to assess the effect of MEDI8897 in the Synagis population	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Preterm babies (between 30 and 35 GA) Cohort 2 : Preterm babies (between 30 and 35 GA) with RSV Cohort 3 : CHD/CLD patients (All) Cohort 4 : CHD/CLD patients (< 5 years old) Cohort 5 : CHD/CLD patients with RSV Cohort 6 : RSV patients (All) Cohort 7 : RSV patients (< 5 years old) Cohort 8 : RSV patients (6 month-2 years old) Cohort 9 : RSV patients (< 6 months) Cohort 10 : RSV patients (< 3 months) Cohort 11 : RSV patients (< 6 months) & Preterm babies	Cohort 1 : 10293 Cohort 2 : 250 Cohort 3 : 6255 Cohort 4 : 4642 Cohort 5 : 177 Cohort 6 : 12252 Cohort 7 : 10974 Cohort 8 : 2832 Cohort 9 : 7941 Cohort 10 : 7174 Cohort 11 : 18234

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 213	22/01/2020	Other	Amyloidosis	Phase 3	Award	CAEL101-302	NCT04512235	EudraCT Numbe	TrialTroveID-381872	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naive Patients With Mayo Stage IIIa AL Amyloidosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : AL Amyloidosis adults Cohort 2 : AL Amyloidosis with heart failure adults Cohort 3 : AL Amyloidosis with heart failure adults with ECG Cohort 4 : AL Amyloidosis with heart failure adults with ECG excluding SCT, Daratumumab, MM and congenital heart disease	Cohort 1 : 6305 Cohort 2 : 2863 Cohort 3 : 2614 Cohort 4 : 2188
ICSPECIC 214	24/01/2020	Oncology	Malignant tumor of prostate	Phase 3a	Award	PRONOUNCE	NCT02663908	EudraCT Numbe	TrialTroveID-271956	A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) (PRONOUNCE)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : Newly diagnosed adenocarcinoma of the prostate. Cohort 2 : Treatment-naïve with regard to ADT Cohort 3 : Pre-existing CVD Cohort 4 : Previous or current hormonal management of prostate cancer	Cohort 1 : 196893 Cohort 2 : 179423 Cohort 3 : 127483 Cohort 4 : 117058
ICSPECIC 215	27/01/2020	Hematology	Non-Hodgkin lymphoma	Phase 1	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: CLL/MCL Cohort 2: CLL Cohort 3: MCL	Cohort 1 : 18285 Cohort 2 : 14782 Cohort 3 : 3549
ICSPECIC 216	03/02/2020	Oncology	Non-small cell lung cancer	Phase 3a	Lost	4020-02-001	NCT04655976	EudraCT Numbe	TrialTroveID-391136	A Randomized, Open Label Phase II/III Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Nonsmall Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Lung Cancer (All) Cohort 2: Metastatic Lung Cancer (All) Cohort 3: Metastatic Lung Cancer (treated with Nivolu/Pembrolizu/Adelimu-mab) Cohort 4: Metastatic Lung Cancer (treated with Pembrolizumab) Cohort 5: Lung Cancer (treated with Nivolu/Pembrolizu/Adelimu-mab) Cohort 6: Lung Cancer (treated with Pembrolizumab) Cohort 7: All Cohort 8: Nivolu/Pembrolizu/Adelimu-mab Cohort 9: Pembrolizumab)	Cohort 1 : 133542 Cohort 2 : 83524 Cohort 3 : 16604 Cohort 4 : 6310 Cohort 5 : 21112 Cohort 6 : 7755 Cohort 7 : 133542 Cohort 8 : 21112 Cohort 9 : 7755

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 217	03/02/2020	Neurology	Epilepsy	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Epilepsy Cohort 2: Epilepsy 18-75 yrs old Cohort 3: Epilepsy with Focal seizures 18-75 yrs old	Cohort 1 : 136618 Cohort 2 : 85401 Cohort 3 : 1586
ICSPECIC 218	03/02/2020	Oncology	Non-small cell lung cancer	Phase 2	Lost	213403	NCT04581824	EudraCT Numbe	TrialTroveID-386635	A Randomized, Phase II, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Lung Cancer (All) Cohort 2 : Metastatic Lung Cancer Cohort 3 : Metastatic Lung Cancer (treated with Nivolu/Pembrolizu/Adelimu-mab) Cohort 4 : Metastatic Lung Cancer (treated with Pembrolizumab) Cohort 5 : Lung Cancer (treated with Nivolu/Pembrolizu/Adelimu-mab) Cohort 6 : Lung Cancer (treated with Pembrolizumab)	Cohort 1 : 133542 Cohort 2 : 83524 Cohort 3 : 16604 Cohort 4 : 6310 Cohort 5 : 21112 Cohort 6 : 7755
ICSPECIC 219	03/02/2020	Oncology	Non-small cell lung cancer	Phase 3a	Lost	3000-03-001	Not Applicable	Not Applicable	TrialTroveID-298868	A Phase III Study to Evaluate Niraparib in Combination with Anti-PD-1 Antibody in Comparison to Anti-PD-1 Alone in Patients with Advanced Non Small Cell Lung Cancer with High Levels of PDL-1 Tumor Expression	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Lung Cancer (All) Cohort 2 : Metastatic Lung Cancer Cohort 3 : Metastatic Lung Cancer (treated with Nivolu/Pembrolizu/Adelimu-mab) Cohort 4 : Metastatic Lung Cancer (treated with Pembrolizumab) Cohort 5 : Lung Cancer (treated with Nivolu/Pembrolizu/Adelimu-mab) Cohort 6 : Lung Cancer (treated with Pembrolizumab)	Cohort 1 : 133542 Cohort 2 : 83524 Cohort 3 : 16604 Cohort 4 : 6310 Cohort 5 : 21112 Cohort 6 : 7755
ICSPECIC 220	04/02/2020	Orthopedics	Degenerative disc disease	Phase 3	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Non-cervical Disk Degeneration Cohort 2: Non-cervical Disk Degeneration with Low Back Pain Cohort 3: Low Back Pain Patients	Cohort 1 : 2294 Cohort 2 : 380 Cohort 3 : 43992

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 221	04/02/2020	Nephrology	IgA nephropathy	Phase 3	Award	CHK01-01	NCT04573478	EudraCT Numbe	TrialTroveID-386004	A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Recurrent Haematuria without major glomerular affection (All) Cohort 2 : Recurrent Haematuria without major glomerular affection (18+) Cohort 3 : Recurrent Haematuria without major glomerular affection without Stage IV/V CKD (18+) Cohort 4 : Recurrent Haematuria without major glomerular affection without Stage IV/V CKD nor Dialysis (18+)	Cohort 1 : 1285 Cohort 2 : 1258 Cohort 3 : 1066 Cohort 4 : 1062
ICSPECIC 222	06/02/2020	Oncology	Non-small cell lung cancer	Phase 3	Award	MS200647_004	NCT03631706	EudraCT Numbe	TrialTroveID-330527	An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Lung cancer Cohort 2: NSCLC Cohort 3: NSCLC adults Cohort 4: NSCLC adults with chemo	Cohort 1 : 133328 Cohort 2 : 113378 Cohort 3 : 113348 Cohort 4 : 68653
ICSPECIC 223	06/02/2020	Oncology	Head and neck cancer	Phase 2	Lost	MS200647_003	NCT04428047	EudraCT Numbe	TrialTroveID-376812	A Phase II Trial Assessing Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-ß and PD-L1, in a Pre-operative Setting for Resectable and Untreated Head and Neck Squamous Cell Carcinoma.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : HNSC patients Cohort 2 : HNSC adults patients Cohort 3 : HNSC adults patients patients who have had surgery Cohort 4 : HNSC adults patients who have had surgery, and radiotherapy and or chemotherapy Cohort 5 : Metastatic HNSC adults patients have had radiotherapy and or chemotherapy	Cohort 1 : 69028 Cohort 2 : 68680 Cohort 3 : 5224 Cohort 4 : 3164 Cohort 5 : 1720
ICSPECIC 224	10/02/2020	Cardiovascular	Hyperlipidemia	Phase 3	Lost	ISIS304801-CS2	Not Applicable	EudraCT Numbe	TrialTroveID-273547	An Open-Label Study of Volanesorsen (ISIS 304801) Administered Subcutaneously to Pediatric Patients with Familial Chylomicronemia Syndrome (FCS)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Chylomicronemia Syndrome Cohort 2: Chylomicronemia Syndrome paediatric	Cohort 1 : 388 Cohort 2 : 2

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 225	11/02/2020	Nephrology	Kidney disease	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : Membranous Nephropathy	Cohort 1 : 1433
ICSPECIC 226	13/02/2020	Oncology	Metastatic cancer	Phase 1	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Pancreatic Cancer Patients (All) Cohort 2: Pancreatic Cancer Patients with internal irradiation (All) Cohort 3: Internal irradiation procedures (All)	Cohort 1 : 40962 Cohort 2 : 121 Cohort 3 : 325
ICSPECIC 227	14/02/2020	Gastrointestina	Crohn's disease	Phase 3a	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Patients with Anal Fistulas (All) Cohort 2: Patients with Anal Fistulas (18/75) Cohort 3: Patients with Anal Fistulas (18/75) With procedure	Cohort 1 : 52892 Cohort 2 : 47752 Cohort 3 : 33133
ICSPECIC 228	18/02/2020	Oncology	Carcinoma of biliary tract	Phase 3	Award	MS200647_005	NCT04066491	EudraCT Numbe	TrialTroveID-355937	A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: BTC (all) Cohort 2: BTC (adults) Cohort 3: Cohort 2-BTC (adults) without PDL Cohort 4: Cohort 1-BTC (adults) without PD1 nor chemo nor immunotherapy Cohort 5: BTC (adults) without chemo nor immunotherapy Cohort 6: Cohort 3-BTC (adults) with checkpoint inhibitors Cohort 7: Cohort 4- Pembrolizumab	Cohort 1 : 13045 Cohort 2 : 13033 Cohort 3 : 12998 Cohort 4 : 6938 Cohort 5 : 6938 Cohort 6 : 35 Cohort 7 : 7779

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 229	18/02/2020	Psychiatry	Major depressive disorder	Phase 3a	Award	42847922MDD	NCT04532749	EudraCT Numbe	TrialTroveID-383335	A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	cohort 1 : MDD without psychotic features cohort 2 : MDD without psychotic features 18-74yrs old cohort 3 : MDD without psychotic features 18-74yrs old without CVD cohort 4 : MDD without psychotic features 18-74yrs old without CVD without epilepsy/ sleep apnea/ narcolepsy/ bipolar disorder cohort 5 : MDD without psychotic features 18-74yrs old without CVD nor epilepsy/ sleep apnea/ narcolepsy/ bipolar disorder nor substance abuse/suicide attempts	cohort 1 : 48583 cohort 2 : 32562 cohort 3 : 28043 cohort 4 : 24909 cohort 5 : 12101
ICSPECIC 230	18/02/2020	Psychiatry	Major depressive disorder	Phase 3a	Award	42847922MDD	NCT04532749	EudraCT Numbe	TrialTroveID-383335	A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	cohort 1 : MDD without psychotic features cohort 2 : MDD without psychotic features 18-74yrs old cohort 3 : MDD without psychotic features 18-74yrs old without CVD cohort 4 : MDD without psychotic features 18-74yrs old without CVD without epilepsy/ sleep apnea/ narcolepsy/ bipolar disorder cohort 5 : MDD without psychotic features 18-74yrs old without CVD nor epilepsy/ sleep apnea/ narcolepsy/ bipolar disorder nor substance abuse/suicide attempts	cohort 1 : 48583 cohort 2 : 32562 cohort 3 : 28043 cohort 4 : 24909 cohort 5 : 12101
ICSPECIC 231	18/02/2020	Psychiatry	Major depressive disorder	Phase 3a	Award	42847922MDD	NCT04513912	EudraCT Numbe	TrialTroveID-381968	Double-Blind, Randomized, Parallel-Group Study With Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	joy Seanehia	MCO	2018	France	cohort 1 : MDD without psychotic features cohort 2 : MDD without psychotic features 18-74yrs old cohort 3 : MDD without psychotic features 18-74yrs old without CVD cohort 4 : MDD without psychotic features 18-74yrs old without CVD without epilepsy/ sleep apnea/ narcolepsy/ bipolar disorder cohort 5 : MDD without psychotic features 18-74yrs old without CVD nor epilepsy/ sleep apnea/ narcolepsy/ bipolar disorder nor substance abuse/suicide attempts	cohort 1 : 48583 cohort 2 : 32562 cohort 3 : 28043 cohort 4 : 24909 cohort 5 : 12101
ICSPECIC 232	19/02/2020	Neurology	Epilepsy	Phase 2	Lost	PTC743-MIT-00	NCT04378075	EudraCT Numbe	TrialTroveID-373982	Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects with Refractory Epilepsy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Specified Metabolic Disorder including Mitochondrial Disorder (All) Cohort 2: Specified Metabolic Disorder including Mitochondrial Disorder with Epilepy (All) Cohort 3: Specified Metabolic Disorder including Mitochondrial Disorder with Epilepy (Pediatrics)	Cohort 1 : 1812 Cohort 2 : 117 Cohort 3 : 53

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 233	19/02/2020	Oncology	Solid tumor configuration	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Female adults with ovarian cancer Cohort 2: Female adults with ovarian cancer with chemo Cohort 3: Female adults with ovarian cancer with avastin (Bevacizumab)	Cohort 1 : 25294 Cohort 2 : 19610 Cohort 3 : 4726
ICSPECIC 234	20/02/2020	Cardiology	Heart failure	Late Phase	Awarde	CARDIO HF	Not applicable	Not applicable	Not applicable	Not applicable	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Sarah Harmand	MCO	2018	France	Cohort 1:Heart failure diagnosis	Cohort 1 : 208161
ICSPECIC 235	21/02/2020	Oncology	Malignant Melanoma	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Melanoma Patient (All) Cohort 2: Melanoma Patient (18+) Cohort 3: Melanoma Patient (18+) as primary reasons for care Cohort 4: Melanoma Patient (18+) as primary reasons for care With surgeries Cohort 5: Melanoma Patient (18+) as primary reasons for care With surgeries Without Chemo	Cohort 1 : 20174 Cohort 2 : 20148 Cohort 3 : 15548 Cohort 4 : 13608 Cohort 5 : 9595
ICSPECIC 236	21/02/2020	Neurology	Multiple sclerosis	Phase 4	Lost	109MS402	NCT01911767	Not Applicable	TrialTroveID-191232	Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Multiple Sclerosis Patients (All) Cohort 2: Multiple Sclerosis Patients (Women) Cohort 3: Multiple Sclerosis Patients (Women between 18-45 years old)	Cohort 1 : 39161 Cohort 2 : 27299 Cohort 3 : 11130

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 237	21/02/2020	Oncology	Glioblastoma multiforme	Phase 2	Award	GBM AGILE	NCT03970447	Not Applicable	TrialTroveID-268904	GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM. Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE).	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Glioblastoma Cohort 2 : Glioblastoma (adults)	Cohort 1 : 21428 Cohort 2 : 19657
ICSPECIC 238	24/02/2020	Infectious Disea	HPV infection	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Hospitalised 16-26year old females Cohort 2: Hospitalised 16-26year old females without cervical cancer and other HPV related symptoms Cohort 3: According to vaccine coverage in 2018 (23%) hospitalised 16-26yr olds Cohort 4: Potential to vaccinate based on 2018 coverage among hospitalised 16-26yr olds(77%) Cohort 5: Gardasil 9 hospital prescription covering August to December (Units)	Cohort 1 : 610709 Cohort 2 : 601000 Cohort 3 : 140463 Cohort 4 : 470261 Cohort 5 : 733.9303
ICSPECIC 239	26/02/2020	Dermatology	Vitiligo	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Vitiligo Patients (All) Cohort 2: Vitiligo Patients (18+) Cohort 3: Total Phototherapy Procedures Cohort 4: Total Skin Graft / Melanocytes Transfer Procedures	Cohort 1 : 1358 Cohort 2 : 1308 Cohort 3 : 415 Cohort 4 : 19608
ICSPECIC 240	26/02/2020	Oncology	Neuroendocrine tumor	Phase 2	Award	CAAA601A322	NCT04711135	EudraCT Numbe	TrialTroveID-393092	A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Adolescents diagnosed with NET Cohort 2 : Patients diagnosed with Malignant Neuroendocrine tumors (NET) and age between 18 and 85 Cohort 3 : Patients diagnosed with Malignant Neuroendocrine tumors (NET) and age between 18 and 85 and received LUTATHERA	Cohort 1 : 75 Cohort 2 : 8548 Cohort 3 : 275

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 241	27/02/2020	Medical Genetic	Rett's disorder	Phase 2	Lost	ACP-2566-009	NCT04988867	Not Applicable	TrialTroveID-410469	An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : All Retts Cohort 2 : Pediatric Retts Cohort 3 : 2-5 years old Retts patients	Cohort 1 : 415 Cohort 2 : 273 Cohort 3 : 39
ICSPECIC 242	28/02/2020	Dermatology	Urticaria	Phase 2	Awarde	D3256C00001	NCT04605094	EudraCT Numbe	TrialTroveID-387954	A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study With a 36-Week Extension to Investigate the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Despite Treatment With Topical Medications (The HILLIER Study)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Urticary (All) Cohort 2 : Chronic Idiopathic Urticary (All) Cohort 3 : Chronic Idiopathic Urticary (Adults 18-75 Years old) Cohort 4 : Chronic Idiopathic Urticary (Pediatrics 12-18 years old)	Cohort 1 : 8666 Cohort 2 : 1718 Cohort 3 : 1218 Cohort 4 : 41
ICSPECIC 243	02/03/2020	Neurology	Ischemic stroke	Phase 3a	Awarde	252LH301	NCT02864953	EudraCT Numbe	TrialTroveID-273452	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Ischemic stroke (18-70 year olds) Cohort 2 : Ischemic stroke (18-70) with thromboectomy Cohort 3 : Ischemic stroke (18-70) with thromboectomy with plasminogen	Cohort 1 : 62513 Cohort 2 : 4537 Cohort 3 : 258
ICSPECIC 244	04/03/2020	Oncology	Malignant tumor of colon	Phase 3a	Awarde	G1T28-207	NCT04607668	EudraCT Numbe	TrialTroveID-358308	PRESERVE 1: A Phase III Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Colo-rectal Cancer Patients (All) Cohort 2 : Metastatic Colo-rectal Cancer Patients (All) Cohort 3 : Metastatic Colo-rectal Cancer Patients with chemotherapy side effects (All) Cohort 4 : Metastatic Colo-rectal Cancer Patients with chemotherapy induced medullary aplasia (All) Cohort 5 : Metastatic Colo-rectal Cancer Patients with blood transfusion (All) Cohort 6 : Metastatic Colo-rectal Cancer Patients with chemotherapy induced medullary aplasia and blood transfusion (All)	Cohort 1 : 134080 Cohort 2 : 63005 Cohort 3 : 5488 Cohort 4 : 1573 Cohort 5 : 1008 Cohort 6 : 173

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 245	05/03/2020	Psychiatry	Major depressive disorder	Phase 3a	Award	42847922MDD	NCT04533529	EudraCT Numbe	TrialTroveID-383318	A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy and an Open-labeled Long-term Safety Extension Treatment With Seltorexant	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	cohort 1 : MDD without psychotic features cohort 2 : MDD without psychotic features 18-74yrs old cohort 3 : MDD without psychotic features 18-74yrs old without CVD cohort 4 : MDD without psychotic features 18-74yrs old without CVD without epilepsy/ sleep apnea/ narcolepsy/ bipolar disorder cohort 5 : MDD without psychotic features 18-74yrs old without CVD nor epilepsy/ sleep apnea/ narcolepsy/ bipolar disorder nor substance abuse/suicide attempts	cohort 1 : 48583 cohort 2 : 32562 cohort 3 : 28043 cohort 4 : 24909 cohort 5 : 12101
ICSPECIC 246	09/03/2020	Hematology	Waldenstrom macroglobulinemia	Phase 1	Lost	APG2575WU10	NCT04260217	Not Applicable	TrialTroveID-361219	A Phase Ib /II Open-label, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Waldenstrom Macroglobulinemia Patients (18+)	Cohort 1 : 4699
ICSPECIC 247	10/03/2020	Cardiovascular	Peripheral vascular disease	Phase 2	Award	CYP-CLI-P2-01	Not Applicable	EudraCT Numbe	TrialTroveID-330748	A Randomised, Double-blind, Placebo-controlled Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of CYP-002 in Adults with Critical Limb Ischaemia who are Unsuitable for Revascularisation	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Peripheral Vascular Disease (All) Cohort 2: Peripheral Vascular Disease and Limb Ischemia (All) Cohort 3: Peripheral Vascular Disease and Limb Ischemia (45+)	Cohort 1 : 4229 Cohort 2 : 923 Cohort 3 : 877
ICSPECIC 248	10/03/2020	Infectious Disea	Influenza	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Influenza patients (All) Cohort 2: Influenza patients (18/80)	Cohort 1 : 46234 Cohort 2 : 23649

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 249	10/03/2020	Respiratory	Sarcoidosis	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Pulmonary Sarcoidosis	Cohort 1 : 6500
ICSPECIC 250	10/03/2020	Oncology	Solid tumor configuration	Phase 1	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Breast cancer adults Cohort 2 : Breast cancer adults without infectious diseases nor cardiovascular dysfuntion Cohort 3 : Triple negative Breast cancer adults without infectious diseases nor cardiovascular dysfuntion (15% of breast cancer) Cohort 4 : Breast cancer adults not on trastuzumab,pertuzumab without infectious diseases nor cardiovascular dysfuntion Cohort 5 : Breast cancer adults not on trastuzumab,pertuzumab without infectious diseases nor cardiovascular dysfuntion (/5.95) corrected to expected national prevalence Cohort 6 : Lung cancer adult Cohort 7 : lung cancer adults without infectious diseases nor severe cardiac dysfunction Cohort 8 : NSCLC adults without infectious diseases nor severe cardiac dysfunction (85%of lung cancer) Cohort 9 : Ovarian cancer adults	Cohort 1 : 170530 Cohort 2 : 153244 Cohort 3 : 22986 Cohort 4 : 136674 Cohort 5 : 22991 Cohort 6 : 133151 Cohort 7 : 94033 Cohort 8 : 79969 Cohort 9 : 23696 Cohort 10 : 20143 Cohort 11 : 123098
ICSPECIC 251	11/03/2020	Rheumatology	Rheumatoid arthritis	Phase 3a	Award	201790	NCT03980483	EudraCT Numbe	TrialTroveID-341094	A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Rhumatoid arthritis patients	Cohort 1 : 29898
ICSPECIC 252	11/03/2020	Dermatology	Hidradenitis Suppurativa	Phase 2	Award	I7P-MC-DSAD	NCT04493502	Not Applicable	TrialTroveID-380730	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Hidradenitis_Suppurativa Cohort 2 : Hidradenitis_Suppurativa (adults) Cohort 3 : Hidradenitis_Suppurativa (adults) without IBD, HIV,HBV, HCV Cohort 4 : Hidradenitis_Suppurativa (adults) without IBD, HIV,HBV, HCV without biologics Cohort 5 : Hidradenitis_Suppurativa (adults) without IBD, HIV,HBV, HCV with biologics	Cohort 1 : 5974 Cohort 2 : 5804 Cohort 3 : 5645 Cohort 4 : 5357 Cohort 5 : 288

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 253	17/03/2020	Oncology	Neoplasm of biliary tract	Phase 2	Award	MS200647_005	NCT04066491	EudraCT Numbe	TrialTroveID-355937	A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: BTC (all) Cohort 2: BTC (adults) Cohort 3: Cohort 2-BTC (adults) without PDL Cohort 4: Cohort 1-BTC (adults) without PD1 nor chemo nor immunotherapy Cohort 5: BTC (adults) without chemo nor immunotherapy Cohort 6: Cohort 3-BTC (adults) with checkpoint inhibitors Cohort 7: Cohort 4-BTC (adults) with pembrolizumab	Cohort 1 : 13063 Cohort 2 : 13051 Cohort 3 : 13016 Cohort 4 : 6947 Cohort 5 : 6947 Cohort 6 : 35 Cohort 7 : 7779
ICSPECIC 254	24/03/2020	Hematology	Sickle cell disease	Phase 1	Lost	EM-SCD-301-0(	NCT04853576	Not Applicable	TrialTroveID-382731	A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Sickle Cell Disease (All) Cohort 2 : Sickle Cell Disease (12-50 Years old) Cohort 3 : Autologous Bone Marrow Transplant (Total Procedures) Cohort 4 : Allogenous Bone Marrow Transplant (Total Procedures)	Cohort 1 : 16224 Cohort 2 : 10769 Cohort 3 : 3433 Cohort 4 : 4273
ICSPECIC 255	24/03/2020	Neurology	Huntington's chorea	Not Applic	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2015-2018	France	Cohort 1 : Hungtington Patients (Diagnosed since 2015) Cohort 2 : Hungtington Patients (Total Seen in 2018) Cohort 3 : Hungtington Patients (Diagnosed in 2018) Cohort 4 : Cranial Stereotaxic Surgery (Implant, Biopsy)	Cohort 1 : 3736 Cohort 2 : 1626 Cohort 3 : 206 Cohort 4 : 2790
ICSPECIC 256	25/03/2020	Dermatology	Urticaria	Phase 3a	Award	CT-P39 3.1	NCT04426890	EudraCT Numbe	TrialTroveID-376947	A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Urticaria (all) Cohort 2 : Urticaria (12-75 years old) Cohort 3 : Idiopathic Urticaria (all) Cohort 4 : Idiopathic Urticaria (12-75 years old) Cohort 5 : Idiopathic Urticaria without autoimmune diseases (12-75 years old)	Cohort 1 : 15585 Cohort 2 : 10360 Cohort 3 : 619 Cohort 4 : 433 Cohort 5 : 386

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 257	26/03/2020	Medical Genetic	Rett's disorder	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : All Retts Cohort 2 : Pediatric Retts Cohort 3 : 2-5 years old Retts patients	Cohort 1 : 415 Cohort 2 : 273 Cohort 3 : 39
ICSPECIC 258	30/03/2020	Cardiovascular	Coronary artery stenosis	Not Applic	Award	cVAD	NCT04136392	Not Applicable	Not Applicable	The Global cVAD Study	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Heart Condition History (Myocardial infraction, Chronic Ischemic Disease, Heart Failure) Cohort 2: Heart Condition History with Ventricular Assist Device (All) Cohort 3: Heart Condition History with Ventricular Assist Device (18-85) Cohort 4: Absolute count for Ventricular Assist Device procedures (18-85)	Cohort 1 : 855314 Cohort 2 : 2454 Cohort 3 : 2454 Cohort 4 : 2976
ICSPECIC 259	31/03/2020	Hematology	von Willebrand disorder	Phase 3a	Award	SHP677-304	NCT03879135	EudraCT Numbe	TrialTroveID-341800	A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Longterm Safety And Efficacy Of rVWF in Pediatric And Adult Subjects With Severe Von Willebrand Disease (Vwd)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: Primary myelofibrosis (adult)	Cohort 1 : 2001
ICSPECIC 260	31/03/2020	Hematology	Myelofibrosis	Phase 3	Award	0610-04	NCT04603495	EudraCT Numbe	TrialTroveID-321341	A Phase III, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Primary myelofibrosis Cohort 2 : Primary myelofibrosis (adult)	Cohort 1 : 1516 Cohort 2 : 1513

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 261	01/04/2020	Oncology	Solid tumor configuration	Phase 1	Lost	XTX101-01/02-	NCT04896697	Not Applicable	TrialTroveID-369159	A First-in-Human, Multicenter, Phase I/II, Open-Label Study of XTX101 in Patients With Advanced Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Lung (NSCL) cancer (18+) Cohort 2: Breast cancer (18+) Cohort 3: stomach cancer (18+) Cohort 4: oesophagial cancer (18+) Cohort 5: liver & billiary cancer (18+) Cohort 6: Pancreatic cancer (18+) Cohort 7: Ovarian cancer (18+) Cohort 8: Colon cancer (18+) Cohort 9: Bladder cancer (18+) Cohort 10: Sarcoma cancer (18+) Cohort 11: adv HNSC cancer (18+) Cohort 12: HC cancer (18+) Cohort 13: Melanoma cancer (18+) Cohort 14: Prostate cancer (18+) Cohort 15: RC cancer (18+)	Cohort 1 : 133294 Cohort 2 : 170530 Cohort 3 : 22573 Cohort 4 : 18892 Cohort 5 : 31143 Cohort 6 : 40883 Cohort 7 : 23722 Cohort 8 : 90131 Cohort 9 : 67043 Cohort 10 : 7666 Cohort 11 : 94509 Cohort 12 : 21437 Cohort 13 : 20148 Cohort 14 : 110356 Cohort 15 : 28382
ICSPECIC 262	01/04/2020	Oncology	Endometrial carcinoma	Phase 2	Award	INCMGA 0012-	NCT04463771	EudraCT Numbe	TrialTroveID-331863	An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Endometrial Cancer Patients Cohort 2: Endometrial Cancer Patients with Metastasis Cohort 3: Endometrial Cancer Patients with Metastasis, treated with Chemotherapy	Cohort 1 : 16673 Cohort 2 : 6098 Cohort 3 : 4330
ICSPECIC 263	06/04/2020	Ophthalmology	Macular degeneration	Phase 3a	Award	OPT-302-1004	NCT04757610	EudraCT Numbe	TrialTroveID-370733	A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : AMD (all) Cohort 2 : AMD (Primary reason for care) Cohort 3 : AMD (Primary reason for care) with age 50+ Cohort 4 : AMD (Primary reason for care) with age 50+, with Opthalmic procedures Cohort 5 : AMD (Primary reason for care) with age 50+, with Opthalmic Injection of pharmaceutical agent Cohort 6 : Neovascular Age-related Macular Degeneration (nAMD) Patients Cohort 7 : Drud included is ELYEA_ AFLIBERCEPT	Cohort 1 : 22841 Cohort 2 : 11202 Cohort 3 : 10905 Cohort 4 : 10230 Cohort 5 : 2766
ICSPECIC 264	07/04/2020	Dermatology	Atopic dermatitis	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : Netherton patients	Cohort 1 : 3645

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 265	07/04/2020	Dermatology	Atopic dermatitis	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : Netherton patients	Cohort 1 : 3645
ICSPECIC 266	08/04/2020	Cardiovascular	Arterial thrombosis	Phase 3a	Award	CR108633	NCT04276441	Not Applicable	Not Applicable	HEARTLINE - A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Atrial Fibrillation (18-80 years old) Cohort 2 : Cerebral stroke / Myocardial Infarction (18-80 years old)	Cohort 1 : 336635 Cohort 2 : 234125
ICSPECIC 267	15/04/2020	Hematology	Paroxysmal nocturnal hemogluria	Phase 3a	Award	ALXN2040-PNH	NCT04469465	EudraCT Numbe	TrialTroveID-349881	A Phase III Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria who have clinically evident Extravascular Hemolysis (EVH)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : PNH (all) Cohort 2 : PNH (> 17) Cohort 3 : PNH (> 17) + Soliris Cohort 4 : Soliris	Cohort 1 : 519 Cohort 2 : 511 Cohort 3 : 332 Cohort 4 : 725
ICSPECIC 268	16/04/2020	Transplantation	Graft versus host disease	Phase 3	Pendin	MSB-GVHD00X	NCT02652130	Not Applicable	TrialTroveID-271249	Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Graft Versus Host Disease (Bone Marrow Transplant Rejection) Cohort 2 : Acute Graft Versus Host Disease (All) Cohort 3 : Acute Graft Versus Host Disease (18+)	Cohort 1 : 2433 Cohort 2 : 1302 Cohort 3 : 1088

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 269	20/04/2020	Oncology	Breast cancer	Late Phas	Award	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Sarah Harmand	MCO	2018	France	Cohort 1: Malignant neoplasm of ovary diagnosis	Cohort 1 : 18892
ICSPECIC 270	21/04/2020	Dermatology	Epidermolysis bullosa	Phase 2	Lost	755-201-EB	NCT04908215	EudraCT Numbe	TrialTroveID-275423	A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (Cannabinol) Cream in Patients With Epidermolysis Bullosa	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: EB (all) Cohort 2: EB (2-11yr olds) Cohort 3: EB (12-18yr olds) Cohort 4: EB (adults)	Cohort 1 : 345 Cohort 2 : 102 Cohort 3 : 43 Cohort 4 : 143
ICSPECIC 271	22/04/2020	Medical Geneti	Niemann-Pick disease, type C	Phase 4	Lost	OR-ARI-EAP-NP	NCT04316637	Not Applicable	Not Applicable	Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the US	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Niemann Pick (all) Cohort 2: Niemann Pick (Pediatric) Cohort 3: Niemann Pick (Adults)	Cohort 1 : 1313 Cohort 2 : 406 Cohort 3 : 907
ICSPECIC 272	22/04/2020	Oncology	Solid tumor configuration	Phase 3a	Lost	DCC-3014-03-C	NCT05059262	Not Applicable	Not Applicable	A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: TSGCT patients (All) Cohort 2: TSGCT patients (18+) Cohort 3: TSGCT patients (18+) with Synovial procedure Cohort 4: TSGCT patients (18+) with Chemo	Cohort 1 : 3653 Cohort 2 : 3266 Cohort 3 : 3140 Cohort 4 : 337

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 273	23/04/2020	Gastrointestina	Gastroesophageal reflux disease	Phase 2	Award	TAK390MR-204	NCT02616302	EudraCT Numbe	TrialTroveID-112806	A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 1 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : GERD Without Oesophagitis; Heartburn Cohort 2 : GERD With Oesophagitis; Oesophagitis	Cohort 1 : 116261 Cohort 2 : 111040
ICSPECIC 274	24/04/2020	Oncology	Bladder cancer	Phase 2	Award	INCB24360-901	NCT04586244	Not Applicable	TrialTroveID-387001	An Open-Label, Randomized, Phase II, Umbrella Study of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Patients with removal of bladder tumors through endoscopy	Cohort 1 : 53815
ICSPECIC 275	24/04/2020	Cardiovascular	Low blood pressure	Phase 3a	Award	0170 Study	NCT03829657	EudraCT Numbe	TrialTroveID-342250	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : Patients diagnosed with either - Parkinson's Disease - Multi-System Degeneration of the Autonomic nervous system - Other Disorders of Autonomic Nervous system Cohort 2 : Orthostatic Hypotension	Cohort 1 : 81001 Cohort 2 : 7828
ICSPECIC 276	24/04/2020	Immunology	Sjögren's syndrome	Phase 2	Award	GLPG3970-CL-2	NCT04700280	EudraCT Numbe	TrialTroveID-393649	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3970 for 12 Weeks in Adult Subjects With Active Primary Sjogren's Syndrome	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1: Sjogren patient	Cohort 1: 10004

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 277	27/04/2020	Hematology	Hemophilia	Phase 3	Award	241502	NCT02895945	EudraCT Numbe	TrialTroveID-262373	A Phase 3, Multicenter, Single-arm, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects with Congenital Hemophilia A with Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures (CHAWI)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Hemophilia A Patients (All) Cohort 2: Hemophilia A Patients (18+) Cohort 3: Hemophilia A Male Patients (18+)	Cohort 1 : 2544 Cohort 2 : 1819 Cohort 3 : 1434
ICSPECIC 278	28/04/2020	Cardiovascular	Heart disease	Not Applic	Award	INZ701-003	NCT05050669	Not Applicable	Not Applicable	A Prospective Observational Study to Evaluate Disease Presentation and Progression in Subjects With ENPP1 Deficiency and the Early-Onset Form of ABCC6 Deficiency	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: ENPP1 Cohort 2: Famillial Hypophosphatemia Cohort 3: GACI Cohort 4: Cole Disease	Cohort 1 : 16333 Cohort 2 : 14966 Cohort 3 : 205 Cohort 4 : 1167
ICSPECIC 279	29/04/2020	Oncology	Malignant Melanoma	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Mesothelioma patients (All) Cohort 2: Mesothelioma active patients (All) Cohort 3: Mesothelioma active patients (adults) Cohort 4: Mesothelioma active patients (adults) under chemo	Cohort 1 : 3385 Cohort 2 : 2755 Cohort 3 : 2754 Cohort 4 : 1897
ICSPECIC 280	29/04/2020	Neurology	Multiple sclerosis	Phase 3a	Award	MS200527_00	NCT04338022	EudraCT Numbe	TrialTroveID-371351	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Multiple Sclerosis	Cohort 1 : 39030

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 281	30/04/2020	Gastrointestina	Celiac disease	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Celiac disease K900 12-75y	Cohort 1 : 3384
ICSPECIC 282	05/05/2020	Oncology	Sarcoma	Phase 2	Award	RG_11-087	NCT02308527	EudraCT Numbe	TrialTroveID-243158	A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide +/- Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Ewing Sarcoma (All) Cohort 2: Ewing Sarcoma (1 to 30) Cohort 3: Ewing Sarcoma (1 to 30) actively treated on site	Cohort 1 : 5887 Cohort 2 : 1547 Cohort 3 : 1085
ICSPECIC 283	07/05/2020	Cardiovascular	Heart failure	Not Applic	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Diastolic heart failure Cohort 2: Age 45 or older Cohort 3: Diagnosis of Type 2 diabetes, Chronic Kidney Disease, or Angina	Cohort 1 : 196046 Cohort 2 : 191568 Cohort 3 : 99851
ICSPECIC 284	07/05/2020	Oncology	Neurofibromatosis syndrome	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Neurofibromatosis type-1 patients 1-7 years Cohort 2 : Patient Count 1: Q85.0 Cohort 3 : Patient Count 3: Q85.0-primary and C72.3-Secondary	Cohort 1 : 3074 Cohort 2 : 524 Cohort 3 : 73

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 285	07/05/2020	Cardiovascular	Heart failure	Phase 3	Lost	D169EC00002	NCT03877237	EudraCT Numbe	TrialTroveID-345336	International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Reduced Ejection Fraction (DETERMINE-reduced)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Congestive or Left Heart Failure Patients (Adult) Cohort 2: Congestive or Left Heart Failure Patients without stroke, myocardial infarction and heart transplant (Adult)	Cohort 1 : 368082 Cohort 2 : 226875
ICSPECIC 286	07/05/2020	Endocrinology	Diabetes mellitus type 2	Phase 2	Lost	D5670C00004	NCT03235050	EudraCT Numbe	TrialTroveID-306333	A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: T2DM (all) Cohort 2: T2DM (18 to 85) Cohort 3: T2DM (18 to 85) actively treated	Cohort 1 : 845911 Cohort 2 : 735567 Cohort 3 : 114663
ICSPECIC 287	11/05/2020	Infectious Disea	Viral hepatitis C	Phase 4	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Hepatitis C (All) Cohort 2: Hepatitis C (12+) Cohort 3: Hepatitis C with Cirrhosis (12+) Cohort 4: Hepatitis C without Cirrhosis (12+)	Cohort 1 : 17668 Cohort 2 : 17656 Cohort 3 : 4120 Cohort 4 : 13536
ICSPECIC 288	13/05/2020	Ophthalmology	Glaucoma	Phase 3a	Award	LT4030-301	NCT04898387	EudraCT Numbe	TrialTroveID-398280	Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Glaucoma Cohort 2 : Glaucoma adults Cohort 3 : Ocular Hypertension and open angle Glaucoma adults Cohort 4 : Glaucoma Cohort 5 : Glaucoma adults	Cohort 1 : 45125 Cohort 2 : 44848 Cohort 3 : 14154

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 289	14/05/2020	Rheumatology	Systemic sclerosis	Phase 2	Lost	APD791-204	NCT04915950	Not Applicable	TrialTroveID-405888	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Systemic Sclerosis (All) Cohort 2: Systemic Sclerosis (18 to 75) Cohort 3: Systemic Sclerosis with Raynault Syndrome (18 to 75) Cohort 4: Systemic Sclerosis with Raynault Syndrome (18 to 75) with exclusion	Cohort 1 : 6366 Cohort 2 : 5396 Cohort 3 : 1798 Cohort 4 : 1652
ICSPECIC 290	19/05/2020	Hematology	Multiple myeloma	Phase 3a	Award	207495	NCT04162210	EudraCT Numbe	TrialTroveID-329164	A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: MM Cohort 2: MM 1L/2L	Cohort 1 : 27429 Cohort 2 : 7480
ICSPECIC 291	21/05/2020	Oncology	Glioma	Phase 1	Lost	FLAG-003	Not Applicable	Not Applicable	TrialTroveID-273973	A Phase I Study of FLAG-003 for the Treatment of Glioma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Malignant neoplasm of the brain (all) Cohort 2: Malignant neoplasm of the brain (Actively treated) Cohort 3: Malignant neoplasm of the brain (Actively treated) with Chemo Cohort 4: Malignant neoplasm of the brain (Actively treated) with Avastin	Cohort 1 : 21532 Cohort 2 : 17656 Cohort 3 : 8078 Cohort 4 : 2405
ICSPECIC 292	21/05/2020	Hematology	Paroxysmal nocturnal hemogluria	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : PNH (All) Cohort 2 : PNH (18/75) Cohort 3 : PNH (18/75) with Soliris Cohort 4 : Soliris patients	Cohort 1 : 459 Cohort 2 : 401 Cohort 3 : 305 Cohort 4 : 682

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 293	21/05/2020	Cardiovascular	Pulmonary arterial hyper	Phase 2	Lost	RVT-1201-2002	NCT04712669	EudraCT Numbe	TrialTroveID-394302	A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Pulmonary Arterial Hypertension Patients (All) Cohort 2 : Pulmonary Arterial Hypertension Patients (without Diabetes, CKD or primary hypertension) Cohort 3 : Pulmonary Arterial Hypertension Patients (with diagnosis test - TEE,TTE...) Cohort 4 : Pulmonary Arterial Hypertension Patients (without Diabetes, CKD or primary hypertension;with diagnosis test - TEE,TTE...)	Cohort 1 : 65156 Cohort 2 : 24532 Cohort 3 : 20707 Cohort 4 : 8611
ICSPECIC 294	27/05/2020	Oncology	Malignant tumor of breast	Phase 2	Award	MS200647_002	NCT04489940	EudraCT Numbe	TrialTroveID-348926	A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Breast Cancer (All) Cohort 2 : Breast Cancer (18+) Cohort 3 : Metastatic Breast Cancer (18+) Cohort 4 : Metastatic Breast Cancer (18+) treated with chemotherapy Cohort 5 : Metastatic Breast Cancer (18+) treated with chemotherapy without organ transplant Cohort 6 : TBNC adults treated with chemotherapy without organ transplant	Cohort 1 : 167468 Cohort 2 : 167469 Cohort 3 : 66361 Cohort 4 : 45898 Cohort 5 : 44777 Cohort 6 : 6686
ICSPECIC 295	28/05/2020	Hematology	Acute myeloid leukemia	Phase 3	Lost	KB-ENTO-3001	NCT05020665	EudraCT Numbe	TrialTroveID-379632	A Phase III, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : AML (18+) Cohort 2 : AML newly diagnosed (18+) Cohort 3 : AML in active treatement (New + treated) (18+) Cohort 4 : AML responsive Patients (18+) Cohort 5 : AML Relapse/refractory Patients (18+)	Cohort 1 : 10740 Cohort 2 : 4489 Cohort 3 : 8467 Cohort 4 : 5897 Cohort 5 : 2544
ICSPECIC 296	28/05/2020	Rheumatology	Osteoarthritis	Phase 2	Award	D5680C00003	NCT04675034	EudraCT Numbe	TrialTroveID-392307	A Randomised, Double-blind, Placebo-controlled, Dose-response Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee:	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Osteoarthritis of knee (All) Cohort 2 : Osteoarthritis of knee (50-90 years old)	Cohort 1 : 138401 Cohort 2 : 128729

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 297	29/05/2020	Nephrology	Kidney disease	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: T2DM (all) Cohort 2: T2DM (30-85 years old) Cohort 3: T2DM (30-85years old) with chronic kidney disease stage 3 and 4 Cohort 4: T2DM (30-85years old) with chronic kidney disease(CKD) stage 3 and 4 excluding (CKD) stage 5 and dialysis	Cohort 1 : 841291 Cohort 2 : 737927 Cohort 3 : 60111 Cohort 4 : 52341
ICSPECIC 298	29/05/2020	Hematology	Non-Hodgkin lymphoma	Phase 3a	Award	GCT3013-05	NCT04628494	EudraCT Numbe	TrialTroveID-388666	A Randomized, Open-Label, Phase III Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : DLBCL Cohort 2 : DLBCL RELAPSED REFRACTORY	Cohort 1 : 13655 Cohort 2 : 6513
ICSPECIC 299	29/05/2020	Nephrology	Kidney disease	Phase 2	Lost	REGEN-007	NCT05018416	Not Applicable	TrialTroveID-412148	A phase 2, randomized, open-label, repeat dose, safety and efficacy study of Renal Autologous Cell Therapy (REACT) in subjects with Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : T2DM (all) Cohort 2 : T2DM (30-85 years old) Cohort 3 : T2DM (30-85years old) with chronic kidney disease stage 3 and 4 Cohort 4 : T2DM (30-85years old) with chronic kidney disease(CKD) stage 3 and 4 excluding (CKD) stage 5 and dialysis	Cohort 1 : 841291 Cohort 2 : 737927 Cohort 3 : 60111 Cohort 4 : 52341
ICSPECIC 300	01/06/2020	Psychiatry	Drug abuse	Phase 2	Award	CLI-06563AA1-	NCT04104646	Not Applicable	TrialTroveID-358066	A Phase II, Multicenter, Double Blind, Double Dummy, Randomized, 2 Arms Parallel Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Neonatal withdrawal symptoms from maternal use of drugs of addiction Cohort 2 : Withdrawal symptoms from therapeutic use of drugs in newborn	Cohort 1 : 706 Cohort 2 : 432

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 301	03/06/2020	Nephrology	Renal transplant rejection	Phase 3	Award	CSL842-3001	NCT03221842	EudraCT Numbe	TrialTroveID-304662	A double-blind, randomized-withdrawal, placebo-controlled study to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care for the treatment of refractory antibody mediated rejection in adult renal transplant recipients	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Kidney transplantee (all) Cohort 2 : Kidney transplantee with immunosupressant (all) Cohort 3 : Kidney transplantee with renal hypertension Cohort 4 : Kidney transplantation (2018) Cohort 5 : Kidney transplantation (2018) with plasmapheresis Cohort 6 : Kidney transplantation (2018) with rituximab Cohort 7 : Kidney transplantation (2018) with rituximab Cohort 8 : Kidney transplantation (2018) with IV immunoglobulin Cohort 9 : Kidney transplantation (2018) with treatment listed Cohort 10 : transplant rejection	Cohort 1 : 30369 Cohort 2 : 1692 Cohort 3 : 2511 Cohort 4 : 3449 Cohort 5 : 292 Cohort 6 : 3417 Cohort 7 : 6 Cohort 8 : 458 Cohort 9 : 476 Cohort 10 : 3423
ICSPECIC 302	04/06/2020	Hematology	Sickle cell disease	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Sickle Cell Cohort 2 : Sickle Cell Adults	Cohort 1 : 16216 Cohort 2 : 9830
ICSPECIC 303	04/06/2020	Respiratory	Fibrosis of lung	Phase 2	Award	CVAY736X2207	NCT03287414	EudraCT Numbe	TrialTroveID-309494	A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : IPF Patient (All) Cohort 2 : IPF Patient (40/80) Cohort 3 : IPF Patient (40/80) - Transplant Cohort 4 : IPF Patient (40/80) - Transplant - immunodefficiencies Cohort 5 : IPF Patient (40/80) - Transplant - immunodefficiencies - malignancies Cohort 6 : IPF Patient (40/80) - Transplant - immunodefficiencies - malignancies - HepB/C Cohort 7 : IPF Patient (40/80) - Transplant - immunodefficiencies - malignancies - HepB/C - tubercolosis Cohort 8 : IPF Patient (40/80) - Transplant - immunodefficiencies - malignancies - HepB/C - tubercolosis - Connective Cohort 9 : IPF Patient (40/80) - Transplant - immunodefficiencies - malignancies - HepB/C - tubercolosis - Connective - cerebrovascular Cohort 10 : IPF Patient (40/80) - Transplant -	Cohort 1 : 29068 Cohort 2 : 17649 Cohort 3 : 16884 Cohort 4 : 16494 Cohort 5 : 12196 Cohort 6 : 12052 Cohort 7 : 11974 Cohort 8 : 9654 Cohort 9 : 8238 Cohort 10 : 6735
ICSPECIC 304	04/06/2020	Hematology	Sickle cell disease	Phase 2	Lost	VIT-2763-SCD-1	NCT04817670	EudraCT Numbe	TrialTroveID-395994	A Phase 2a, Double-blind, Randomised, Placebo-controlled, Ascending Dose and Maintenance Dose, Efficacy, and Safety Study of Multiple Doses of VIT-2763 in Subjects With Sickle Cell Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Thalassemia Cohort 2 : Thalassemia paediatric Cohort 3 : Thalassemia adult	Cohort 1 : 4848 Cohort 2 : 580 Cohort 3 : 4268

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 305	04/06/2020	Hematology	Thalassemia	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	joy Seanehia	MCO	2018	France	Cohort 1 : Thalassemia Cohort 2 : Thalassemia paediatric Cohort 3 : Thalassemia adult	Cohort 1 : 4848 Cohort 2 : 580 Cohort 3 : 4268
ICSPECIC 306	04/06/2020	Hematology	Thalassemia	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	joy Seanehia	MCO	2018	France	Cohort 1 : Thalassemia Cohort 2 : Thalassemia paediatric Cohort 3 : Thalassemia adult	Cohort 1 : 4848 Cohort 2 : 580 Cohort 3 : 4268
ICSPECIC 307	04/06/2020	Hematology	Thalassemia	Phase 2	Lost	VIT-2763-THAL	NCT04364269	EudraCT Numbe	TrialTroveID-340446	A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of VIT-2763 in Subjects with Non-transfusion Dependent Beta-thalassaemia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	joy Seanehia	MCO	2018	France	Cohort 1 : Thalassemia Cohort 2 : Thalassemia paediatric Cohort 3 : Thalassemia adult	Cohort 1 : 4848 Cohort 2 : 580 Cohort 3 : 4268
ICSPECIC 308	04/06/2020	Hematology	Thalassemia	Phase 2	Lost	VIT-2763-THAL	NCT04938635	EudraCT Numbe	TrialTroveID-407269	A Phase 2b, Double-blind, Randomised, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of VIT-2763 Multiple Doses in Adults With Transfusion-dependent Beta-thalassaemia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Thalassemia Cohort 2 : Thalassemia paediatric Cohort 3 : Thalassemia adult	Cohort 1 : 4848 Cohort 2 : 580 Cohort 3 : 4268

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 309	05/06/2020	Psychiatry	Autistic disorder	Phase 2	Award	GWND19189	NCT04745026	EudraCT Numbe	TrialTroveID-396486	An Exploratory, Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Austism Spectrum Disorder Cohort 2 : Austism Spectrum Disorder aged 6-17 years Cohort 3 : Austism Spectrum Disorder aged 6-17 years without low IQ Cohort 4 : Austism Spectrum Disorder aged 6-17 years without low IQ without epilepsy	Cohort 1 : 5067 Cohort 2 : 2049 Cohort 3 : 1874 Cohort 4 : 1615
ICSPECIC 310	08/06/2020	Respiratory	Asthma	Phase 2	Award	TBD	Not Applicable	Not Applicable	TrialTroveID-391980	Double-blind, randomised, placebo-controlled trial to evaluate PK/PD, safety and efficacy of GSK3772847 as add-on to standard of care in children from 6 to less than 12 years of age with moderate-severe uncontrolled asthma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Diagnosis of Wheezing Cohort 2 : Age 0 - 5, Male or Female Cohort 3 : Treated with Salbutamol, Fluticasone propionate / Salmeterol, Ciclesonide, Fluticasone furoate, Mometasone, Ipratropium bromide, Beclometasone, Fluticasone propionate, Montelukast, Budesonide, budesonide/formoterol in past 24 months Cohort 4 : Treatment with oral corticosteroids two or more time in past 12 months	Cohort 1 : 1631093 Cohort 2 : 380834 Cohort 3 : 294051 Cohort 4 : 58502
ICSPECIC 311	08/06/2020	Nephrology	Kidney disease	Phase 3	Lost	COR-001-XXX	NCT05021835	EudraCT Numbe	TrialTroveID-376993	ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : CKD stage 3/4 (all) Cohort 2 : CKD stage 3/4 (18+) Cohort 3 : CKD stage 3/4 (18+) without progression to stage 5 Cohort 4 : CKD stage 3/4 (18+) without progression to stage 5 nor transplant Cohort 5 : CKD stage 3/4 (18+) without progression to stage 5 nor transplant nor dialysis Cohort 6 : CKD stage 3/4 (18+) without progression to stage 5 nor transplant nor dialysis with Coronary artey disease,TIA and other peripheral vascular diseases	Cohort 1 : 167826 Cohort 2 : 167386 Cohort 3 : 154865 Cohort 4 : 149186 Cohort 5 : 148057 Cohort 6 : 40365
ICSPECIC 312	08/06/2020	Oncology	Solid tumor configuration	Phase 2	Award	D419EC00001	NCT03837899	EudraCT Numbe	TrialTroveID-343419	Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination With Tremelimumab in Pediatric Patients With Advanced Solid Tumors and Hematological Malignancies	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Non-Hodgkin's Lymphoma Cohort 2 : Other Solid Tumors Cohort 3 : Sarcoma	Cohort 1 : 595 Cohort 2 : 2424 Cohort 3 : 1423

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 313	10/06/2020	Hepatology	Disease of liver	Phase 2	Lost	AXA1665-101	NCT04816916	Not Applicable	Not Applicable	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Liver Cirrhosis (all) Cohort 2 : Liver Cirrhosis (18+) Cohort 3 : Liver Cirrhosis (18+) with hepathic encephalopathy Cohort 4 : Hepathic encephalopathy (all) Cohort 5 : Hepathic encephalopathy (18+)	Cohort 1 : 26282 Cohort 2 : 26090 Cohort 3 : 1971 Cohort 4 : 8510 Cohort 5 : 8295
ICSPECIC 314	10/06/2020	Hematology	Blood disease	Phase 3a	Award	071102	NCT02932618	EudraCT Numbe	TrialTroveID-288412	A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : VWD patient (all ages) Cohort 2 : VWD patient (all ages) Cohort 3 : VWD patient (paediatric) Cohort 4 : VWD patient (paediatric) Cohort 5 : VWD patient (0-6) Cohort 6 : VWD patient (0-6) Cohort 7 : VWD patient (7-12) Cohort 8 : VWD patient (7-12) Cohort 9 : VWD patient (13-18) Cohort 10 : VWD patient (13-18) Cohort 11 : All VWD patient (all ages) Cohort 12 : Surgery VWD patient (all ages) Cohort 13 : All VWD patient (paediatric) Cohort 14 : Surgery VWD patient (paediatric) Cohort 15 : All VWD patient (0-6) Cohort 16 : Surgery VWD patient (0-6) Cohort 17 : All VWD patient (7-12) Cohort 18 : Surgery VWD patient (7-12) Cohort 19 : All VWD patient (13-18)	Cohort 1 : 3128 Cohort 2 : 779 Cohort 3 : 673 Cohort 4 : 211 Cohort 5 : 252 Cohort 6 : 90 Cohort 7 : 180 Cohort 8 : 48 Cohort 9 : 277 Cohort 10 : 82 Cohort 11 : 3128 Cohort 12 : 779 Cohort 13 : 673 Cohort 14 : 211 Cohort 15 : 252 Cohort 16 : 90 Cohort 17 : 180 Cohort 18 : 48 Cohort 19 : 277
ICSPECIC 315	10/06/2020	Gastrointestina	Pancreatitis	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Acute pancreatitis Cohort 2 : Acute pancreatitis (adults) Cohort 3 : Acute pancreatitis (adults) without chronic pancreatitis Cohort 4 : Acute pancreatitis (adults) without chronic pancreatitis with ERCP	Cohort 1 : 36001 Cohort 2 : 35167 Cohort 3 : 28820 Cohort 4 : 971
ICSPECIC 316	11/06/2020	Rheumatology	Osteoarthritis	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Osteoarthritis of knee (All) Cohort 2 : Osteoarthritis of knee (50-90 years old)	Cohort 1 : 138401 Cohort 2 : 128729

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 317	15/06/2020	Ophthalmology	Retinitis pigmentosa	Phase 3a	Award	MGT-RPGR-021	NCT04671433	EudraCT Numbe	TrialTroveID-392122	Phase 3 Randomized, Controlled Study of AAV5-RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Inherited Retinal Dystrophy (all) Cohort 2 : Inherited Retinal Dystrophy (3 and above)	Cohort 1 : 755 Cohort 2 : 726
ICSPECIC 318	15/06/2020	Nephrology	Focal Glomerular Sclerosis	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2018	France	Cohort 1 : Focal Glomerular Sclerosis (All) Cohort 2 : Focal Glomerular Sclerosis (18+) Cohort 3 : Focal Glomerular Sclerosis (18+) without advanced CKD Cohort 4 : Focal Glomerular Sclerosis (18+) without advanced CKD or Dialysis Cohort 5 : Focal Glomerular Sclerosis (18+) without advanced CKD or Dialysis or renal transplant	Cohort 1 : 2536 Cohort 2 : 2392 Cohort 3 : 1343 Cohort 4 : 1305 Cohort 5 : 1276
ICSPECIC 319	16/06/2020	Neurology	Mucopolysaccharidosis	Phase 3a	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : MPS - All types (All) Cohort 2 : MPS - All types (0-15) Cohort 3 : MPS - All types (16+)	Cohort 1 : 706 Cohort 2 : 478 Cohort 3 : 228
ICSPECIC 320	18/06/2020	Cardiovascular	Obstructive Hypertrophic Cardiomyopathy	Phase 3	Award	MYK-461-005	NCT03470545	EudraCT Numbe	TrialTroveID-290709	A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM).	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Hypertrophic Caardiomyopathy Cohort 2 : Obstructive Hypertrophic Caardiomyopathy Cohort 3 : Hypertrophic Caardiomyopathy with septal ablationprocedures	Cohort 1 : 43065 Cohort 2 : 4922 Cohort 3 : 170

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 321	18/06/2020	Oncology	Bladder cancer	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Diagnosed with Bladder Cancer Cohort 2 : Patients Taking Pembrolizumab Cohort 3 : Bladder cancer patients taking Pembrolizumab	Cohort 1 : 67095 Cohort 2 : 290 Cohort 3 : 7784
ICSPECIC 322	18/06/2020	Oncology	Bladder cancer	Phase 3a	Award	rAd-IFN-CS-003	NCT02773849	Not Applicable	TrialTroveID-278906	A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN (rAd-IFN)/Syn3) Administered Intravesically to Patients With High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Diagnosed with Bladder Cancer Cohort 2 : Patients Taking Pembrolizumab Cohort 3 : Bladder cancer patients taking Pembrolizumab	Cohort 1 : 67095 Cohort 2 : 290 Cohort 3 : 7784
ICSPECIC 323	19/06/2020	Oncology	Solid tumor configuration	Phase 2	Lost	TAS-117-201	NCT04770246	EudraCT Numbe	TrialTroveID-397774	A Phase II Study of TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Solid Tumours (all) Cohort 2 : All active Solid Tumours (all) Cohort 3 : All active Solid Tumours (18/75) Cohort 4 : All active Solid Tumours (18/75) without brain tumor Cohort 5 : All active metastatic Solid Tumours (18/75) without brain tumor Cohort 6 : All Refractory active metastatic Solid Tumours (18/75) without brain tumor	Cohort 1 : 546498 Cohort 2 : 411454 Cohort 3 : 317485 Cohort 4 : 316699 Cohort 5 : 116079 Cohort 6 : 30808
ICSPECIC 324	22/06/2020	Dermatology	Atopic dermatitis	Phase 3	Lost	TBD	Not Applicable	Not Applicable	TrialTroveID-415219	A Phase III Study of KHK-4083 in Patients with Atopic Dermatitis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Atopic dermatitis (All) Cohort 2 : Atopic dermatitis (12+) Cohort 3 : Atopic dermatitis with dupilumab (12+) Cohort 4 : Atopic dermatitis (12-17) Cohort 5 : Atopic dermatitis with dupilumab (12-17) Cohort 6 : Atopic dermatitis (18+) Cohort 7 : Atopic dermatitis with dupilumab (18+)	Cohort 1 : 6598 Cohort 2 : 4492 Cohort 3 : 309 Cohort 4 : 384 Cohort 5 : 13 Cohort 6 : 4108 Cohort 7 : 296

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 325	22/06/2020	Dermatology	Atopic dermatitis	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Atopic dermatitis (All) Cohort 2 : Atopic dermatitis (12+) Cohort 3 : Atopic dermatitis with dupilumab (12+) Cohort 4 : Atopic dermatitis (12-17) Cohort 5 : Atopic dermatitis with dupilumab (12-17) Cohort 6 : Atopic dermatitis (18+) Cohort 7 : Atopic dermatitis with dupilumab (18+)	Cohort 1 : 6598 Cohort 2 : 4492 Cohort 3 : 309 Cohort 4 : 384 Cohort 5 : 13 Cohort 6 : 4108 Cohort 7 : 296
ICSPECIC 326	22/06/2020	Dermatology	Atopic dermatitis	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Atopic dermatitis (All) Cohort 2 : Atopic dermatitis (12+) Cohort 3 : Atopic dermatitis with dupilumab (12+) Cohort 4 : Atopic dermatitis (12-17) Cohort 5 : Atopic dermatitis with dupilumab (12-17) Cohort 6 : Atopic dermatitis (18+) Cohort 7 : Atopic dermatitis with dupilumab (18+)	Cohort 1 : 6598 Cohort 2 : 4492 Cohort 3 : 309 Cohort 4 : 384 Cohort 5 : 13 Cohort 6 : 4108 Cohort 7 : 296
ICSPECIC 327	23/06/2020	Nephrology	Active Lupus Nephritis	Phase 3	Awarde	AUR-VCS-2016	NCT03021499	EudraCT Numbe	TrialTroveID-290414	A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Lupus (All) Cohort 2 : Lupus (Ped) Cohort 3 : Lupus nephritis (Ped)	Cohort 1 : 4219 Cohort 2 : 196 Cohort 3 : 91
ICSPECIC 328	24/06/2020	Gynecology/Wo	Female infertility	Phase 3	Lost	8415-060	NCT04626596	EudraCT Numbe	TrialTroveID-389222	A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel (MK-8415) Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Hospital patients (All) Cohort 2 : Hospital Female patients (All) Cohort 3 : Hospital Female patients (18-35) Cohort 4 : Hospital Female patients (18-35) with IUD / Implants Cohort 5 : Hospital Female patients (18-35) with IUD Cohort 6 : Hospital Female patients (18-35) with Implants (implementation & removal) Cohort 7 : Hospital Female patients (18-35) with Implants (implementation)	Cohort 1 : 14063025 Cohort 2 : 7628474 Cohort 3 : 1550953 Cohort 4 : 11279 Cohort 5 : 3150 Cohort 6 : 9425 Cohort 7 : 8154

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 329	24/06/2020	Hematology	Blood disease	Phase 1	Lost	BCV-PA01	NCT04706923	Not Applicable	Not Applicable	A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: HSCT Patients Cohort 2: HSCT Patients with CMV infection Cohort 3: HSCT Patients with CMV infection without transplant rejection Cohort 4: HSCT Patients with CMV infiection without rejection (adults)	Cohort 1: 5019 Cohort 2: 607 Cohort 3: 202 Cohort 4: 166
ICSPECIC 330	25/06/2020	Neurology	Multiple sclerosis	Phase 3b	Lost	COMB157G33(	NCT04788615	EudraCT Numbe	TrialTroveID-398653	Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMS	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016-2018	France	Cohort 1 : MS (All) Cohort 2 : MS as reason for visit in 2018 Cohort 3 : MS as reason for visit in 2018 and not seen in 2017/2016 Cohort 4 : MS as reason for visit in 2018 and not seen in 2017/2016 (18-45 years old)	Cohort 1 : 39043 Cohort 2 : 7437 Cohort 3 : 4080 Cohort 4 : 2349
ICSPECIC 331	26/06/2020	Hepatology	Nonalcoholic steatohepatitis	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Cirrhosis Cohort 2 : Cirrhosis with non-NASH-related causes excluded Cohort 3 : NASH	Cohort 1 : 27173 Cohort 2 : 14110 Cohort 3 : 4498
ICSPECIC 332	29/06/2020	Medical Geneti	Rett's disorder	Phase 3	Lost	ACP-2566-009	NCT04988867	Not Applicable	TrialTroveID-410469	An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : All Retts Cohort 2 : Pediatric Retts Cohort 3 : 2-5 years old Retts patients	Cohort 1 : 415 Cohort 2 : 273 Cohort 3 : 39

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 333	06/07/2020	Hematology	Chronic myeloid leukemia	Phase 3b	Lost	CABL001A2302	NCT04948333	EudraCT Numbe	TrialTroveID-407771	A Phase IIIb, Multi-center, Open-label, Treatment Optimization Study of Oral Asciminib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Previously Treated With 2 or More Tyrosine Kinase Inhibitors.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Chronic Myeloid Leucemia Cohort 2 : Chronic Myeloid Leucemia 18 plus Cohort 3 : Chronic Myeloid Leucemia adults without pancreatitis Cohort 4 : Chronic Myeloid Leucemia adults without pancreatitis nor chronic kidney disease	Cohort 1 : 2639 Cohort 2 : 2615 Cohort 3 : 2576 Cohort 4 : 2569
ICSPECIC 334	06/07/2020	Cardiovascular	Peripheral arterial disease	Phase 3a	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Dialysis Cohort 2 : Either over 45 yr old diabetes or over 55 yr old patients on dialysis Cohort 3 : Either over 45 yr old diabetes or over 55 yr old patients on dialysis with PAD	Cohort 1 : 58967 Cohort 2 : 48952 Cohort 3 : 7613
ICSPECIC 335	07/07/2020	Hematology	Multiple myeloma	Phase 4	Award	OBS16577	NCT04458831	Not Applicable	TrialTroveID-378778	A Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Multiple Myeloma (All) Cohort 2 : Chemotherapy-treated Multiple Myeloma (All) Cohort 3 : Chemotherapy-treated Multiple Myeloma (18+)	Cohort 1 : 26524 Cohort 2 : 19085 Cohort 3 : 19085
ICSPECIC 336	08/07/2020	Oncology	Gastrointestinal cancer	Phase 2	Lost	AIO- HEP-0419	NCT04511455	EudraCT Numbe	TrialTroveID-381895	Translational Study of Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to Lenvatinib Treatment	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: GI cancer (all ages) Cohort 2: GI cancer with carcinod syndrome(all ages) Cohort 3: GI cancer with carcinod syndrome(18-70yrs olds) Cohort 4: Endocrine pancreas Tumour Cohort 5: Endocrine pancreas Tumour(18-70 yrs olds) Cohort 6: GI cancer or Endocrine pancreas Tumour (18-70 yrs olds) Cohort 7: GI cancer or Endocrine pancreas Tumour with carcinoid syndrome (18-70 yrs olds)	Cohort 1 : 131872 Cohort 2 : 226 Cohort 3 : 151 Cohort 4 : 2026 Cohort 5 : 1416 Cohort 6 : 69213 Cohort 7 : 168

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 337	13/07/2020	Cardiovascular	Heart failure	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	joy Seanehia	MCO	2018	France	Cohort 1 : Cardiomyopathy Cohort 2 : Cardiomyopathy (2-17 yrs) Cohort 3 : Cardiomyopathy (2-17 yrs) without heart transplants	Cohort 1 : 102653 Cohort 2 : 635 Cohort 3 : 578
ICSPECIC 338	13/07/2020	Oncology	Non-small cell lung cancer	Phase 2	Award	GO40782	NCT02568267	EudraCT Numbe	TrialTroveID-265482	An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements. Studies of Tumor Alterations Responsive to Targeting Receptor Kinases (STARTRK-2)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Total number of packs dispensed Cohort 2 : Total mg of Crizotinib dispensed	Cohort 1 : 4087 Cohort 2 : 976948
ICSPECIC 339	14/07/2020	Neurology	Degenerative disease of CNS	Phase 2	Lost	REC-3599-001	Not Applicable	Not Applicable	TrialTroveID-420181	A Phase II study of REC-359 in GM2 gangliosidosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : GM2 Gangliosidosis (under 3yrs old)	Cohort 1 : less than 30
ICSPECIC 340	15/07/2020	Other	Chronic inflammatory demyelinating polyneuropathy	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : CIDP Cohort 2 : CIDP adults	Cohort 1 : 4643 Cohort 2 : 4597

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 341	16/07/2020	Neurology	Duchenne muscular dystrophy	Phase 3a	Lost	Lupin-MEX-DM	NCT04700046	Not Applicable	TrialTroveID-393656	A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Mexiletine During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 [The MIND Study]	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Myotonic dystrophy Patient Cohort 2 : Myotonic dystrophy adults	Cohort 1 : 2845 Cohort 2 : 2560
ICSPECIC 342	20/07/2020	Oncology	Sarcoma	Phase 2	Award	AL-DES-01	NCT04871282	EudraCT Numbe	TrialTroveID-397025	A Pivotal Phase II/III Study of AL102 in Adult and Adolescent Patients with Progressive Desmoid Tumors.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Desmoid tumours (all ages) Cohort 2 : Desmoid tumours adults Cohort 3 : Pediatric Desmoid tumours Cohort 4 : Desmoid tumours 10-17 years old	Cohort 1 : 1392 Cohort 2 : 1238 Cohort 3 : 154 Cohort 4 : 62
ICSPECIC 343	21/07/2020	Gastrointestina	Incontinence of feces	Phase 3a	Award	IC-01-02-5-009	NCT04976153	Not Applicable	Not Applicable	Skeletal Muscle-derived Cell Implantation for the Treatment of Fecal Incontinence: a Phase III, Randomized, Controlled, Double Blind, Two Armed Clinical Study	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Fecal incontinence due to rectal tear or anal sphincter degeneration (18+) Cohort 2 : Fecal incontinence due to rectal tear or anal sphincter degeneration or surgeries (18+)	Cohort 1 : 274281 Cohort 2 : 298254
ICSPECIC 344	23/07/2020	Oncology	Solid tumor configuration	Phase 3a	Award	CO-338-063	NCT02975934	EudraCT Numbe	TrialTroveID-271547	TRITON3: A Multicenter, Randomized, Open Label Phase III Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1: Prostate Cancer patients (male, 18+) Cohort 2: Metastatic Prostate Cancer patients (male, 18+) Cohort 3: Metastatic Prostate Cancer patients with at surgery follow up (male, 18+) Cohort 4: Treatment resistant Metastatic Prostate Cancer patients (male, 18+)	Cohort 1 : 72816 Cohort 2 : 13461 Cohort 3 : 450 Cohort 4 : 4625

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 345	23/07/2020	Endocrinology	Growth hormone deficiency	Phase 3a	Lost	TCP-304	NCT04701203	EudraCT Numbe	Not Applicable	PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Growth Hormone deficiency Cohort 2 : Growth Hormone deficiency (under 18yrs old) Cohort 3 : Growth Hormone deficiency (18-75 years old)	Cohort 1 : 8864 Cohort 2 : 2207 Cohort 3 : 5687
ICSPECIC 346	28/07/2020	Dermatology	Chronic Hand Eczema	Phase 3a	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Chronic hand eczema Cohort 2 : Chronic hand eczema (adults)	Cohort 1 : 35585 Cohort 2 : 31575
ICSPECIC 347	28/07/2020	Hepatology	Disease of liver	Phase 3a	Lost	ALXN1840-WD	NCT05047523	EudraCT Numbe	TrialTroveID-414098	A Multicenter, Randomized, Controlled, Open-label, Rater-blinded Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Wilson's disease (3yrs to 18yrs) Cohort 2 : Wilson's disease (3yrs to 10yrs) Cohort 3 : Wilson's disease (11yrs to 18yrs)	Cohort 1 : 77 Cohort 2 : 30 Cohort 3 : 49
ICSPECIC 348	30/07/2020	Hematology	Acute myeloid leukemia	Phase 3a	Award	GMI-1271-301	NCT03616470	EudraCT Numbe	TrialTroveID-302585	A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : AML Cohort 2 : AML diagnosis visit Cohort 3 : AML diagnosis visit (18-75)	Cohort 1 : 11724 Cohort 2 : 4828 Cohort 3 : 3198

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 349	04/08/2020	Endocrinology	Obesity	Phase 3	Award	NN9932-4737	NCT05035095	EudraCT Numbe	TrialTroveID-407213	Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in Subjects With Overweight or Obesity (OASIS 1)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Diagnosis of obesity and/or evidence of BMI >= 35 Cohort 2 : Diagnosis of obesity excluding Type II diabetes	Cohort 1 : 60363 Cohort 2 : 53442
ICSPECIC 350	04/08/2020	Oncology	Metastatic cancer	Phase 3a	Lost	TBD	NCT04961996	EudraCT Numbe	TrialTroveID-408811	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016-2019	France	Cohort 1 : Breast Cancer (2016-2018) Cohort 2 : Stage I-III Breast Cancer (2016-2018) Cohort 3 : Breast Cancer (2018 - All) Cohort 4 : Stage I-III Breast Cancer (2018)	Cohort 1 : 448718 Cohort 2 : 249997 Cohort 3 : 170691 Cohort 4 : 128001
ICSPECIC 351	05/08/2020	Endocrinology	Obesity	Phase 3a	Lost	TM008	NCT05147415	EudraCT Numbe	Not Applicable	A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding, Multi-center, 36-week Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Hypothalamic Obesity	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1 : Hypothalamic Obesity Patient adults	Cohort 1 : 57349
ICSPECIC 352	06/08/2020	Hematology	Acute myeloid leukemia	Phase 2	Award	KO-MEN-001	NCT04067336	EudraCT Numbe	TrialTroveID-296277	A Phase I/IIa First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO 539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1 : AML Patientss (All) Cohort 2 : AML Patients (Chemotherapy Treated) Cohort 3 : AML Patients (2nd Line) Cohort 4 : AML Patients (Tested for Biomarkers)	Cohort 1 : 11349 Cohort 2 : 8165 Cohort 3 : 3013 Cohort 4 : 2555

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 353	10/08/2020	Neurology	Alzheimer's disease	Phase 3a	Award	GV971-004	NCT04520412	EudraCT Numbe	TrialTroveID-373189	A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2016	France	Cohort 1 : Alzheimers (all) Cohort 2 : Mild to medium Alzheimers (all) Cohort 3 : Mild to medium Alzheimers (50-85) Cohort 4 : Mild to medium Alzheimers (50-85) excluding different other causes of dementia	Cohort 1 : 106112 Cohort 2 : 15697 Cohort 3 : 8545 Cohort 4 : 7563
ICSPECIC 354	10/08/2020	Hematology	Malignant lymphoma	Phase 2	Lost	VT3996-202	NCT05011058	EudraCT Numbe	TrialTroveID-390642	An Open-Label, Phase II Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : All 4 lymphomas 18-75 year olds Cohort 2 : DLBCL 18-75 year olds Cohort 3 : DLBCL+PTLD 18-75 year olds Cohort 4 : ENK/T cell 18-75 year olds Cohort 5 : PTCL 18-75 year olds Cohort 6 : HL 18-75 year olds Cohort 7 : DLBCL+PTLD taking rituximab 18-75 year olds Cohort 8 : ENK/T cell chemo patients 18-75 year olds Cohort 9 : PTCL brentuximab vedotin/doxorubicin (anthracycline-based regimen) 18-75 year olds Cohort 10 : HL on doxorubicin (anthracycline-based regimen) 18-75 year olds	Cohort 1 : 17704 Cohort 2 : 10469 Cohort 3 : 10583 Cohort 4 : 75 Cohort 5 : 859 Cohort 6 : 6418 Cohort 7 : 6835 Cohort 8 : 66 Cohort 9 : 37 Cohort 10 : 162
ICSPECIC 355	13/08/2020	Gastrointestina	Crohn's disease	Phase 2	Award	1425-0003	NCT04978493	EudraCT Numbe	TrialTroveID-409764	A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BI 706321 Orally Administered for 12 Weeks in Patients With Crohn's Disease (CD) Receiving Ustekinumab Induction Treatment	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Crohn's disease Cohort 2: Crohn's disease(18-75yr) Cohort 3: Crohn's disease (18-75yr) taking adalimumb, certolizumab and infliximab Cohort 4: Crohn's disease (18-75yr) excluding the other IBD Cohort 5: Crohn's disease (18-75yr) excluding the other IBD taking adalimumb, certolizumab and infliximab Cohort 6: Crohn's disease (18-75yr) excluding the other IBD taking adalimumb, certolizumab and infliximab and taking additional biologic ustekinumab Cohort 7: Crohn's disease (18-75yr) excluding the other IBD but taking additional biologic ustekinumab	Cohort 1 : 56155 Cohort 2 : 50769 Cohort 3 : 11510 Cohort 4 : 48402 Cohort 5 : 10856 Cohort 6 : 440 Cohort 7 : 2075
ICSPECIC 356	14/08/2020	Oncology	Solid tumor configuration	Phase 2	Award	Debio1143-108	NCT04122625	EudraCT Numbe	TrialTroveID-345647	A Dose-optimization, Exploratory Phase Ib/II Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143, When Given in Combination With the Anti-PD-1 Antibody Nivolumab in Patients With Specific Solid Tumors Who Have Progressed During or Immediately After Anti-PD-1/PD-L1 Treatment	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Gynaecological cancers Cohort 2 : Gynaecological cancer adults Cohort 3 : Gynaecological cancer adults with adalimumab,nivolumab,ipilimumab	Cohort 1 : 48315 Cohort 2 : 48160 Cohort 3 : 76

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 357	17/08/2020	Rheumatology	Psoriatic arthritis	Phase 3	Lost	CR109039	NCT04936308	EudraCT Numbe	Not Applicable	A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1: Psoriatic Arthritis Patients (All) Cohort 2: Psoriatic Arthritis Patients without Chemotherapy (All) Cohort 3: Psoriatic Arthritis Patients (Biologics) Cohort 4: Psoriatic Arthritis Patients (Abatacept) Cohort 5: Psoriatic Arthritis Patients (adalimumab) Cohort 6: Psoriatic Arthritis Patients (certolizumab) Cohort 7: Psoriatic Arthritis Patients (ethanercept) Cohort 8: Psoriatic Arthritis Patients (golimumab) Cohort 9: Psoriatic Arthritis Patients (gueslkumab) Cohort 10: Psoriatic Arthritis Patients (infliximab) Cohort 11: Psoriatic Arthritis Patients (secukinumab) Cohort 12: Psoriatic Arthritis Patients (ustekimab)	Cohort 1 : 7258 Cohort 2 : 4611 Cohort 3 : 2133 Cohort 4 : 73 Cohort 5 : 133 Cohort 6 : 33 Cohort 7 : 63 Cohort 8 : 36 Cohort 9 : 2 Cohort 10 : 1718 Cohort 11 : 70 Cohort 12 : 48
ICSPECIC 358	18/08/2020	Dermatology	Dermatitis	Phase 2	Lost	C3291038	NCT04091087	Not Applicable	Not Applicable	A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Local Tolerability of Crisaborole Ointment, 2%, in Adult Participants With Stasis Dermatitis Without Active Skin Ulceration	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Statis Dermatitis Cohort 2 : Statis Dermatitis 45years and over	Cohort 1 : 55399 Cohort 2 : 47094
ICSPECIC 359	19/08/2020	Cardiovascular	Thromboembolism of vein	Phase 3a	Award	ANT-008	NCT05171075	EudraCT Numbe	TrialTroveID-421585	A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Gastrointestinal or Genitourinary cancers Cohort 2 : Gastrointestinal or Genitourinary cancers excluding atrial fibrillation Cohort 3 : Cancer patients Cohort 4 : Cancer patients without atrial fibrillation	Cohort 1 : 240569 Cohort 2 : 210405 Cohort 3 : 1195942 Cohort 4 : 1078144
ICSPECIC 360	21/08/2020	Oncology	Solid tumor configuration	Phase 2	Lost	ONO-4059-09	NCT04947319	Not Applicable	TrialTroveID-407793	An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : DLBCL Cohort 2 : DLBCL adult Cohort 3 : DLBCL adult with cranial procedure Cohort 4 : DLBCL adult with HIV	Cohort 1 : 15719 Cohort 2 : 15646 Cohort 3 : 404 Cohort 4 : 211

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 361	24/08/2020	Gastrointestina	Crohn's disease	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Crohns disease Cohort 2: Crohns disease adults Cohort 3: Crohns disease adults with anal fistula Cohort 4: Crohns disease adults with recto-vaginal fistula Cohort 5: Crohns disease adults with recto-vaginal fistula associated with procedures Cohort 6: Crohns disease adults with recto-vaginal procedures Cohort 7: Crohns disease adults with recto-vaginal fistula or anal fistulas	Cohort 1 : 45050 Cohort 2 : 43020 Cohort 3 : 1405 Cohort 4 : 173 Cohort 5 : 401 Cohort 6 : 32 Cohort 7 : 1683
ICSPECIC 362	26/08/2020	Respiratory	Asthma	Phase 3a	Award	213744	NCT04718103	EudraCT Numbe	TrialTroveID-394933	A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Asthma Cohort 2: Asthma 12 and above Cohort 3: Asthma caused by allergies, 12yrs and above without HIV Cohort 4: Asthma caused by allergies, 12yrs and above without HIV nor respiratory diseases Cohort 5: Asthma caused by allergies, 12yrs and above without HIV nor respiratory diseases nor liver diseases	Cohort 1 : 147741 Cohort 2 : 111000 Cohort 3 : 96447 Cohort 4 : 93147 Cohort 5 : 92631
ICSPECIC 363	27/08/2020	Endocrinology	Gaucher's disease	Phase 2	Lost	TBD	Not Applicable	Not Applicable	TrialTroveID-424106	A Pivotal Phase II Study To Evaluate AZ-3102 for the Treatment of GM2 Gangliosidosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Gangliosidosis all Cohort 2 : Gangliosidosis pediatric Cohort 3 : Gangliosidosis adults Cohort 4 : Gangliosidosis GM2 pediatric Cohort 5 : Gangliosidosis GM2 adults	Cohort 1 : 90 Cohort 2 : 31 Cohort 3 : 59 Cohort 4 : 12 Cohort 5 : 36
ICSPECIC 364	28/08/2020	Cardiovascular	Thromboembolism of vein	Phase 3a	Award	DU176b-D-U31	NCT02798471	EudraCT Numbe	TrialTroveID-280481	A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Venous Thromboembolism Cohort 2 : Venous Thromboembolism 2years and under Cohort 3 : Venous Thromboembolism 2years and under with central venous access	Cohort 1 : 30681 Cohort 2 : 344 Cohort 3 : 141

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 365	01/09/2020	Oncology	Solid tumor configuration	Phase 2	Award	ST-067-001	NCT04787042	Not Applicable	TrialTroveID-398601	A Phase Ia Open-Label, Dose-Escalation, and a Phase II Study to Investigate the Safety, PK, PD, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients With Relapsed or Refractory Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Patients taking Pembrolizumab Cohort 2 : Breast cancer without HER2 therapies with checkpoint inhibitors (ipilimu, nivolu,prembroliz,atezolizumab) Cohort 3 : Lung cancer with checkpoint inhibitors Cohort 4 : RCC with checkpoint inhibitors Cohort 5 : Melanoma with checkpoint inhibitors Cohort 6 : Head and neck with checkpoint inhibitors Cohort 7 : Sum of solid tumours with checkpoint inhibitors	Cohort 1 : 10525 Cohort 2 : 329 Cohort 3 : 15981 Cohort 4 : 1542 Cohort 5 : 4510 Cohort 6 : 1956 Cohort 7 : 24318
ICSPECIC 366	01/09/2020	Infectious Disea	HPV infection	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018-2019	France	Cohort 1 : Hospitalised 16-26 year olds in 2019 Cohort 2 : Hospitalised 16-26 year olds in 2019 excluding cervical cancer and other HPV related symptoms Cohort 3 : According to vaccine coverage in 2018 (23%) hospitalised 16-26yr olds Cohort 4 : Potential to vaccinate based on 2018 coverage among hospitalised 16-26yr olds(77%)	Cohort 1 : 1125445 Cohort 2 : 1113034 Cohort 3 : 255989 Cohort 4 : 857036.180000001
ICSPECIC 367	01/09/2020	Oncology	Neurofibromatosis syndrome	Phase 1	Lost	FCN-159-002	NCT04954001	Not Applicable	Not Applicable	A Multi-center, Open-label, Single-arm Phase I Dose-escalation and Phase II Dose-expansion Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Neurofibromatosis Cohort 2 : Neurofibromatosis adult	Cohort 1 : 3091 Cohort 2 : 2016
ICSPECIC 368	03/09/2020	Neurology	Neuropathy	Phase 3a	Award	S18-01562	NCT03750552	EudraCT Numbe	TrialTroveID-337441	A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Patients diagnosed with either - Parkinson's Disease - Multi-System Degeneration of the Autonomic nervous system - Other Disorders of Autonomic Nervous system Cohort 2 : Orthostatic Hypotension	Cohort 1 : 81001 Cohort 2 : 7828

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 369	04/09/2020	Neurology	Epilepsy	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1 : Psoriatic Arthritis Patients (All) Cohort 2 : Psoriatic Arthritis Patients without Chemotherapy (All) Cohort 3 : Psoriatic Arthritis Patients (Biologics) Cohort 4 : Psoriatic Arthritis Patients (Abatacept) Cohort 5 : Psoriatic Arthritis Patients (adalimumab) Cohort 6 : Psoriatic Arthritis Patients (certolizumab) Cohort 7 : Psoriatic Arthritis Patients (ethanercept) Cohort 8 : Psoriatic Arthritis Patients (golimumab) Cohort 9 : Psoriatic Arthritis Patients (inflixmab) Cohort 10 : Psoriatic Arthritis Patients (secukinumab) Cohort 11 : Psoriatic Arthritis Patients (ustekimab)	Cohort 1 : 7258 Cohort 2 : 4611 Cohort 3 : 2133 Cohort 4 : 73 Cohort 5 : 133 Cohort 6 : 33 Cohort 7 : 63 Cohort 8 : 36 Cohort 9 : 1718 Cohort 10 : 70 Cohort 11 : 48
ICSPECIC 370	08/09/2020	Cardiovascular	Hypertensive disorder	Phase 3	Lost	QGC001-3QG2	NCT04857840	EudraCT Numbe	TrialTroveID-356409	A Phase III, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-treat/Resistant Hypertension	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Hypertension Cohort 2: Hypertension adults Cohort 3: Principal diagnosis as Hypertension adults	Cohort 1 : 1765050 Cohort 2 : 1763414 Cohort 3 : 24474
ICSPECIC 371	08/09/2020	Endocrinology	Lipodystrophy	Phase 3	Award	APG-20	NCT05164341	Not Applicable	TrialTroveID-400236	A Randomized, Placebo-controlled Phase III Study of Myalept to Evaluate Safety and Efficacy of Myalept in Partial Lipodystrophy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1 : Lipodystrophy Patients (All)	Cohort 1 : 2214
ICSPECIC 372	08/09/2020	Cardiovascular	Cardiovascular Disease	Not Applic	Lost	Surpass	NCT05100836	Not Applicable	Not Applicable	SURPASS Study - The Surgical Unloading Renal Protection And Sustainable Support Study	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Cardiac surgeries (CABG, Cardiopulmonary bypass)	Cohort 1 : 22282

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 373	14/09/2020	Psychiatry	Schizophrenia	Phase 1	Award	ROV-RISP-2020	NCT05179525	Not Applicable	TrialTroveID-422117	An Open-Label, One-Sequence Study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal (Sourced From Germany)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019-2020	France	Cohort 1 : Schizophenia Cohort 2 : Risperidone (units) 1yr lookback till feb 2019 Cohort 3 : long acting injectables- ARIPIPRAZOLE (units) 1yr lookback till feb 2019 Cohort 4 : long acting injectables- OLANZAPINE (units) 1yr lookback till feb 2020 Cohort 5 : Sum of units of all 3 LAI	Cohort 1 : 17206 Cohort 2 : 2163.2513 Cohort 3 : 113698.8482 Cohort 4 : 1098.3907 Cohort 5 : 116977
ICSPECIC 374	16/09/2020	Psychiatry	Alcohol dependence	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1: Patients with Alcohol Disorders (All) Cohort 2: Patients with Alcohol Disorders (Severe Mental disorder, dependency) Cohort 3: Patients with Alcohol Disorders (Liver disease) Cohort 4: Patients with Alcohol Disorders (Gastrointestinal Disease) Cohort 5: Patients with Alcohol Disorders (Poisoning) Cohort 6: Patients with Alcohol Disorders (Other)	Cohort 1 : 196029 Cohort 2 : 171640 Cohort 3 : 37685 Cohort 4 : 9443 Cohort 5 : 3714 Cohort 6 : 7454
ICSPECIC 375	16/09/2020	Oncology	Advanced solid tumours	Phase 1	Award	MVX-2021-01	NCT05071846	Not Applicable	TrialTroveID-415721	An Open Label, Single Arm, Phase I Clinical Study Assessing Safety, Tolerability, and Efficacy of MVX-ONCO-2 in Patients With Advanced Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Adult cancer Cohort 2: lung cancer adults Cohort 3: HNSCC adults Cohort 4: Urethelial cancer adults Cohort 5: Melanoma adults	Cohort 1 : 865653 Cohort 2 : 112918 Cohort 3 : 40284 Cohort 4 : 41378 Cohort 5 : 13916
ICSPECIC 376	17/09/2020	Dermatology	Epidermolysis bullosa	Phase 3a	Award	D325AC00002	NCT04612790	Not Applicable	Not Applicable	A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Bullous pemphigoid (All) Cohort 2 : Bullous pemphigoid (Adults) Cohort 3 : Bullous pemphigoid without Cicatricial pemphigoid nor Acquired epidermolysis bullosa(Adults) Cohort 4 : Bullous pemphigoid without Cicatricial pemphigoid, Acquired epidermolysis bullosa nor Pemphigus (Adults) Cohort 5 : Bullous pemphigoid without Cicatricial pemphigoid, Acquired epidermolysis bullosa, Pemphigus nor Guillain-Bare Syndrome (Adults) Cohort 6 : Bullous pemphigoid without Cicatricial pemphigoid, Acquired epidermolysis bullosa, Pemphigus nor Guillain-Bare Syndrome with Chemotherapy (Adults)	Cohort 1 : 2171 Cohort 2 : 2171 Cohort 3 : 2128 Cohort 4 : 2098 Cohort 5 : 2097 Cohort 6 : 189

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 377	17/09/2020	Infectious Disea	Acute hepatitis	Phase 3a	Award	EIG-LNF-011	NCT03719313	EudraCT Numbe	TrialTroveID-335560	A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1: Hepatitis B or D with Delta component Cohort 2: Hepatitis B or D with Delta component adults	Cohort 1 : 9465 Cohort 2 : 9280
ICSPECIC 378	22/09/2020	Oncology	Non-small cell lung cancer	Phase 3	Award	BGB-A317-A12	NCT04866017	EudraCT Numbe	TrialTroveID-402854	Phase III, Randomized, Open Label Study to Compare Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody BGB-A1217 Plus Concurrent Chemoradiotherapy (cCRT) Followed by Tislelizumab Plus BGB-A1217 Versus cCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Lung cancer Cohort 2: Lung cancer adult Cohort 3: NSCLC cancer adult prevalence (85%)	Cohort 1 : 112945 Cohort 2 : 112918 Cohort 3 : 96025
ICSPECIC 379	22/09/2020	Cardiovascular	Abdominal Aortic Aneurysm	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Abdominal Aortic Aneurysm adults	Cohort 1 : 21468
ICSPECIC 380	22/09/2020	Oncology	Solid tumor configuration	Phase 1	Award	PBI-200-101	NCT04901806	EudraCT Numbe	TrialTroveID-404908	A Phase I/II Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Solid tumours Cohort 2 : Solid tumours adults Cohort 3 : Metastatic solid tumours adults	Cohort 1 : 291776 Cohort 2 : 289470 Cohort 3 : 139612

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 381	22/09/2020	Hematology	Chronic myeloid leukemia	Phase 2	Award	CLR_15_03_PA	NCT02629692	EudraCT Numbe	TrialTroveID-260619	A Two-Part Phase I/II Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL).	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : CML Cohort 2 : CML adults Cohort 3 : Iclusig (Ponatinib) dispensation (units) from Jan 2018 till Feb2019 Cohort 4 : Iclusig prescribed according to Xponent panel data with CML adult patients	Cohort 1 : 3016 Cohort 2 : 2989 Cohort 3 : 1536,86 units Cohort 4 : 1073
ICSPECIC 382	22/09/2020	Neurology	Diabetic peripheral neuropathy	Phase 3	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : All Diabetes with neurologic complications, polyneuritis Cohort 2 : Adult patients : Diabetes with neurologic complications, polyneuritis Cohort 3 : Adult patients : Diabetes with neurologic complications Cohort 4 : Adult patients : Diabetes with neurologic complications, polyneuritis and insulin treated Cohort 5 : Adult patients : Diabetes with neurologic complications, polyneuritis, with pain	Cohort 1 : 59787 Cohort 2 : 59756 Cohort 3 : 44013 Cohort 4 : 22444 Cohort 5 : 4936
ICSPECIC 383	23/09/2020	Hematology	Multiple myeloma	Phase 2	Lost	TIG-006	NCT05060432	Not Applicable	TrialTroveID-414957	A Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Multiple Myeloma Cohort 2: Multiple Myeloma adults Cohort 3: Multiple Myeloma adults with autologous stem cell transplant	Cohort 1 : 27359 Cohort 2 : 27357 Cohort 3 : 2098
ICSPECIC 384	23/09/2020	Cardiovascular	Cardiomyopathy	Phase 2	Lost	MYK-491-301	Not Applicable	Not Applicable	TrialTroveID-377864	A Phase 2 study of danicamtiv (MYK-491) in patients with systolic heart failure and paroxysmal or persistent atrial fibrillation.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Atrial fibrillation Cohort 2: Atrial fibrillation adult Cohort 3: Left Ventricular Ejection Failure (LVEF) Cohort 4: Atrial fibrillation or LVEF adult	Cohort 1 : 661272 Cohort 2 : 661119 Cohort 3 : 179123 Cohort 4 : 758624

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 385	24/09/2020	Psychiatry	Autistic disorder	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Autism Spectrum Disorder Cohort 2: Autism Spectrum Disorder adults Cohort 3: Autism Spectrum Disorder without psychosis, seizures,bipolar disorder, schizophrenia and depression	Cohort 1 : 7616 Cohort 2 : 3310 Cohort 3 : 2406
ICSPECIC 386	29/09/2020	Neurology	Degenerative disease of CNS	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Cervical dystonia adults	Cohort 1 : 616
ICSPECIC 387	01/10/2020	Dermatology	Hidradenitis Suppurativa	Phase 2	Award	IFX-1-P2.5	NCT03895801	Not Applicable	Not Applicable	A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Granulomatosis with polyangitis Cohort 2: Microscopic Polyangitis	Cohort 1 : 3021 Cohort 2 : 1378
ICSPECIC 388	05/10/2020	Neurology	Neuropathic pain	Phase 3a	Award	802NP302	NCT03637387	EudraCT Numbe	TrialTroveID-297527	A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1: Disorders of trigeminal nerve Cohort 2: Trigeminal neuralgia adults Cohort 3: Trigeminal neuralgia as main reason for hospitalisation, adults excluding clinically evident neurological deficit Cohort 4: Trigeminal neuralgia as main reason for hospitalisation, adults excluding clinically evident neurological deficit and also excluding tumours, AI and MS	Cohort 1 : 4143 Cohort 2 : 3249 Cohort 3 : 1830 Cohort 4 : 1574

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 389	06/10/2020	Oncology	Neuroendocrine tumor	Phase 1	Award	CO40778	NCT02650401	EudraCT Numbe	TrialTroveID-271136	A Phase I/II, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (RXDX-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: All paediatric neuroblastoma (under 18yrs old) Cohort 2: Neuroblastoma (5yrs and under) Cohort 3: Neuroblastoma (6-12yrs old) Cohort 4: Neuroblastoma (13-17yrs old) Cohort 5: All paediatric malignant neuroplasm unspecified part of adrenal gland (under 18yrs old)	Cohort 1 : 577 Cohort 2 : 398 Cohort 3 : 153 Cohort 4 : 38 Cohort 5 : 317
ICSPECIC 390	07/10/2020	Oncology	Solid tumor configuration	Phase 1	Award	MS201924_00(	NCT04170153	EudraCT Numbe	TrialTroveID-361719	An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Cancer Cohort 2: Cancer adults Cohort 3: Cancer adults without liquid tumours Cohort 4: Cancer adults without liquid tumours on treatment (chemo/radiotherapy	Cohort 1 : 875109 Cohort 2 : 865653 Cohort 3 : 811381 Cohort 4 : 451577
ICSPECIC 391	09/10/2020	Neurology	Neuropathic pain	Phase 3a	Award	802NP301	NCT03070132	EudraCT Numbe	TrialTroveID-211016	A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Sejourne	MCO	2016	France	Cohort 1 : Trigeminal Neuralgia Cohort 2 : Trigeminal Neuralgia adults Cohort 3 : Trigeminal Neuralgia adults without HIV Cohort 4 : Trigeminal Neuralgia adults without HIV nor HepC	Cohort 1 : 3362 Cohort 2 : 3337 Cohort 3 : 3332 Cohort 4 : 3323
ICSPECIC 392	13/10/2020	Hematology	Sickle cell disease	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1: Sickle Cell disease patients (all) Cohort 2: Sickle Cell disease patients (18-38)	Cohort 1 : 1059 Cohort 2 : 522

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 393	14/10/2020	Cardiovascular	Cardiovascular Disease	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2015-2019	France	Cohort 1: ST-Elevation Myocardial Infarction (STEMI) Cohort 2: ST-Elevation Myocardial Infarction (STEMI) adults Cohort 3: ST-Elevation Myocardial Infarction (STEMI) adults with percutaneous coronary intervention Cohort 4: ST-Elevation Myocardial Infarction (STEMI) adults with percutaneous coronary intervention without stroke or acute MI from the period 2015-2018	Cohort 1 : 127164 Cohort 2 : 79835 Cohort 3 : 51239 Cohort 4 : 47911
ICSPECIC 394	14/10/2020	Rheumatology	Systemic sclerosis	Phase 2	Award	CER-FT011-SSc	NCT04647890	EudraCT Numbe	TrialTroveID-390626	A Phase II, Randomised, Double Blind, Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamic Effects, and Safety, of Oral FT011 in Participants With Diffuse Systemic Sclerosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Scleroderma Cohort 2: Scleroderma adults Cohort 3: Scleroderma adults without patients with drug-induced scleroderma	Cohort 1 : 9919 Cohort 2 : 9865 Cohort 3 : 9839
ICSPECIC 395	22/10/2020	Rheumatology	Psoriatic arthritis	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1: Psoriatic Arthitis Patients Cohort 2: Juvenile Psoriatic Arthitis Patients	Cohort 1 : 5610 Cohort 2 : 81
ICSPECIC 396	28/10/2020	Hematology	Anemia	Phase 3a	Lost	TMP-0916_03	NCT03817957	EudraCT Numbe	TrialTroveID-341790	Safety and Efficacy of Postoperative i.v. Iron Substitution With Polyglucoferron Compared to Ferric Carboxymaltose and Oral Iron in Patients With Diagnosed Iron Deficiency Who Develop Anaemia Peri- or Postoperatively (IDA II)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Iron deficiency anemia secondary to blood loss with surgery or anaesthesia with blood transfusion Cohort 2: Iron deficiency anemia secondary to blood loss Cohort 3: Iron deficiency anemia secondary to blood loss with surgery	Cohort 1 : 5922 Cohort 1 : 91825 Cohort 1 : 24625

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 397	02/11/2020	Oncology	Non-small cell lung cancer	Phase 1	Award	GCT1044-01	NCT04424641	EudraCT Numbe	TrialTroveID-376785	First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1 : Breast Cancer (Adults) Cohort 2 : Breast Cancer (Chemotherapy treated) Cohort 3 : Breast Cancer (Metastatic) Cohort 4 : Breast Cancer (Metastatic & Chemotherapy treated) Cohort 5 : Head & Neck Cancer (Adults) Cohort 6 : Head & Neck Cancer (Chemotherapy treated) Cohort 7 : Head & Neck Cancer (Metastatic) Cohort 8 : Head & Neck Cancer (Metastatic & Chemotherapy treated) Cohort 9 : Lung Cancer (Adults) Cohort 10 : Lung Cancer (Chemotherapy treated) Cohort 11 : Lung Cancer (Metastatic) Cohort 12 : Lung Cancer (Metastatic & Chemotherapy treated) Cohort 13 : Prostate Cancer (Adults) Cohort 14 : Prostate Cancer (Chemotherapy treated) Cohort 15 : Prostate Cancer (Metastatic) Cohort 16 : Prostate Cancer (Metastatic &	Cohort 1 : 144375 Cohort 2 : 72052 Cohort 3 : 56441 Cohort 4 : 37989 Cohort 5 : 38987 Cohort 6 : 19278 Cohort 7 : 14858 Cohort 8 : 10488 Cohort 9 : 116837 Cohort 10 : 72937 Cohort 11 : 72131 Cohort 12 : 51664 Cohort 13 : 82143 Cohort 14 : 13764 Cohort 15 : 21146 Cohort 16 : 13764 Cohort 17 : 19651 Cohort 18 : 13138 Cohort 19 : 9429
ICSPECIC 398	04/11/2020	Nephrology	Focal Glomerular Sclerosis	Phase 3a	Lost	RTRX-RE021-20	NCT05003986	EudraCT Numbe	TrialTroveID-411362	A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: FSGS 1-5yrs Cohort 2: FSGS 6-10 yrs old Cohort 3: FSGS 11-18 years old Cohort 4: Immunoglobulin A nepropathy 1-5 years old Cohort 5: Immunoglobulin A nepropathy 6-10 years old Cohort 6: Immunoglobulin A nepropathy 11-18 years old	Cohort 1 : 18 Cohort 2 : 29 Cohort 3 : 66 Cohort 4 : 1 Cohort 5 : 5 Cohort 6 : 17
ICSPECIC 399	05/11/2020	Infectious Disea	Disease due to Rhinovirus	Phase 2	Lost	LYR-210-2018-(	NCT04041609	EudraCT Numbe	TrialTroveID-333940	A Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects With Chronic Sinusitis (LANTERN Study)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1: Chronic Sinusitis Cohort 2: Chronic Sinusitis w/o sinus endoscopic procedures	Cohort 1 : 14832 Cohort 2 : 5960
ICSPECIC 400	10/11/2020	Oncology	Non-small cell lung cancer	Phase 2	Award	AB-106-G208	NCT04919811	Not Applicable	TrialTroveID-357972	A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1 : Patients treated with Ciritinib OR Lorlatinib OR Cabozantinib Cohort 2 : Patients treated with Lorlatinib Cohort 3 : Patients treated with Cabozantinib Cohort 4 : Patients treated with Ceritinib	Cohort 1 : 769 Cohort 2 : 680 Cohort 3 : 42 Cohort 4 : 33

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 401	13/11/2020	Oncology	Malignant tumor of breast	Phase 1	Lost	SCO-120-19-22	NCT04942054	Not Applicable	TrialTroveID-385276	A Phase I Study to Determine Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SCO-120 in Hormone Receptor Positive, HER-2 Negative Advanced Breast Cancer Patients	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2017-2019	France	Cohort 1: Adult Breast Cancer patients seen between 2017-2019 Cohort 2: Metastatic Adult Breast Cancer patients seen between 2017-2019 Cohort 3: Metastatic Adult Breast Cancer patients seen between 2017-2019 without HER2 biologic treatment Cohort 4: Metastatic Adult Breast Cancer patients seen in 2019 without HER2 biologic treatment Cohort 5: Chemotherapy treated Metastatic Adult Breast Cancer patients seen in 2019 without HER2 biologic treatment Cohort 6: Chemotherapy treated Metastatic Adult Breast Cancer patients seen in 2019 without HER2 biologic treatment (first admitted to to the hospital for BC between 31-36 month ago - Semester 1 2017) Cohort 7: Chemotherapy treated Metastatic Adult Breast Cancer patients seen in 2019 without HER2 biologic treatment (first admitted to to the hospital for BC between 30-25 month ago - Semester 2 2017)	Cohort 1 : 279207 Cohort 2 : 98069 Cohort 3 : 84740 Cohort 4 : 43117 Cohort 5 : 26949 Cohort 6 : 5330 Cohort 7 : 2520 Cohort 8 : 2769 Cohort 9 : 5831 Cohort 10 : 6601 Cohort 11 : 4068 Cohort 12 : 486 Cohort 13 : 713184 Cohort 14 : 3949716 Cohort 15 : 5980532 Cohort 16 :
ICSPECIC 402	18/11/2020	Hematology	von Willebrand disorder	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1: Hereditary Hemorrhagic Telangiectasia (18-75 years old)	Cohort 1 : 1442
ICSPECIC 403	27/11/2020	Hematology	Diffuse large B-cell lymphoma	Not Applic	Award	MOR208C213	NCT04697160	Not Applicable	Not Applicable	An Observational Retrospective Cohort Study of Systemic Therapies for Relapsed or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL), to Compare Outcomes to Those From Tafasitamab + Lenalidomide in the L-MIND Study	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : DLBCL patients	Cohort 1 : 15826
ICSPECIC 404	01/12/2020	Oncology	Malignant neoplasm of brain	Phase 2	Lost	REC-2282-201	NCT05130866	Not Applicable	Not Applicable	A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1: Meningioma (Adults) Cohort 2: Meningioma with neurofibromatosis (Adults) Cohort 3: Treatment naive Meningioma with neurofibromatosis (Adults) Cohort 4: Neurofibromatosis (Adults)	Cohort 1 : 3574 Cohort 2 : 3080 Cohort 3 : 2574 Cohort 4 : 4307

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 405	01/12/2020	Dermatology	Psoriasis	Phase 3b	Award	TILD-19-12	NCT03997786	EudraCT Numbe	TrialTroveID-336519	A Multicenter, Randomized, Placebo and Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque Psoriasis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1 : Psoriasis Cohort 2 : Psoriasis 6-17yrs Cohort 3 : Psoriasis 6-11yrs Cohort 4 : Psoriasis 12-17yrs Cohort 5 : Psoriasis 6-17yrs taking either adalimumab, ustekinumab, etanercept, secukinumab	Cohort 1 : 19392 Cohort 2 : 163 Cohort 3 : 26 Cohort 4 : 138 Cohort 5 : 11
ICSPECIC 406	03/12/2020	Neurology	Narcolepsy	Phase 3a	Award	TAK-994-1504	NCT04820842	EudraCT Numbe	TrialTroveID-400325	A 3-Period Extension Study With Dose-Blind Period; Double-blind, Placebo-Controlled, Randomized Withdrawal Period; and Open-label Extension Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Subjects With Narcolepsy With Cataplexy (Narcolepsy Type 1)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1: Narcoleptic Patients (Adults)	Cohort 1 : 1510
ICSPECIC 407	03/12/2020	Psychiatry	Opioid dependency	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1 : Opioid related hospital admission Cohort 2 : Opioid Dependency	Cohort 1 : 1061 Cohort 2 : 468
ICSPECIC 408	10/12/2020	Oncology	Malignant tumor of breast	Phase 2	Lost	OTT 20-11 (IT-(	NCT04781725	Not Applicable	TrialTroveID-398320	A Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological Effects of Intratumoral INT230-6 in Early Stage Breast Cancer: The INVINCIBLE Trial	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1 : TNBC	Cohort 1 : 22497

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 409	10/12/2020	Cardiovascular	Essential hypertension	Phase 3a	Lost	KBP5074-3-001	NCT04968184	Not Applicable	TrialTroveID-382020	A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Chronic Kidney Disease adults Cohort 2 : Stage 3 & 4 Chronic Kidney Disease adults Cohort 3 : Stage 3 & 4 Chronic Kidney Disease adults with hypertension	Cohort 1 : 434991 Cohort 2 : 205410 Cohort 3 : 13520
ICSPECIC 410	10/12/2020	Ophthalmology	Glaucoma	Phase 3a	Award	LT4030-301	NCT04898387	EudraCT Numbe	TrialTroveID-398280	Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2018	France	Cohort 1 : Glaucoma Cohort 2 : Glaucoma adults Cohort 3 : Ocular Hypertension and open angle Glaucoma adults Cohort 4 : Glaucoma Cohort 5 : Glaucoma adults	Cohort 1 : 45125 Cohort 2 : 44848 Cohort 3 : 14154
ICSPECIC 411	14/12/2020	Women's Healt	Pre-term labor	Phase 2	Award	ER004-CLIN01/	NCT04980638	Not Applicable	Not Applicable	A Prospective, Open-label, Genotype-match Controlled, Multicenter Clinical Trial to Investigate the Efficacy and Safety of Intra-amniotic ER004 as a Prenatal Treatment for Male Subjects With XLHED	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2015-2019	France	Cohort 1 : HED Adult Female 18-40yrs (2yr lookback) Cohort 2 : HED Adult Female 18-40yrs (4-10yr lookback) Cohort 3 : HED all age & gender 2yr lookback Cohort 4 : HED Diagnosis (4- 10yr lookback) Cohort 5 : HED Pediatric All Genders < 18 yrs (2yr lookback) Cohort 6 : HED Pediatric All Genders < 18 yrs (4 - 10yr lookback) Cohort 7 : XLHED Pediatric Male < 18 yrs (2yr lookback) Cohort 8 : XLHED Pediatric Male < 18 yrs (4 - 10yr lookback))	Cohort 1 : 182 Cohort 2 : 113 Cohort 3 : 66 Cohort 4 : 22 Cohort 5 : 96 Cohort 6 : 63 Cohort 7 : 43 Cohort 8 : 11
ICSPECIC 412	14/12/2020	Respiratory	COPD	Phase 1	Lost	BP43098	Not Applicable	EudraCT Numbe	TrialTroveID-421426	Phase Ib, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety of RO7486967 in Patients with Chronic Obstructive Pulmonary Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : COPD	Cohort 1 : 260900

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 413	14/12/2020	Gastrointestina	Ulcerative colitis	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Ulcerative Colitis (all) Cohort 2 : Ulcerative Colitis (12-17 years old)	Cohort 1 : 46668 Cohort 2 : 1747
ICSPECIC 414	16/12/2020	Neurology	Multiple sclerosis	Phase 2	Award	272MS201	Not Applicable	EudraCT Numbe	Not Applicable	A Multicenter, Open-Label, Phase 2 Study to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Diroximel Fumarate (BIIB098) in Children From 10 to Less Than 18 Years of Age with Relapsing Forms of Multiple Sclerosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Multiple Sclerosis (All) Cohort 2 : Pediatric Multiple Sclerosis (10-17)	Cohort 1 : 41072 Cohort 2 : 223
ICSPECIC 415	18/12/2020	Neurology	Spinal muscular atrophy	Phase 4	Award	232SM404	NCT04488133	EudraCT Numbe	TrialTroveID-380036	A Phase 4 Study of Nusinersen (BIIB058) Among Patients With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Spinraza	Cohort 1 : 363
ICSPECIC 416	22/12/2020	Neurology	Friedreich's ataxia	Phase 1	Award	260SA101	NCT05160558	EudraCT Numbe	TrialTroveID-420861	A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia 3	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : friedreich ataxia Cohort 2 : Other inherited ataxia (G111)	Cohort 1 : 1169 Cohort 2 : 297

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 417	23/12/2020	Oncology	Solid tumor configuration	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Solid tumours	Cohort 1 : 712034
ICSPECIC 418	03/01/2021	Nephrology	Focal Glomerular Sclerosis	Phase 3a	Award	DMX-200-301	NCT05183646	Not Applicable	Not Applicable	A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : FSGS 8-75yrs old Cohort 2 : FSGS 8-75yrs old without late stage CKD Cohort 3 : FSGS 8-75yrs old without late stage CKD without dialysis Cohort 4 : FSGS 8-75yrs old without late stage CKD without dialysis nor T1D Cohort 5 : FSGS 8-17yrs old without late stage CKD without dialysis nor T1D Cohort 6 : FSGS 18-75yrs old without late stage CKD without dialysis nor T1D	Cohort 1 : 1153 Cohort 2 : 748 Cohort 3 : 737 Cohort 4 : 720 Cohort 5 : 67 Cohort 6 : 654
ICSPECIC 419	05/01/2021	Rheumatology	Osteoarthritis	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1: Presence of orthopaedic joint implants (Z966) Cohort 2: Procedure code Cohort 3: Patients with orthopaedic joint implants who have undergone knee implant procedure	Cohort 1 : 10100 Cohort 2 : 129575 Cohort 3 : 201947
ICSPECIC 420	08/01/2021	Oncology	Malignant tumor of breast	Phase 2	Lost	ACE-Breast-03	NCT04829604	Not Applicable	TrialTroveID-400729	A Global, Phase II Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM-1 or T-DXd, and/or Tucatinib-containing Regimens	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Breast cancer Cohort 2 : Breast cancer adult Cohort 3 : Breast cancer adult metastatic Cohort 4 : Breast cancer adult metastatic, with kadcyla	Cohort 1 : 180219 Cohort 2 : 180211 Cohort 3 : 59896 Cohort 4 : 1353

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 421	08/01/2021	Oncology	Malignant Melanoma	Phase 3a	Award	HBI-8000-303	NCT04674683	Not Applicable	TrialTroveID-392321	A Multicenter, Randomized, Double-Blind Phase III Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Chemo (Z51.1*) Cohort 2 : Patients 12 years or more, diagnosed with Malignant melanoma (C43*)	Cohort 1 : 5218 Cohort 2 : 21170
ICSPECIC 422	12/01/2021	Hematology	Diffuse large B-cell lymphoma	Phase 2	Award	GCT3013-02	NCT04663347	EudraCT Numbe	TrialTroveID-385006	A Phase Ib/II, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : DLBCL adults Cohort 2 : DLBCL adults with chemo	Cohort 1 : 16047 Cohort 2 : 8820
ICSPECIC 423	12/01/2021	Gastrointestina	Extra-intestinal Pathogenic E. coli	Phase 3	Award	VAC52416BAC3	NCT04899336	EudraCT Numbe	TrialTroveID-404846	Randomized, double-blind, placebo-controlled, multicenter phase 3 study to assess the efficacy, safety and immunogenicity of vaccination with ExPEC9V in the prevention of invasive extraintestinal pathogenic Escherichia Coli disease in adults aged 60 years and older with a history of Urinary Tract Infection in the past 2 years	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : E coli Septecaemia all ages Cohort 2 : E coli Septecaemia 60 years and over Cohort 3 : Patients with E coli Septecaemia and E.coli as the cause of diseases classified elsewhere,all ages Cohort 4 : Patients with E coli Septecaemia and E.coli as the cause of diseases classified elsewhere 60yrs and above Cohort 5 : Patients with E coli Septecaemia and and Invasive disease,all ages Cohort 6 : Patients with E coli Septecaemia and and Invasive disease, 60yrs and above Cohort 7 : Patients with E coli Septecaemia and E.coli as the cause of diseases classified elsewhere and Invasive disease,all ages Cohort 8 : Patients with E coli Septecaemia and E.coli as the cause of diseases classified elsewhere,and Invasive disease 60yrs and above Cohort 9 : Patients with E.coli as the cause of diseases classified elsewhere and Invasive disease all ages	Cohort 1 : 72688 Cohort 2 : 57860 Cohort 3 : 38541 Cohort 4 : 31532 Cohort 5 : 30405 Cohort 6 : 23541 Cohort 7 : 16520 Cohort 8 : 13198 Cohort 9 : 79869 Cohort 10 : 55988
ICSPECIC 424	14/01/2021	Neurology	Multiple sclerosis	Phase 3a	Lost	WN42086	NCT05123703	EudraCT Numbe	TrialTroveID-412327	A phase III multicenter, randomized, double-blind, double-dummy study to evaluate safety and efficacy of ocrelizumab in comparison with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : MS Cohort 2 : MS 10-18yrs Cohort 3 : MS 10-18yrs, with optic nevritis Cohort 4 : MS 10-18yrs, with optic nevritis and lumbar puncture Cohort 5 : MS 10-18yrs with lumbar puncture	Cohort 1 : 25157 Cohort 2 : 144 Cohort 3 : 13 Cohort 4 : 3 Cohort 5 : 17

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 425	15/01/2021	Oncology	Non-small cell lung cancer	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : lung cancer adults	Cohort 1 : 141647
ICSPECIC 426	15/01/2021	Nephrology	Focal Glomerular Sclerosis	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : FSGS Cohort 2 : FSGS 12yrs and above Cohort 3 : FSGS 12yrs and above excluding Type 1 diabetes, late stage kidney disease	Cohort 1 : 1473 Cohort 2 : 1432 Cohort 3 : 841
ICSPECIC 427	15/01/2021	Nephrology	Alport syndrome	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Alport Cohort 2 : Alport 12yrs and above Cohort 3 : Alport 12yrs and above excluding Type 1 diabetes, late stage kidney disease	Cohort 1 : 2027 Cohort 2 : 967 Cohort 3 : 763
ICSPECIC 428	15/01/2021	Infectious Disea	Bacterial infectious disease	Phase 2	Lost	TBD	Not Applicable	Not Applicable	TrialTroveID-338285	A Randomized, Double-blind, Multicenter, Phase IIb Clinical Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of LSVT-1701 Compared to Placebo as an Add-on to Standard of Care Antibiotics for the Treatment of Complicated Methicillin-resistant Staphylococcus aureus(MRSA) Bacteremia Including Left-and Right-sided Infective Endocarditis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : MRSA adults Cohort 2 : MRSA adults with endocarditis	Cohort 1 : 23242 Cohort 2 : 2056

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 429	19/01/2021	Cardiovascular	Heart failure	Phase 2	Award	CDR132L-P2-01	Not Applicable	EudraCT Numbe	TrialTroveID-390335	Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction (≤ 45%) After Myocardial Infarction (HF-REVERT)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Myocardial Infarction Cohort 2 : Myocardial Infarction without non-ischemic heart failure Cohort 3 : Myocardial Infarction without non-ischemic heart failure nor liver disease Cohort 4 : Myocardial Infarction without non-ischemic heart failure nor liver disease,thrombocytopenia Cohort 5 : Myocardial Infarction Cohort 6 : Myocardial Infarction without non-ischemic heart failure Cohort 7 : Myocardial Infarction without non-ischemic heart failure nor liver disease Cohort 8 : Myocardial Infarction without non-ischemic heart failure nor liver disease,thrombocytopenia	Cohort 1 : 134752 Cohort 2 : 108060 Cohort 3 : 107466 Cohort 4 : 106456 Cohort 5 : 134752 Cohort 6 : 108060 Cohort 7 : 107466 Cohort 8 : 106456
ICSPECIC 430	21/01/2021	Gastrointestina	Crohn's disease	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Crohn's disease Cohort 2 : Crohn's disease adults Cohort 3 : Crohn's disease adults with illeocecal resection	Cohort 1 : 59423 Cohort 2 : 56669 Cohort 3 : 736
ICSPECIC 431	27/01/2021	Neurology	Postherpetic neuralgia	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Adults patients with Postherpatic Neuralgia	Cohort 1 : 1783
ICSPECIC 432	29/01/2021	Oncology	Non-small cell lung cancer	Phase 2	Award	MS200095_003	NCT03940703	EudraCT Numbe	TrialTroveID-348972	A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1 : Lung cancer Cohort 2 : Metastatic lung cancer	Cohort 1 : 133328 Cohort 2 : 73509

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 433	04/02/2021	Gastrointestina	Ulcerative colitis	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Ulcerative colitis patients 18-75 with drugs Cohort 2 : Ulcerative colitis patients 18-75 without drugs (tsDMARDs or bDMARDs)	Cohort 1 : 5493 Cohort 2 : 35892
ICSPECIC 434	04/02/2021	Oncology	Cholangiocarcinoma	Phase 3a	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Cholangiocarcinoma	Cohort 1 : 7453
ICSPECIC 435	05/02/2021	Allergy	Angioedema	Phase 2	Award	PHA022121-C3	NCT05047185	EudraCT Numbe	TrialTroveID-414109	A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Thomas Verrier	MCO	2019	France	Cohort 1 : Angioedema 12-18yrs Cohort 2 : Angioedema 18-75yrs Cohort 3 : HAE 12 to 18 Cohort 4 : HAE 18 to 75	Cohort 1 : 70 Cohort 2 : 1709 Cohort 3 : 9 Cohort 4 : 217
ICSPECIC 436	09/02/2021	Respiratory	Fibrosis of lung	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Fibrosing ILD patients 18-85 year olds Cohort 2 : Respiratory diseases linked to connective tissue disease	Cohort 1 : 20536 Cohort 2 : 1942

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 437	11/02/2021	Hematology	Acute lymphocytic leukemia	Phase 2	Lost	MB-CART2219.	NCT03853616	EudraCT Numbe	TrialTroveID-324535	A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients with Relapsed or Refractory CD19 Positive B Cell Malignancies	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Acute lymphoblastic leukemia Cohort 2 : Acute lymphoblastic leukemia with allogenic HSCT	Cohort 1 : 2643 Cohort 2 : 318
ICSPECIC 438	12/02/2021	Respiratory	Fibrosis of lung	Phase 4	Award	HQ-NIS-CHF-07	NCT04864795	Not Applicable	Not Applicable	Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia (CARE-HK in HF Registry)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018-2019	France	Cohort 1 : Heart Failure adults 2018 &2019 Cohort 2 : Heart Failure adults 2018 &2019 with hyperkalemia	Cohort 1 : 920395 Cohort 2 : 123154
ICSPECIC 439	12/02/2021	Nephrology	Polycystic kidney disease	Phase 3	Lost	PA-ADPKD-301	NCT04064346	EudraCT Numbe	TrialTroveID-355694	A 2-Year, Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants With Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-label Phase	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : ADPKD patients (18-60 years) Cohort 2 : ADPKD patients excluding CKD stage 4/5 or ESRD	Cohort 1 : 1061 Cohort 2 : 468
ICSPECIC 440	17/02/2021	Oncology	Head and neck cancer	Phase 1	Award	H-200-001	NCT04180215	EudraCT Numbe	TrialTroveID-315015	A Phase I/II Study of TheraT Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Head and Neck Cancer Cohort 2 : HPV Tumors	Cohort 1 : 52354 Cohort 2 : 3454

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 441	18/02/2021	Immune system	Thrombocytopenia	Late Phas	Lost	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Guillaume Barbe	MCO	2017-2019	France	Cohort 1: Immune thrombocytopenic purpura diagnosis	Cohort 1 : 3030
ICSPECIC 442	19/02/2021	Gastrointestina	Ulcerative colitis	Phase 3a	Award	I6T-MC-AMBI	NCT04469062	EudraCT Numbe	TrialTroveID-379245	A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in Participants With Moderately to Severely Active Ulcerative Colitis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2016	France	Cohort 1 : Ulcerative colitis Cohort 2 : Ulcerative colitis (18-80 yr olds) Cohort 3 : Ulcerative colitis (18-80 yr olds) without TB Cohort 4 : Ulcerative colitis (18-80 yr olds) without TB nor hepatitis Cohort 5 : Ulcerative colitis (18-80 yr olds) without TB nor hepatitis nor colonic surgery Cohort 6 : Ulcerative colitis (18-80 yr olds) without TB nor hepatitis nor colonic surgery on drugs	Cohort 1 : 21475 Cohort 2 : 18892 Cohort 3 : 18851 Cohort 4 : 18764 Cohort 5 : 18250 Cohort 6 : 324
ICSPECIC 443	19/02/2021	Oncology	Bladder cancer	Phase 2	Award	213152	NCT04349280	EudraCT Numbe	TrialTroveID-372105	A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Bladder cancer Cohort 2 : Bladder cancer (adults) Cohort 3 : Bladder cancer (adults) with chemotherapy Cohort 4 : Metastatic Bladder cancer (adults) Cohort 5 : Metastatic Bladder cancer (adults) with chemotherapy	Cohort 1 : 71155 Cohort 2 : 71093 Cohort 3 : 21479 Cohort 4 : 2012 Cohort 5 : 1115
ICSPECIC 444	22/02/2021	Respiratory	Asthma	Phase 2	Lost	601-0014	NCT03960606	EudraCT Numbe	TrialTroveID-320329	A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Asthma adults Cohort 2 : Asthma adults with ABPA	Cohort 1 : 94430 Cohort 2 : 439

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 445	23/02/2021	Ophthalmology	Graves ophthalmopathy	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Macular degeneration (diabetic or age-related)	Cohort 1 : 73158
ICSPECIC 446	25/02/2021	Hematology	Immune thrombocytopenic purpur	Phase 3a	Award	TAK-755-3002	NCT04683003	Not Applicable	Not Applicable	A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS-13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : TTP (18-75yrs old) Cohort 2 : TTP (18-75yrs old) with exclusions Cohort 3 : TTP (18-75yrs old) with exclusions with plasmapheresis	Cohort 1 : 1538 Cohort 2 : 1008 Cohort 3 : 218
ICSPECIC 447	02/03/2021	Infectious Disea	Sepsis	Phase 2	Lost	ADR-02	NCT03085758	EudraCT Numbe	TrialTroveID-297960	A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Proof of Concept and Dose-Finding Phase II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of ADRECIZUMAB in Patients With Septic Shock and Elevated Adrenomedullin	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Septic shock Cohort 2 : Septic shock with resuscitation fluids Cohort 3 : Toxic Shock	Cohort 1 : 231020 Cohort 2 : 28809 Cohort 3 : 247
ICSPECIC 448	03/03/2021	Neurology	Epilepsy	Phase 2	Award	N01269	NCT04666610	EudraCT Numbe	TrialTroveID-391740	A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Epilepsy 2-25yr olds Cohort 2 : Absence Epilepsy 2-25yr olds	Cohort 1 : 23592 Cohort 2 : 4353

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 449	05/03/2021	Endocrinology	Obesity	Phase 2	Award	RM-493-030	NCT04725240	Not Applicable	TrialTroveID-395119	A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects With Hypothalamic Obesity	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : OBESITY PATIENTS	Cohort 1 : 35703
ICSPECIC 450	11/03/2021	Neurology	Spinal cord disease	Phase 2	Award	232SM203	NCT04089566	EudraCT Numbe	TrialTroveID-357159	Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Spinal muscular atrophy and related syndromes Cohort 2 : Spinal muscular atrophy and related syndromes with Cohort 3 : lumbar puncture	Cohort 1 : 341 Cohort 2 : 40 Cohort 3 : 12889
ICSPECIC 451	12/03/2021	Neurology	Alzheimer's disease	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Mild Alzheimers disease Cohort 2 : Mild Alzheimers disease without exlusion criteria Cohort 3 : Mild Alzheimers disease without exlusion criteria nor cardiovascular diseases	Cohort 1 : 2329 Cohort 2 : 2179 Cohort 3 : 1735
ICSPECIC 452	16/03/2021	Cardiovascular	Thromboembolism of vein	Phase 3a	Award	ALXN1210-TMA	NCT04557735	Not Applicable	Not Applicable	A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants With Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplantation (HSCT)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Paediatric Bone Marrow Transplant Cohort 2 : Thrombotic microangiopathy post Bone Marrow Transplant	Cohort 1 : 1053 Cohort 2 : 55

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 453	16/03/2021	Hematology	Hemolytic Anemia	Phase 3a	Award	ALXN1210-TMA	NCT04543591	Not Applicable	Not Applicable	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants Who Have Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Adult Bone Marrow Transplant	Cohort 1 : 6460
ICSPECIC 454	16/03/2021	Neurology	Amyotrophic lateral sclerosis	Phase 3	Lost	MN-166-ALS-2	NCT04057898	EudraCT Numbe	TrialTroveID-333564	A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Amyotrophic lateral sclerosis	Cohort 1 : 7251
ICSPECIC 455	19/03/2021	Oncology	Malignant tumor of breast	Phase 3	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Breast cancer adults Cohort 2 : Metastatic Breast cancer adults Cohort 3 : Metastatic Breast cancer adults with trastuzimab and trastizumab emtansine Cohort 4 : Metastatic Breast cancer adults with trastuzimab Cohort 5 : Metastatic Breast cancer adults with trastuzimab emtansine	Cohort 1 : 143223 Cohort 2 : 50902 Cohort 3 : 5622 Cohort 4 : 5237 Cohort 5 : 1069
ICSPECIC 456	19/03/2021	Other	Amyloidosis	Phase 3	Award	CAEL101-302	NCT04512235	EudraCT Numbe	TrialTroveID-381872	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naive Patients With Mayo Stage IIIa AL Amyloidosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : AL Amyloidosis adults Cohort 2 : AL Amyloidosis with heart failure adults Cohort 3 : AL Amyloidosis with heart failure adults with ECG Cohort 4 : AL Amyloidosis with heart failure adults with ECG excluding SCT, Daratumumab, MM and congenital heart disease	Cohort 1 : 6305 Cohort 2 : 2863 Cohort 3 : 2614 Cohort 4 : 2188

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 457	24/03/2021	Oncology	Carcinoma of biliary tract	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Patients with Biliary tract cancers	Cohort 1 : 14149
ICSPECIC 458	30/03/2021	Transplantation	Transplant	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : adult_IIM_pateints Cohort 2 : IIM patients excluding vaccinated patients Cohort 3 : IIM patients excluding HBV, HCV, HIV	Cohort 1 : 723 Cohort 2 : 723 Cohort 3 : 714
ICSPECIC 459	31/03/2021	Hematology	Myelodysplastic syndrome	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : AML and CMML Excluded Cohort 2 : Excluded Drugs Cohort 3 : ICD 10	Cohort 1 : 22395 Cohort 2 : 22395 Cohort 3 : 24574
ICSPECIC 460	31/03/2021	Cardiovascular	Aortic thromboembolism	Phase 3	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Aortic stenosis Cohort 2 : Aortic stenosis 50 plus Cohort 3 : Aortic stenosis 50 plus with procedures	Cohort 1 : 94997 Cohort 2 : 93853 Cohort 3 : 91649

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 461	07/04/2021	Respiratory	Asthma	Phase 3	Award	206785	NCT04718389	EudraCT Numbe	TrialTroveID-394923	A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Asthma Cohort 2 : Patients on Benralizumab (Faserna) and Mepolizumab (Nucula)	Cohort 1 : 119638 Cohort 2 : 2957
ICSPECIC 462	09/04/2021	Oncology	Malignant neoplasm of skin	Phase 4	Lost	W00118 CR 40	NCT04875026	Not Applicable	Not Applicable	Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Actinic keratosis patients aged 18 and older (L57.0)	Cohort 1 : 6255
ICSPECIC 463	13/04/2021	Women's Healt	Pre-term labor	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Tocolysis for prevention of preterm labour	Cohort 1 : 13302
ICSPECIC 464	13/04/2021	Hematology	Blood disease	Phase 3a	Award	071102	NCT02932618	EudraCT Numbe	TrialTroveID-288412	A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2018	France	Cohort 1 : VWD patient (all ages) Cohort 2 : VWD patient (all ages) Cohort 3 : VWD patient (paediatric) Cohort 4 : VWD patient (paediatric) Cohort 5 : VWD patient (0-6) Cohort 6 : VWD patient (0-6) Cohort 7 : VWD patient (7-12) Cohort 8 : VWD patient (7-12) Cohort 9 : VWD patient (13-18) Cohort 10 : VWD patient (13-18) Cohort 11 : All VWD patient (all ages) Cohort 12 : Surgery VWD patient (all ages) Cohort 13 : All VWD patient (paediatric) Cohort 14 : Surgery VWD patient (paediatric) Cohort 15 : All VWD patient (0-6) Cohort 16 : Surgery VWD patient (0-6) Cohort 17 : All VWD patient (7-12) Cohort 18 : Surgery VWD patient (7-12) Cohort 19 : All VWD patient (13-18)	Cohort 1 : 3128 Cohort 2 : 779 Cohort 3 : 673 Cohort 4 : 211 Cohort 5 : 252 Cohort 6 : 90 Cohort 7 : 180 Cohort 8 : 48 Cohort 9 : 277 Cohort 10 : 82 Cohort 11 : 3128 Cohort 12 : 779 Cohort 13 : 673 Cohort 14 : 211 Cohort 15 : 252 Cohort 16 : 90 Cohort 17 : 180 Cohort 18 : 48 Cohort 19 : 277

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 465	16/04/2021	Cardiovascular	Cardiomyopathy	Phase 1	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : PATIENTS WITH Implantable Cardioverter-Defibrillators	Cohort 1 : 9822
ICSPECIC 466	19/04/2021	Oncology	Malignant tumor of breast	Phase 2	Award	MS200647_00	NCT04489940	EudraCT Numbe	TrialTroveID-348926	A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : TNBC	Cohort 1 : 3598
ICSPECIC 467	20/04/2021	Respiratory	Pneumonia	Phase 3a	Lost	AR-320-001	NCT03816956	EudraCT Numbe	TrialTroveID-341291	A Randomized double-blind placebo-controlled multicenter Phase 3 study of efficacy and safety of AR-301 as adjunct therapy to antibiotics in the treatment of Ventilator-Associated Pneumonia (VAP) caused by S. aureus	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : all patients on ventilators Cohort 2 : all patients on ventilators due to pneumonia Cohort 3 : all adult patients on ventilators Age 18 _ 65 Cohort 4 : adult patients on ventilators due to pneumonia Age 18 _ 65 Cohort 5 : all child patients on ventilators Age 12 _ 17 Cohort 6 : child patients on ventilators due to pneumoniaAge 12 _ 17	Cohort 1 : 572476 Cohort 2 : 86187 Cohort 3 : 213800 Cohort 4 : 28812 Cohort 5 : 7485 Cohort 6 : 741
ICSPECIC 468	20/04/2021	Pneumology	Asthma	Late Phas	Award	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Guillaume Barbe	MCO	2017-2019	France	Cohort 1: Status asthmaticus diagnosis	Cohort 1 : 34846

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 469	21/04/2021	Nephrology	Kidney disease	Phase 3	Award	REGEN-006	NCT05099770	Not Applicable	TrialTroveID-417144	A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease (REGEN-006)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : T2DM and CKD patients (excluding T1DM, Renal transplant and dialysis patients)	Cohort 1 : 642262
ICSPECIC 470	26/04/2021	Hematology	Chronic lymphocytic leukemia	Phase 3	Award	LOXO-BTK-200	NCT05023980	Not Applicable	TrialTroveID-412513	A Phase III Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : patients with CLL/SLL Cohort 2 : patients with CLL/SLL treated with Bendamustine	Cohort 1 : 19395 Cohort 2 : 893
ICSPECIC 471	27/04/2021	Endocrinology	Obesity	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Gastric Bypass stent Cohort 2 : Obesity Cohort 3 : Obesity + Gastric Bypass Stent	Cohort 1 : 10186 Cohort 2 : 346941 Cohort 3 : 9936
ICSPECIC 472	28/04/2021	Respiratory	Asthma	Phase 3	Award	213744	NCT04718103	EudraCT Numbe	TrialTroveID-394933	A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Asthma Cohort 2 : Asthma 12 and above Cohort 3 : Asthma caused by allergies, 12yrs and above without HIV Cohort 4 : Asthma caused by allergies, 12yrs and above without HIV nor respiratory diseases Cohort 5 : Asthma caused by allergies, 12yrs and above without HIV nor respiratory diseases nor liver diseases	Cohort 1 : 147741 Cohort 2 : 111000 Cohort 3 : 96447 Cohort 4 : 93147 Cohort 5 : 92631

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 473	28/04/2021	Respiratory	Asthma	Phase 3a	Award	206713	NCT04719832	EudraCT Numbe	TrialTroveID-394886	A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Asthma Cohort 2 : Asthma 12 and above Cohort 3 : Asthma caused by allergies, 12yrs and above without HIV Cohort 4 : Asthma caused by allergies, 12yrs and above without HIV nor respiratory diseases Cohort 5 : Asthma caused by allergies, 12yrs and above without HIV nor respiratory diseases nor liver diseases	Cohort 1 : 147741 Cohort 2 : 111000 Cohort 3 : 96447 Cohort 4 : 93147 Cohort 5 : 92631
ICSPECIC 474	29/04/2021	Neurology	Degenerative disease of CNS	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Patient diagnosed with SCA Cohort 2 : Patients diagnosed with SCA 18-75yrs and obese (BMI under 35)	Cohort 1 : 4448 Cohort 2 : 4097
ICSPECIC 475	03/05/2021	Dermatology	Alopecia	Phase 3	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Adult female patients diagnosed with Androgenic Alopecia	Cohort 1 : 98
ICSPECIC 476	04/05/2021	Hematology	Chronic lymphocytic leukemia	Phase 3a	Award	LOXO-BTK-200	NCT04666038	EudraCT Numbe	TrialTroveID-391752	A Phase III Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2018	France	Cohort 1 : Patients with CLL/SLL; Age 18+ Cohort 2 : Drug basket IBRUTINIB Cohort 3 : CLL or SLL (All) Cohort 4 : CLL or SLL (18+)	Cohort 1 : 14302 Cohort 2 : 1639

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 477	04/05/2021	Hematology	Non-Hodgkin lymphoma	Phase 3a	Award	LOXO-BTK-200	NCT04662255	EudraCT Numbe	TrialTroveID-391067	A Phase III, Head-to-head Study of LOXO-305 versus Investigator's Choice of Covalent BTK Inhibitor in Relapsed-Refractory Mantle Cell Lymphoma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2018	France	Cohort 1 : Patients with Mantel cell lymphoma Cohort 2 : Patients with Mantel cell lymphoma with chemo Cohort 3 : CLL or SLL (All) Cohort 4 : CLL or SLL (18+)	Cohort 1 : 3861 Cohort 2 : 2333
ICSPECIC 478	04/05/2021	Neurology	Parkinson's disease	Phase 3a	Award	BIA-91067-303	NCT04978597	EudraCT Numbe	TrialTroveID-405422	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel-Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add-on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson's Disease Patients, With an Open-Label Extension	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2015-2019	France	Cohort 1: Parkinsons from 30-80 years from 2015-2019	Cohort 1: 160 367
ICSPECIC 479	11/05/2021	Oncology	Solid tumor configuration	Phase 1	Lost	M21-404	NCT05029882	EudraCT Numbe	TrialTroveID-412852	A Phase I First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects With Advanced Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Patients with colorectal cancers Cohort 2 : NSCLC Cohort 3 : Patients with gastroesophageal adenocarcinoma	Cohort 1 : 136518 Cohort 2 : 119891 Cohort 3 : 11922
ICSPECIC 480	11/05/2021	Endocrinology	Diabetes mellitus type 1	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : 18-40 years, Diabetes mellitus Type I Cohort 2 : Type 1 diabetes aged 18-40years excluding obesity and infectious diseases Cohort 3 : Type 1 diabetes mellitus without complications 18-40years excluding obesity and infectious diseases Cohort 4 : Type 1 diabetes mellitus without complications aged 18-40years	Cohort 1 : 23001 Cohort 2 : 20909 Cohort 3 : 13500 Cohort 4 : 14758

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 481	13/05/2021	Hematology	Anemia	Phase 2	Award	KER047-IR-201	Not Applicable	EudraCT Numbe	TrialTroveID-410277	A Phase 2, Open-label, Dose Escalation and Dose Expansion Study of KER-047 for the Treatment of IRIDA	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Anemia of other cause	Cohort 1 : 171381
ICSPECIC 482	14/05/2021	Neurology	Traumatic brain injury	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Patients with traumatic brain injury	Cohort 1 : 30538
ICSPECIC 483	17/05/2021	Hematology	Myelofibrosis	Phase 2	Award	NS-018-201	NCT04854096	Not Applicable	TrialTroveID-402252	A Phase IIb, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 Versus Best Available Therapy in Subjects With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/µL)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : MF	Cohort 1 : 1702
ICSPECIC 484	20/05/2021	Respiratory	Chronic cough	Phase 3a	Award	BUS-P2-02	NCT04678206	EudraCT Numbe	TrialTroveID-378715	A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2b Study to Evaluate the Efficacy and Safety of Multiple Doses of BLU-5937 in Adult Participants With Refractory Chronic Cough	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018-2019	France	Cohort 1 : Cough as main reason for hospitalisation 2018-2019 Cohort 2 : Cough as main reason for hospitalisation in 2018-2019 without respiratory comorbities Cohort 3 : Cough as main reason for hospitalisation in 2018-2019 without respiratory comorbities nor smoke Cohort 4 : Chronic Cough as main reason for hospitalisation in 2018-2019 without respiratory comorbities nor smoke	Cohort 1 : 7602 Cohort 2 : 6571 Cohort 3 : 6214 Cohort 4 : 98

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 485	24/05/2021	Infectious Disea	COVID-19	Phase 3	Award	GT0918-US-30	NCT05009732	Not Applicable	TrialTroveID-411544	A Randomized, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : rsv all Cohort 2 : rsv adults Cohort 3 : Grippe adults	Cohort 1 : 26271 Cohort 2 : 4804 Cohort 3 : 36088
ICSPECIC 486	27/05/2021	Hematology	Chronic lymphocytic leukemia	Phase 3a	Award	LOXO-BTK-200	NCT04965493	EudraCT Numbe	TrialTroveID-398433	A Phase III Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : CLL or SLL	Cohort 1 : 18945
ICSPECIC 487	27/05/2021	Oncology	Malignant tumor of ovary	Phase 2	Award	IMGN853-0419	NCT05041257	EudraCT Numbe	TrialTroveID-413645	A Phase II, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Inpatient Admission of Ovarian Cancer Cohort 2 : Ovarian cancer patients on Bevacizumab Cohort 3 : Platinum sensitive ovarian cancer	Cohort 1 : 28381 Cohort 2 : 3110 Cohort 3 : 232
ICSPECIC 488	28/05/2021	Hematology	Myelodysplastic syndrome	Phase 2	Award	KER050-MD-20	NCT04419649	Not Applicable	TrialTroveID-376276	A Phase II, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : MDS Drug basket Cohort 2 : Patients with MDS	Cohort 1 : 38346 Cohort 2 : 24613

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 489	31/05/2021	Oncology	Erythropoiesis-stimulating agents among chemotherapy patients	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Anaemia Cohort 2 : Solid tumours with anaemia Cohort 3 : Solid tumours with therapy & anaemia	Cohort 1 : 370757 Cohort 2 : 86582 Cohort 3 : 45684
ICSPECIC 490	31/05/2021	Neurology	Epilepsy	Phase 3	Award	GWEP17005	NCT04485104	EudraCT Numbe	TrialTroveID-380300	An Open-label, Randomized Trial to Assess the Safety, Pharmacokinetics, and Exploratory Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) Compared With Standard of Care Antiseizure Medication, in Patients Age 1 Month to Less Than 12 Months of Age With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Doose Syndrome	Cohort 1 : 3732
ICSPECIC 491	07/06/2021	Other	Amyloidosis	Phase 2	Lost	54767414AMY	NCT05250973	EudraCT Numbe	TrialTroveID-425767	A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Patients diagnosed with Amyloid Light Chain (AL) Amyloidosis Cohort 2 : Drugs included are DARATUMUMAB, BORTEZOMIB Cohort 3 : Amyloidosis patient excluding those with COPD, MM, HIV, and Stem cell transplants Cohort 4 : Patients with AL Amyloidosis treated with Daratumumab and Bortezomib and excluding those with COPD, MM, HIV, and Stem cell transplants	Cohort 1 : 1469 Cohort 2 : 114 Cohort 3 : 1203 Cohort 4 : 57
ICSPECIC 492	09/06/2021	Oncology	Gastrointestinal cancer	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Gastroesophageal cancer patients	Cohort 1 : 30542

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 493	10/06/2021	Oncology	Solid tumor configuration	Phase 1	Award	BDTX-1535-101	NCT05256290	Not Applicable	TrialTroveID-407960	Phase I Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Participants With Glioblastoma or Non-Small Cell Lung Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Adult Patients Diagnosed with GBM Cohort 2 : Adult Patients Diagnosed with NSCLC Cohort 3 : Adult Patients diagnosed with NSCLC and treated with Osimertinib	Cohort 1 : 20194 Cohort 2 : 137734 Cohort 3 : 927
ICSPECIC 494	15/06/2021	Infectious Disea	Clostridium difficile colitis	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Patients with C; Difficile infection and treated with Fidaxomicin or Bezlotoxumab	Cohort 1 : 1017
ICSPECIC 495	16/06/2021	Rheumatology	Systemic sclerosis	Phase 2	Award	EHP-101-SS01	NCT04166552	Not Applicable	TrialTroveID-361501	A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : PATIENTS WITH DCSSc	Cohort 1 : 2296
ICSPECIC 496	17/06/2021	Oncology	Small cell carcinoma of lung	Phase 2	Award	MS201923_005	NCT04768296	EudraCT Numbe	TrialTroveID-397672	A Phase II, Open-label, Single-arm Study of Berzosertib (M6620) in Combination With Topotecan in Participants With Relapsed Platinum-resistant Small-Cell Lung Cancer (DDRiver SCLC 250)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Adult patients diagnosed with SCLC	Cohort 1 : 137734

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 497	21/06/2021	Oncology	Malignant tumor of prostate	Phase 2	Lost	IRAS ID 239796	NCT03436485	EudraCT Numbe	TrialTroveID-318882	Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Prostate cancer patients on Cabazitaxel treatment Cohort 2 : Drugs included are Abiraterone and Enzalutamide Cohort 3 : Prostate cancer patients Cohort 4 : Drugs included are Abiraterone and Enzalutamide	Cohort 1 : 118035 Cohort 2 : 1760 Cohort 3 : 118035 Cohort 4 : 5506
ICSPECIC 498	21/06/2021	Gastrointestina	Crohn's disease	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Postoperative Crohn's Disease	Cohort 1 : 707
ICSPECIC 499	22/06/2021	Immunology	Eosinophilic Granulomatosis with Polyangiitis (EGPA)	Phase 3	Lost	217102	NCT05263934	Not Applicable	Not Applicable	A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : EGPA, Adults, all incl/excl Cohort 2 : Eosinophilic Granulomatosis with Polyangiitis (EGPA), Adults â‰¥ 18 years	Cohort 1 : 33 Cohort 2 : 890
ICSPECIC 500	22/06/2021	Respiratory	Cystic fibrosis	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : CF patients on Ivacaftor and Ivacaftor+Lumacaftor (drug basket) Cohort 2 : Patients with Cystic Fibrosis	Cohort 1 : 655 Cohort 2 : 5137

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 501	22/06/2021	Immunology	Hypereosinophilic syndrome (HES)	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : HES-related worsening of clinical symptoms Cohort 2 : Hypereosinophilic syndrome, Adults â‰¥ 18 years	Cohort 1 : 6901 Cohort 2 : 8030
ICSPECIC 502	30/06/2021	Oncology	Solid tumor configuration	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : PATIENTS WITH CRC Cohort 2 : PATIENTS WITH DLBCL Cohort 3 : PATIENTS WITH MCL Cohort 4 : PATIENTS WITH NSCLC Cohort 5 : PATIENTS WITH PANCREATIC CANCER Cohort 6 : PATIENTS WITH TNBC	Cohort 1 : 110789 Cohort 2 : 10260 Cohort 3 : 1680 Cohort 4 : 98017 Cohort 5 : 42373 Cohort 6 : 110789
ICSPECIC 503	05/07/2021	Neurology	Parkinson's disease	Phase 3a	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : PD	Cohort 1 : 36040
ICSPECIC 504	05/07/2021	Hematology	Aneurysmal subarachnoid hemorrhage	Late Phas	Lost	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Guillaume Barbe	MCO	2017-2019	France	Cohort 1: Nontraumatic subarachnoid hemorrhage diagnosis	Cohort 1 : 7150

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 505	06/07/2021	Oncology	Bladder cancer	Phase 2	Award	MS100070_01	NCT03674424	EudraCT Numbe	TrialTroveID-320948	Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Patients with Urothelial cancers	Cohort 1 : 73192
ICSPECIC 506	06/07/2021	Oncology	Non-small cell lung cancer	Phase 2	Award	m14 - 239	NCT03539536	EudraCT Numbe	TrialTroveID-325157	Phase II, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Patients with lung caners NSCLC Cohort 2 : Drugs included are Erlotinib, Osimertinib, Loratinib, Brigatinib, and Alectinib	Cohort 1 : 95443 Cohort 2 : 2439
ICSPECIC 507	06/07/2021	Neurology	Parkinson's disease	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : PD	Cohort 1 : 36040
ICSPECIC 508	06/07/2021	Neurology	Parkinson's disease	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : PD	Cohort 1 : 36040

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 509	07/07/2021	Hepatology	Cirrhosis of liver	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Patient with Liver cirrhosis	Cohort 1 : 87961
ICSPECIC 510	09/07/2021	Hematology	Non-Hodgkin lymphoma	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : DLBCL All Cohort 2 : DLBCL with cardiac comorbidities	Cohort 1 : 15714 Cohort 2 : 2795
ICSPECIC 511	12/07/2021	Hematology	Multiple myeloma	Phase 3a	Award	207495	NCT04162210	EudraCT Numbe	TrialTroveID-329164	A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2018	France	Cohort 1- MM Cohort 2- MM 1L/2L	Cohort 1 : 27429 Cohort 2 : 7480
ICSPECIC 512	14/07/2021	Oncology	Malignant tumor of pancreas	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Pancreatic Cancer	Cohort 1 : 26944

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 513	14/07/2021	Neurology	Multiple system atrophy	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Patients between 30 to 75 years, diagnosed with MSA-P or MSA-C	Cohort 1 : 483
ICSPECIC 514	25/07/2021	Psychiatry	Bipolar disorder	Phase 3a	Award	SEP380-301	NCT05169710	EudraCT Numbe	TrialTroveID-419035	A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2019	France	Cohort 1 : Bipolar and Manic Disorder adults Cohort 2 : Bipolar Disorder adults	Cohort 1 : 33906 Cohort 2 : 32290
ICSPECIC 515	26/07/2021	Rheumatology	Giant cell arteritis	Phase 2	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : GCA ICD10 or temporal artery biopsy codes Cohort 2 : Takayasu arteritis ICD10 code	Cohort 1 : 11679 Cohort 2 : 616
ICSPECIC 516	26/07/2021	Oncology	Non-small cell lung cancer	Phase 3	Lost	213391	NCT04475939	EudraCT Numbe	TrialTroveID-379652	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L).	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : SCLC lung cancer Patients	Cohort 1 : 141717

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 517	26/07/2021	Oncology	Bladder cancer	Phase 1	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Patients with Urothelial cancers	Cohort 1 : 74004
ICSPECIC 518	27/07/2021	Infectious Disea	Type B viral hepatitis	Phase 2	Lost	NMRR-19-1382	NCT03982186	EudraCT Numbe	TrialTroveID-351286	A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : All patients diagnosed > 18 yrs with all exclusions Cohort 2 : Number of patients on treatment for hepatitis Cohort 3 : Of those on treatment how many are on 1. Entecavir, and/or 2. Tenofovir Disoproxil and/or 3. Tenofovir Alafenamide	Cohort 1 : 17811 Cohort 2 : 43098 Cohort 3 : 36741
ICSPECIC 519	30/07/2021	Oncology	Small cell carcinoma of lung	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : SCLC/Lung Cancer/Adult patients Cohort 2 : SCLC/Lung Cancer/Adult patients + Drug Basket 1L	Cohort 1 : 137741 Cohort 2 : 4342
ICSPECIC 520	30/07/2021	Oncology	Non-small cell lung cancer	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Lung cancer Cohort 2 : PD-1/PD-L1	Cohort 1 : 232670 Cohort 2 : 25334

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 521	30/07/2021	Nephrology	Acute renal impairment	Phase 2	Award	ALXN2050-NEP	NCT05097989	Not Applicable	TrialTroveID-417054	A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Kidney transplant patients	Cohort 1 : 29309
ICSPECIC 522	03/08/2021	Neurology	Parkinson's disease	Phase 1	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Patients with Parkinson's disease and sleep disorder	Cohort 1 : 194
ICSPECIC 523	04/08/2021	Oncology	Endometrial carcinoma	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Adult Female Patients with Endometrial Cancer	Cohort 1 : 17553
ICSPECIC 524	06/08/2021	Infectious Disea	Neisseria gonorrhoeae	Phase 3	Lost	116577	NCT04010539	Not Applicable	Not Applicable	A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Patients with Gonorrhea; Age 15 - 49 years	Cohort 1 : 586

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 525	06/08/2021	Nephrology	Sepsis-Associated Acute Kidney Injury	Phase 3	Lost	AP-recAP-AKI-0	NCT04411472	EudraCT Numbe	TrialTroveID-354524	A DB, Placebo-Controlled, Two-Arm Parallel-Group, Phase 3 RCT to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients With SA-AKI	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2018-2020	France	Cohort 1: Cardiac Surgery in 2018 Cohort 2: Cardiac Surgery in 2019 Cohort 3: Cardiac Surgery in 2020 Cohort 4: Cardiac Surgery and Chronic Kidney Disease in 2018 Cohort 5: Cardiac Surgery and Chronic Kidney Disease in 2019 Cohort 6: Cardiac Surgery and Chronic Kidney Disease in 2020 Cohort 7: Cardiac Surgery and Acute Kidney Injury 2018 Cohort 8: Cardiac Surgery and Acute Kidney Injury 2019 Cohort 9: Cardiac Surgery and Acute Kidney Injury 2020 Cohort 10: Cardiac Surgery and Chronic Kidney Disease and Chronic Kidney Disease in 2019 Cohort 11: Cardiac Surgery and Chronic Kidney Disease and Kidney Failure in 2018 Cohort 12: Cardiac Surgery and Chronic Kidney Disease and Kidney Failure in 2020	Cohort 1 : 125081 Cohort 2 : 126306 Cohort 3 : 114591 Cohort 4 : 124932 Cohort 5 : 126146 Cohort 6 : 114456 Cohort 7 : 124922 Cohort 8 : 126161 Cohort 9 : 114439 Cohort 10 : 126146 Cohort 11 : 124922 Cohort 12 : 114437
ICSPECIC 526	10/08/2021	Neurology	Mucopolysaccharidosis	Phase 2	Lost	DNLI-E-0002	NCT04251026	Not Applicable	Not Applicable	A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : MPS_ Mucopolysaccharidosis Type II/Hunter's syndrome patients all Cohort 2 : MPS_ Mucopolysaccharidosis Type II/Hunter's syndrome patients 6 to 15 years Cohort 3 : MPS_ Mucopolysaccharidosis Type II/Hunter's syndrome patients 2 to <6 years	Cohort 1 : 172 Cohort 2 : 79 Cohort 3 : 44
ICSPECIC 527	11/08/2021	Respiratory	Sarcoidosis	Phase 3a	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Pulmonary Sarcoidosis	Cohort 1 : 8588
ICSPECIC 528	11/08/2021	Neurology	Alzheimer's disease	Phase 2	Lost	UB-311-203 - E	NCT03531710	Not Applicable	TrialTroveID-324759	An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh AD Immunotherapeutic Vaccine (UB-311)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Mild to Moderate AD	Cohort 1 : 48706

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 529	12/08/2021	Oncology	Malignant tumor of prostate	Phase 3	Award	CURLu177PSM	NCT05204927	Not Applicable	Not Applicable	A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T Versus Hormone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Drug basket Cohort 2 : mCRPC Cohort 3 : mCRPC plus Cabazitaxel	Cohort 1 : 8439 Cohort 2 : 13630 Cohort 3 : 939
ICSPECIC 530	13/08/2021	Nephrology	Lupus nephritis	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Lupus Nephritis	Cohort 1 : 3737
ICSPECIC 531	17/08/2021	Hematology	Chronic lymphocytic leukemia	Phase 1	Award	2021-760-GLO	NCT05176691	Not Applicable	TrialTroveID-419862	A Multicenter, Open-label, Phase I Study Evaluating the Safety and Tolerability of HMPL-760 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Other Non-Hodgkin Lymphoma (NHL)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : WM Cohort 2 : NHL	Cohort 1 : 4678 Cohort 2 : 19021
ICSPECIC 532	18/08/2021	Hematology	Malignant lymphoma (clinical)	Phase 1	Award	2018-689-00U	NCT03786926	Not Applicable	TrialTroveID-339587	A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : FL Cohort 2 : MZL	Cohort 1 : 10265 Cohort 2 : 3327

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 533	18/08/2021	Hematology	Myelofibrosis	Phase 3	Award	0610-04	NCT04603495	EudraCT Numbe	TrialTroveID-321341	A Phase III, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2018	France	Cohort 1 : drug basket: Ruxolitinib Cohort 2 : Myelofibrosis	Cohort 1 : 1516 Cohort 2 : 1513
ICSPECIC 534	19/08/2021	Other	Cisplatin-Induced ototoxicity (CIO)	Phase 2	Award	SENS 401-201	NCT03603314	Not Applicable	Not Applicable	A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : Chemo (platinum based) in all tumors types Cohort 2 : Ototoxicity Cohort 3 : Ototoxicity + Chemo (platinum based)	Cohort 1 : 221129 Cohort 2 : 192 Cohort 3 : 67
ICSPECIC 535	20/08/2021	Hematology	Chronic lymphocytic leukemia	Phase 3	Award	LOXO-BTK-200	NCT05254743	EudraCT Numbe	TrialTroveID-398434	A Phase III Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : CLL_SLL Patients Cohort 2 : Drug included is Imbruvica	Cohort 1 : 1343 Cohort 2 : 541
ICSPECIC 536	23/08/2021	Respiratory	Respiratory tract infection	Phase 2	Award	B04-03	NCT04367077	Not Applicable	TrialTroveID-371647	A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStem Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19) MultiStem Administration for COVID-19 Induced Acute Respiratory Distress Syndrome (MACOVIA)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : All ARDS patients aged 18-89 Cohort 2 : All ARDS patients with pneumonia or sepsis and with exclusions aged 18-89 Cohort 3 : All C19 pneumonia agde 18-89 with intubation procedures Cohort 4 : All Covid 19 aged 18-89 for past 1 year Cohort 5 : Covid19 pneumonia aged 18-89 using J12.8 code	Cohort 1 : 36832 Cohort 2 : 1071 Cohort 3 : 6771 Cohort 4 : 726531 Cohort 5 : 116279

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 537	24/08/2021	Hematology	Hematologic malignancy	Phase 1	Award	WU-CART-007	NCT04984356	Not Applicable	TrialTroveID-410086	A Phase I/IIDose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : Chronic lymphocytic leukemia or Small lymphocytic lymphoma	Cohort 1 : 3106
ICSPECIC 538	25/08/2021	Oncology	Glioma	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Low grade glioma patients; Kids under 15 Cohort 2 : Low grade glioma patients; 15-21 Years	Cohort 1 : 1967 Cohort 2 : 535
ICSPECIC 539	26/08/2021	Hematology	Malignant lymphoma (clinical)	Phase 1	Award	2018-523-00U	NCT03779113	Not Applicable	TrialTroveID-339184	A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : CLL and SLL Patients Cohort 2 : Cutaneous B-cell Lymphoma Patients Cohort 3 : FL Patients Cohort 4 : MCL Patients Cohort 5 : MZL Patients Cohort 6 : Peripheral T-cell Lymphoma Patients Cohort 7 : Waldenstrom_MG_LPL Patients Cohort 8 : Hodgkin LymphomaS Patients	Cohort 1 : 19021 Cohort 2 : 5178 Cohort 3 : 10743 Cohort 4 : 7528 Cohort 5 : 4063 Cohort 6 : 3453 Cohort 7 : 1148 Cohort 8 : 4678
ICSPECIC 540	01/09/2021	Oncology	Non-small cell lung cancer	Phase 2	Award	INCB54828-21	NCT02872714	EudraCT Numbe	TrialTroveID-252116	A Phase II, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations - (FIGHT-201)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Lung Cancer patients Cohort 2 : Glioblastoma patients	Cohort 1 : 141990 Cohort 2 : 3469

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 541	03/09/2021	Oncology	Neuroendocrine tumor	Phase 2	Award	CAAA601A322	NCT04711135	EudraCT Numbe	TrialTroveID-393092	A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2018	France	Cohort 1 : Adolescents diagnosed with NET Cohort 2 : Patients diagnosed with Malignant Neuroendocrine tumors (NET) and age between 18 and 85 Cohort 3 : Patients diagnosed with Malignant Neuroendocrine tumors (NET) and age between 18 and 85 and received LUTATHERA	Cohort 1 : 75 Cohort 2 : 8548 Cohort 3 : 275
ICSPECIC 542	13/09/2021	Oncology	Cervical cancer	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : Cervical cancer	Cohort 1 : 11023
ICSPECIC 543	17/09/2021	Oncology	Malignant tumor of breast	Phase 3	Lost	G1T28-208	NCT04799249	EudraCT Numbe	TrialTroveID-358310	Phase III randomized, double-blind, Clinical Study of Trilaciclib in combination with a chemotherapy regimen of GC in Metastatic Triple-Negative Breast Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Overall Breast Cancer Patients	Cohort 1 : 166889
ICSPECIC 544	17/09/2021	Ophthalmology	Macular degeneration	Phase 3a	Award	OPT-302-1004	NCT04757610	EudraCT Numbe	TrialTroveID-370733	A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2018	France	Cohort 1 : AMD (all) Cohort 2 : AMD (Primary reason for care) Cohort 3 : AMD (Primary reason for care) with age 50+ Cohort 4 : AMD (Primary reason for care) with age 50+, with Opthalmic procedures Cohort 5 : AMD (Primary reason for care) with age 50+, with Opthalmic Injection of pharmaceutical agent Cohort 6 : Neovascular Age-related Macular Degeneration (nAMD) Patients Cohort 7 : Drud included is ELYEA_ AFLIBERCEPT	Cohort 1 : 22841 Cohort 2 : 11202 Cohort 3 : 10905 Cohort 4 : 10230 Cohort 5 : 2766

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 545	17/09/2021	Ophthalmology	Age related macular degenerati	Phase 3	Award	OPT-302-1005	NCT04757636	EudraCT Numbe	TrialTroveID-382644	A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Aflibercept, Compared With Aflibercept Alone, in Participants With nAMD	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Neovascular Age-related Macular Degeneration (nAMD) Patients Cohort 2 : Drud included is ELYEA_ AFLIBERCEPT	Cohort 1 : 39690 Cohort 2 : 670
ICSPECIC 546	17/09/2021	Oncology	Bladder cancer	Phase 2	Lost	RC45-G001	NCT04879329	Not Applicable	TrialTroveID-373470	A Phase II Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) in Subjects With HER2 Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : Bladder Cancer Cohort 2 : PD1	Cohort 1 : 66229 Cohort 2 : 4100
ICSPECIC 547	22/09/2021	Oncology	Malignant tumor of colon	Phase 3	Lost	NuTide:323	Not Applicable	Not Applicable	TrialTroveID-390853	A Phase III, randomized, open-label study comparing NUC-3373 to 5-FU both in combination with leucovorin, irinotecan and bevacizumab for the treatment of patients with unresectable locally advanced/metastatic colorectal cancer who have previously received one fluoropyrimidine and oxaliplatin-containing regimen for advanced disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Colorectal Caners Patients Cohort 2 : Colorectal Caners Patients on drugs Panitumumab and Aflibercept	Cohort 1 : 130245 Cohort 2 : 3869
ICSPECIC 548	24/09/2021	Hematology	Multiple myeloma	Phase 3a	Award	207499	NCT04484623	EudraCT Numbe	TrialTroveID-329205	A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8).	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : Multiple Myeloma	Cohort 1 : 27429

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 549	28/09/2021	Rheumatology	Ankylosing spondylitis	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : Ankylosing spondylitis Cohort 2 : Ankylosing spondylitis adults Cohort 3 : Ankylosing spondylitis with drugs	Cohort 1 : 21852 Cohort 2 : 21696 Cohort 3 : 7593
ICSPECIC 550	28/09/2021	Oncology	Solid tumor configuration	Phase 2	Award	D419EC00001	NCT03837899	EudraCT Numbe	TrialTroveID-343419	Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination With Tremelimumab in Pediatric Patients With Advanced Solid Tumors and Hematological Malignancies	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2018	France	Cohort 1 : Non-Hodgkin's Lymphoma Cohort 2 : Other Solid Tumors Cohort 3 : Sarcoma	Cohort 1 : 595 Cohort 2 : 2424 Cohort 3 : 1423
ICSPECIC 551	30/09/2021	Oncology	Solid tumor configuration	Phase 2	Award	CMP-001-010	NCT04698187	Not Applicable	TrialTroveID-391423	A Multicenter, Open-label, Phase II Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Melanoma Patients Cohort 2 : U/M FIRST-LINE MELANOMA	Cohort 1 : 15487 Cohort 2 : 5820
ICSPECIC 552	01/10/2021	Respiratory	Fibrosis of lung	Phase 3	Lost	RIN-PF-302	NCT04905693	Not Applicable	TrialTroveID-405287	An Open-label Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Patients with Pulmonary Fibrosis aged ≥40 years Cohort 2 : Drugs included are Pirfenidone and Nintedanib	Cohort 1 : 21081 Cohort 2 : 1613

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 553	07/10/2021	Ophthalmology	Geographical atrophy	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Geographic Atrophy Patients Cohort 2 : nAMD treated patients	Cohort 1 : 71159 Cohort 2 : 541
ICSPECIC 554	11/10/2021	Infectious Disea	Clostridium difficile colitis	Phase 3	Lost	SERES-012	NCT03183128	Not Applicable	TrialTroveID-303216	A Phase III Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety,Tolerability and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : C difficile Cohort 2 : Fidaxomicin Cohort 3 : C difficile with Fidaxomicin	Cohort 1 : 15292 Cohort 2 : 3876 Cohort 3 : 3817
ICSPECIC 555	12/10/2021	Rheumatology	Psoriatic arthritis	Phase 3a	Award	CNTO1275JPA3	NCT05083182	EudraCT Numbe	TrialTroveID-416275	A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Juvenile Psoriatic Arthritis	Cohort 1 : 88
ICSPECIC 556	13/10/2021	Hematology	Hemolytic Anemia	Phase 3	Pendin	MOM-M281-0(	NCT04119050	EudraCT Numbe	TrialTroveID-354510	Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With a Long-term Open-label Extension	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Patients Haemolytic Anemia	Cohort 1 : 2892

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 557	15/10/2021	Rheumatology	Lupus erythematosus	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Patients Diagnosed with Discoid Lupus erythematosus	Cohort 1 : 4207
ICSPECIC 558	19/10/2021	Dermatology	Congenital Ichthyosis	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Aurélie Lampuré	MCO	2020	France	Cohort 1 : Netherthon Syndrome patients (Q80.3,.8,.9), 18+ years	Cohort 1 : 66
ICSPECIC 559	20/10/2021	Oncology	Basal cell carcinoma	Phase 2	Award	nkt2152 - 201	NCT05119335	Not Applicable	TrialTroveID-418374	A Phase I/II, Open Label Dose-escalation and Expansion Trial of NKT2152, an Orally Administered HIF2 alpha Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : PATIENTS DIAG WITH ccRCC AND TREATED WITH ANTI-PDs AND VEGFi Cohort 2 : PATIENTS WITH ccRCC	Cohort 1 : 541 Cohort 2 : 29250
ICSPECIC 560	25/10/2021	Endocrinology	Precocious puberty	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : CPP (2 to 9 years)	Cohort 1 : 202

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 561	26/10/2021	Oncology	Non-small cell lung cancer	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : NSCLC, 18+years Cohort 2 : NSCLC, 18+years, Treatment with osimertinib Cohort 3 : NSCLC, 18+years, Durvalumab	Cohort 1 : 103040 Cohort 2 : 2108 Cohort 3 : 1380
ICSPECIC 562	27/10/2021	Allergy	Angioedema	Phase 1	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : HAE 18 to 75	Cohort 1 : 2332
ICSPECIC 563	01/11/2021	Oncology	Non-small cell lung cancer	Phase 2	Award	AB-106-G208	NCT04919811	Not Applicable	TrialTroveID-357972	A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019	France	Cohort 1 : Patients treated with Ciritinib OR Lorlatinib OR Cabozantinib Cohort 2 : Patients treated with Lorlatinib Cohort 3 : Patients treated with Cabozantinib Cohort 4 : Patients treated with Ceritinib	Cohort 1 : 769 Cohort 2 : 680 Cohort 3 : 42 Cohort 4 : 33
ICSPECIC 564	03/11/2021	Other	Amyloidosis	Phase 3b	Award	CAEL101-301	NCT04504825	Not Applicable	TrialTroveID-381376	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naive Patients With Mayo Stage IIIb AL Amyloidosis	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Amyloidosis Patients	Cohort 1 : 4301

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 565	04/11/2021	Rheumatology	Dermatomyositis	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Aurélie Lampuré	MCO	2020	France	Cohort 1 : Dermatomyoitis Polymyositis patients (M33.1,.2,.9) 18+ years	Cohort 1 : 2351
ICSPECIC 566	08/11/2021	Oncology	Hepatocellular carcinoma	Phase 3	Lost	XL184-312	NCT03755791	EudraCT Numbe	TrialTroveID-337719	A Randomized, Controlled Phase III Study of Cabozantinib (XL184) in Combination with Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Patients with Hepatocellular Carcinoma Cohort 2 : Patients with Hepatocellular Carcinoma treated with Atezolizumab; Bevacizumab Cohort 3 : Drug included is Cabozantinib	Cohort 1 : 22349 Cohort 2 : 505 Cohort 3 : 680
ICSPECIC 567	08/11/2021	Gastrointestina	Crohn's disease	Phase 2b	Awarde	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Fistulizing CD patients	Cohort 1 : 62078
ICSPECIC 568	08/11/2021	Infectious Disea	Clostridium difficile colitis	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : CDI >=65 yrs Cohort 2 : CDI >=75 yrs Cohort 3 : CDI Recurrent >=18 yrs	Cohort 1 : 10499 Cohort 2 : 7171 Cohort 3 : 14458

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 569	12/11/2021	Neurology	Duchenne muscular dystrophy	Phase 1	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2018-2020	France	Cohort 1 : DM1_2018 Cohort 2 : DM1_2019 Cohort 3 : DM1_2020 Cohort 4 : DM_3years_lookback	Cohort 1 : 3149 Cohort 2 : 3212 Cohort 3 : 2680 Cohort 4 : 6891
ICSPECIC 570	16/11/2021	Hematology	Hematologic malignancy	Phase 1	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : CLL Cohort 2 : DLBCL Cohort 3 : FL Cohort 4 : MCL Cohort 5 : MZL	Cohort 1 : 542 Cohort 2 : 7637 Cohort 3 : 5366 Cohort 4 : 1848 Cohort 5 : 1095
ICSPECIC 571	16/11/2021	Neurology	Parkinson's disease	Phase 2	Awarde	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : PD Patients	Cohort 1 : 74732
ICSPECIC 572	02/12/2021	Dermatology	Epidermolysis bullosa	Phase 3a	Awarde	D325AC00002	NCT04612790	Not Applicable	Not Applicable	A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2019-2020	France	Cohort 1 : Bullous Pemphigoid adult hospitalisations in 2019-2020 Cohort 2 : Bullous Pemphigoid adult hospitalisations in 2020 Cohort 3 : Bullous Pemphigoid adult hospitalisations in 2019	Cohort 1 : 6370 Cohort 2 : 3355 Cohort 3 : 3624

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 573	03/12/2021	Medical Genetic	Tuberous sclerosis syndrome	Phase 1	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Patient Diagnosed with Tuberous Sclerosis aged 18-65 Cohort 2 : Patients diagnosed with Tuberous Sclerosis	Cohort 1 : 463 Cohort 2 : 1008
ICSPECIC 574	09/12/2021	Endocrinology	Autoimmune thyroiditis	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : GRAVE'S DISEASE	Cohort 1 : 7306
ICSPECIC 575	14/12/2021	Neurology	Alzheimer's disease	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : AD patients	Cohort 1 : 43490
ICSPECIC 576	14/12/2021	Oncology	Solid tumor configuration	Phase 2a	Award	SAKK 66/17	NCT03993678	EudraCT Numbe	TrialTroveID-351973	Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. A Multicenter Phase Ib/IIa Trial With Expansion Cohorts in Melanoma and Soft Tissue Sarcoma Patients.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : NSCLC + Colorectal Cancer Cohort 2 : Radiofrequency Ablation Cohort 3 : STS	Cohort 1 : 452546 Cohort 2 : 7070 Cohort 3 : 13776

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 577	15/12/2021	Oncology	Non-small cell lung cancer	Phase 3	Award	SHR-1210-III-3	NCT05106335	Not Applicable	TrialTroveID-411000	A Randomized, Open-Label, Controlled, Multi-Center Phase III Clinical Study of Camrelizumab Combined With Famitinib Malate Versus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer Who Progressed on Prior Immune Checkpoint Inhibitor Treatment and Platinum-Based Chemotherapy	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Patients treated for Metastatic NSCLC Cohort 2 : Patients with NSCLC	Cohort 1 : 12436 Cohort 2 : 103250
ICSPECIC 578	28/12/2021	Hematology	Myelodysplastic syndrome	Phase 2	Award	ASTX727-07	NCT04657081	Not Applicable	TrialTroveID-388275	A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination With Venetoclax in Adult Patients With Acute Myeloid Leukemia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : MDS patients on Azacitidine treatment Cohort 2 : MDS >= 18 years	Cohort 1 : 2609 Cohort 2 : 23415
ICSPECIC 579	06/01/2022	Hematology	Acute myeloid leukemia	Phase 1	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : Acute Myeloid Leukemia	Cohort 1 : 11503
ICSPECIC 580	06/01/2022	Neurology	Sleep disorder	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Adult patients diagnosed with Idiopathic hypersomnia	Cohort 1 : 4840

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 581	06/01/2022	Neurology	Muscle weakness	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : XLMTM	Cohort 1 : 579
ICSPECIC 582	10/01/2022	Infectious Disea	Clostridium difficile colitis	Phase 3	Lost	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : C difficile Cohort 2 : Fidaxomicin Cohort 3 : C difficile with Fidaxomicin	Cohort 1 : 15292 Cohort 2 : 3876 Cohort 3 : 3817
ICSPECIC 583	17/01/2022	Oncology	Bone sarcoma	Phase 3	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Osteosarcoma	Cohort 1 : 1685
ICSPECIC 584	17/01/2022	Oncology	Thrombocytopenic disorder	Phase 3	Award	HR-TPO-CIT-30	NCT05261646	Not Applicable	TrialTroveID-426396	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Stage Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets in Treatment of Chemotherapy-Induced Thrombocytopenia	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Patients with Solid Tumors who went through chemotherapy and got thrombocytopenia Cohort 2 : Solid Tumors Cohort 3 : Solid Tumors on chemo if available Cohort 4 : Thrombocytopenia	Cohort 1 : 264 Cohort 2 : 1028890 Cohort 3 : 101756 Cohort 4 : 30960

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 585	18/01/2022	Oncology	Solid tumor configuration	Phase 1	Award	DCC-3116-01-0	NCT04892017	Not Applicable	TrialTroveID-360049	A Phase I, First-in-Human Study of DCC-3116 as a Single Agent and in Combination With Trametinib in Patients With Advanced or Metastatic Solid Tumors With RAS or RAF Mutations.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 Metastatic Pancreatic Ductal Adenocarcinoma Cohort 2 NSCLC Cohort 3 Colorectal Cancer Cohort 4 Melanoma	Cohort 1 : 250 Cohort 2 : 137851 Cohort 3 : 124568 Cohort 4 : 21708
ICSPECIC 586	21/01/2022	Gastrointestina	Crohn's disease	Phase 3	Award	Darvadstrocel-	NCT04701411	EudraCT Numbe	TrialTroveID-216462	A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn's Disease over a Period of 24 Weeks and an Extended Follow-up Period for a Total of up to 52 Weeks.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Pediatric Crohn	Cohort 1 : 4379
ICSPECIC 587	24/01/2022	Oncology	Malignant tumor of colon	Phase 3	Pendin	XL092-303	Not Applicable	EudraCT Numbe	Not Applicable	A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenibin Subjects with Metastatic Colorectal Cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Colorectal Cancer patients Cohort 2 : CRC patients_Regorafenib Cohort 3 : CRC patients_Tipiracil Cohort 4 : CRC patients_Tipiracil or Regorafenib	Cohort 1 : 124568 Cohort 2 : 8306 Cohort 3 : 541 Cohort 4 : 9271
ICSPECIC 588	24/01/2022	Oncology	Malignant melanoma	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Patients diagnosed with Melanoma Cohort 2 : Patients diagnosed with Melanoma and treated with with anti-PD-1/PD-L1 agents	Cohort 1 : 21852 Cohort 2 : 6018

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 589	24/01/2022	Oncology	Solid tumor configuration	Phase 1	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Patients diagnosed with Gastro Esophageal Cancer & Treated with HER 2 drugs Cohort 2 : Patients diagnosed with UBC Cohort 3 : Patients with advanced (locally recurrent/unresectable or metastatic) TNBC	Cohort 1 : 632 Cohort 2 : 70426 Cohort 3 : 13542
ICSPECIC 590	25/01/2022	Neurology	Multiple system atrophy	Phase 2	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : MSA	Cohort 1 : 878
ICSPECIC 591	26/01/2022	Hematology	von Willebrand disorder	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Pediatric Von Willebrand	Cohort 1 : 535
ICSPECIC 592	28/01/2022	Oncology	Endometrial carcinoma	Phase 2	Award	INCMGA 0012-	NCT04463771	EudraCT Numbe	TrialTroveID-331863	An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Endometrial carcionoma, Adults	Cohort 1 : 16700

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 593	31/01/2022	Women's Healt	Bronchopulm dysplasia newborn	Phase 2	Award	ER004-CLIN01/	NCT04980638	Not Applicable	Not Applicable	A Prospective, Open-label, Genotype-match Controlled, Multicenter Clinical Trial to Investigate the Efficacy and Safety of Intra-amniotic ER004 as a Prenatal Treatment for Male Subjects With XLHED	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : HED all ages 4 year lookback Cohort 2 : Paediatric HED (<18years) 4 year lookback Cohort 3 : XLHED Paediatric Male (<18 years) 4 year lookback Cohort 4 : HED Adult Female (18 - 40 years) 4 year lookback Cohort 5 : HED all ages 2 year lookback Cohort 6 : Paediatric HED (<18years) 2 year lookback Cohort 7 : XLHED Paediatric Male (<18 years) 2 year lookback Cohort 8 : HED Adult Female (18 - 40 years) 2 year lookback	Cohort 1 : 182 Cohort 2 : 113 Cohort 3 : 66 Cohort 4 : 22 Cohort 5 : 96 Cohort 6 : 63 Cohort 7 : 43 Cohort 8 : 11
ICSPECIC 594	01/02/2022	Gastrointestina	Bowel dysfunction	Phase 3	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : functional intestinal disorder Cohort 2 : Postprandial Distress Syndrome	Cohort 1 : 4106 Cohort 2 : 15345
ICSPECIC 595	03/02/2022	Rheumatology	Lupus erythematosus	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : SLE	Cohort 1 : 6272
ICSPECIC 596	03/02/2022	Oncology	Head and neck cancer	Phase 2	Award	H-200-001	NCT04180215	EudraCT Numbe	TrialTroveID-315015	A Phase I/II Study of TheraT Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Head and Neck Cancer Cohort 2 : HPV Tumors	Cohort 1 : 52354 Cohort 2 : 3454

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 597	07/02/2022	Oncology	Non-small cell lung cancer	Phase 2	Award	MS200095_003	NCT03940703	EudraCT Numbe	TrialTroveID-348972	A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Lung cancer Cohort 2 : Metastatic lung cancer	Cohort 1 : 133328 Cohort 2 : 73509
ICSPECIC 598	07/02/2022	Women's Healt	Female infertility	Phase 4	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Contraception Z30, 16+ years, Women Cohort 2 : Estetrol with Drospirenone	Cohort 1 : 238067 Cohort 2 : 153961
ICSPECIC 599	08/02/2022	Gastrointestina	Celiac disease	Phase 2a	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Celiac Disease (18-75 years) excluding pregnant and breastfeeding patients	Cohort 1 : 14234
ICSPECIC 600	09/02/2022	Oncology	Non-small cell lung cancer	Phase 2	Lost	A2A-005	Not Applicable	EudraCT Numbe	Not Applicable	A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed as a second-line therapy in adults with metastatic nonsquamous non-small cell lung cancer	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : NSCLC - PDL-1 treated	Cohort 1 : 22650

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 601	16/02/2022	Oncology	Hepatocellular carcinoma	Phase 3	Award	JS001-027-III-H	NCT04523493	EudraCT Numbe	TrialTroveID-381102	A Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study to Compare Toripalimab Combined With Lenvatinib Versus Placebo Combined With Lenvatinib as the 1st-line Therapy for Advanced HCC	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : HCC, 18-75 yrs, Drug Basket Cohort 2 : Hepatocellular carcinoma, 18-75 years, Adults	Cohort 1 : 435 Cohort 2 : 14561
ICSPECIC 602	18/02/2022	Hematology	Paroxysmal nocturnl hemogluria	Phase 3	Award	BO42161	NCT04432584	EudraCT Numbe	TrialTroveID-377177	A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1: Eculizumab last 12 months Cohort 2: Eculizumab last 6 months Cohort 3: Paroxysmal nocturnal hemoglobinuria patients (diag code)	Cohort 1 : 986 Cohort 2 : 747 Cohort 3 : 499
ICSPECIC 603	22/02/2022	Nephrology	Kidney disease	Phase 3	Award	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : DKD Patient Count for Claims	Cohort 1 : 558776
ICSPECIC 604	22/02/2022	Cardiovascular	Essential hypertension	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : HTN diagnosis, 18-85 years old Cohort 2 : HTN Diagnosis, 18-85 years old, prevalence of rHTN applied	Cohort 1 : 3377346 Cohort 2 : 675474

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 605	22/02/2022	Ophthalmology	Glaucoma	Phase 3	Award	LT4030-301	NCT04898387	EudraCT Numbe	TrialTroveID-398280	Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : Glaucoma Cohort 2 : Glaucoma adults Cohort 3 : Ocular Hypertension and open angle Glaucoma adults Cohort 4 : Glaucoma Cohort 5 : Glaucoma adults	Cohort 1 : 45125 Cohort 2 : 44848 Cohort 3 : 14154
ICSPECIC 606	23/02/2022	Nephrology	Polycystic kidney disease	Phase 3	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Ahmad Wali	MCO	2020	France	Cohort 1 : Patients with ADPKD	Cohort 1 : 4594
ICSPECIC 607	28/02/2022	Nephrology	Kidney disease	Phase 2	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : AAV + Acute Kidney Injury	Cohort 1 : 1171
ICSPECIC 608	28/02/2022	Neurology	Spinal cord injury	Phase 3	Pendin	A2017SCI03	NCT03935724	EudraCT Numbe	Not Applicable	A Multi-center, Double-blind, Randomized, Placebo-controlled, Delayedstart Phase II/III Study to Assess the Efficacy and Safety of Neuro-Cells in (Sub)Acute Spinal Cord Injury Patients	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Aurélie Lampuré	MCO	2020	France	Cohort 1 : Patients with SCI (ICD)	Cohort 1 : 2098

Code Projet IQVIA	Opportunity Start Date	Therapeutic Area	Indication	Phase	Award Status	Protocol Number	NCT Number	EudraCT Code	Trail Trove ID	Title Clinical Trial	"Reponsable de traitement"	"Finalité de traitement"	Regional Analyst assigned	PMSI Database (MCO, SSR, ...)	Lookback period (PMSI years)	"Zone géographique"	Criteria inclusion/exclusion	Results (patient count)
ICSPECIC 609	01/03/2022	Gastrointestina	Ulcerative colitis	Phase 3	Pendin	Confidential	Not Applicable	Not Applicable	Not Applicable	Confidential	IQVIA	Ciblage d'établissements de soins et capacité de ces établissements à pouvoir accueillir différentes études cliniques	Joy Seanehia	MCO	2020	France	Cohort 1 : UC Age 2-17	Cohort 1 : 1632